US03/29176

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 12 April 2001 (12.04.2001)

PCT

(10) International Publication Number WO 01/25273 A2

(51) International Patent Classification⁷: C07

C07K 14/00

(21) International Application Number: PCT/US00/27465

(22) International Filing Date: 4 October 2000 (04.10.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/157.459

4 October 1999 (04.10.1999) US

- (71) Applicant (for all designated States except US): CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SKEIKY, Yasir,
 A., W. [CA/US]; 15106 SE 47th Place, Bellevue, WA
 98006 (US). XU, Jiangehun [US/US]; 15805 SE 43rd

Place, Bellevue, WA 98006 (US). CHEEVER, Martin, A. [US/US]; 6210 Southeast 22nd, Mercer Island, WA 98040 (US). REED, Steven, G. [US/US]; 2843 - 122nd-Place NE, Bellevue, WA 98005 (US).

- (74) Agents: POTTER, Jane, E., R.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 et al. (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY

HO: HESELVAENT NET TENANCEST CONTROLLEN SCHOOL MATAINEN DE CREATEUR.

MO: COM YEAR YEAR EASTERS AND ENGINEERS CONTRACTOR CONTRACTOR AND ENGINEERS CONTRACTOR AND ENGINEERS CONTRACTOR CONTRACTOR AND ENGINEERS CONTRACTOR C

m:)caaasaasasaacheedhaasaaraanscaedhaanacaeaaaaa

MC: ACELLS SEENYCE SAFERI VERTERACTOR TOROCTA SABAR CONSTRUCTOR CON

BU: SCALLLETTYS SINE YOUTS CLEARING WHE GAT ANY AGSSSSTANTS
BU: SCALLLETTYS SINE YOUTS CLEARING WHE GAT ANY AGSSSSTANTS

ac:edemecrates mente incordistrata contrata cont

M: HERBITICATOR HATELY CONTROL CONTROL

EU: SIQLAMEQNIETY: MITQUITQUITSRSIELANDERROETGATSRAFFSCR SC: SIQLAMEQNIETY: MITQUITQUITSRSIELANDERROETGATSRAFFSCR

SU: NTSCQAUTARSDELTREEDEGATATECQUA MC: WESCQAUTARSDELTREEDEGATATETTE

(57) Abstract: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

) 01/25273 A2

WO 01/25273 A2



Published:

 Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette. WO 01/25273 PCT/US00/27465

1

COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY

TECHNICAL FIELD

5

10

15

20

25

The present invention relates generally to the immunotherapy of malignant diseases such as leukemia and cancers. The invention is more specifically related to compositions for generating or enhancing an immune response to WT1, and to the use of such compositions for preventing and/or treating malignant diseases.

BACKGROUND OF THE INVENTION

Cancer and leukemia are significant health problems in the United States and throughout the world. Although advances have been made in detection and treatment of such diseases, no vaccine or other universally successful method for prevention or treatment of cancer and leukemia is currently available. Management of the diseases currently relies on a combination of early diagnosis and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy. The course of treatment for a particular cancer is often selected based on a variety of prognostic parameters, including an analysis of specific tumor markers. However, the use of established markers often leads to a result that is difficult to interpret, and the high mortality continues to be observed in many cancer patients.

Immunotherapies have the potential to substantially improve cancer and leukemia treatment and survival. Recent data demonstrate that leukemia can be cured by immunotherapy in the context of bone marrow transplantation (e.g., donor lymphocyte infusions). Such therapies may involve the generation or enhancement of an immune response to a tumor-associated antigen (TAA). However, to date, relatively few TAAs are known and the generation of an immune response against such antigens has, with rare exceptions, not been shown to be therapeutically beneficial.

10

15

20

Accordingly, there is a need in the art for improved methods for leukemia and cancer prevention and therapy. The present invention fulfills these needs and further provides other related advantages.

SUMMARY OF THE INVENTION

Briefly stated, this invention provides compositions and methods for the diagnosis and therapy of diseases such as leukemia and cancer. In one aspect, the present invention provides polypeptides comprising an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished. Within certain embodiments, the polypeptide comprises no more than 16 consecutive amino acid residues of a native WT1 polypeptide. Within other embodiments, the polypeptide comprises an immunogenic portion of amino acid residues 1 - 174 of a native WT1 polypeptide or a variant thereof, wherein the polypeptide comprises no more than 16 consecutive amino acid residues present within amino acids 175 to 449 of the native WT1 polypeptide. The immunogenic portion preferably binds to an MHC class I and/or class II molecule. Within certain embodiments, the polypeptide comprises a sequence selected from the group consisting of (a) sequences recited in any one or more of Tables II - XLVI, (b) variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished and (c) mimetics of the polypeptides recited above, such that the ability of the mimetic to react with antigen-specific antisera and/or T cell lines or clones is not substantially diminished.

Within other embodiments, the polypeptide comprises a sequence selected from the group consisting of (a) ALLPAVPSL (SEQ ID NO:34), GATLKGVAA (SEQ ID NO:88), CMTWNQMNL (SEQ ID NOs: 49 and 258), SCLESQPTI (SEQ ID NOs: 199 and 296), SCLESQPAI (SEQ ID NO:198), NLYQMTSQL (SEQ ID NOs: 147 and 284),

ን

10

15

20

25

ALLPAVSSL (SEQ ID NOs: 35 and 255), RMFPNAPYL (SEQ ID NOs: 185 and 293), (b) variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished and (c) mimetics of the polypeptides recited above, such that the ability of the mimetic to react with antigen-specific antisera and/or T cell lines or clones is not substantially diminished. Mimetics may comprises amino acids in combination with one or more amino acid mimetics or may be entirely nonpeptide mimetics.

Within further aspects, the present invention provides polypeptides comprising a variant of an immunogenic portion of a WT1 protein, wherein the variant differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1 protein.

The present invention further provides WT1 polynucleotides that encode a WT1 polypeptide as described above.

Within other aspects, the present invention provides pharmaceutical compositions and vaccines. Pharmaceutical compositions may comprise a polypeptide or mimetic as described above and/or one or more of (i) a WT1 polynucleotide; (ii) an antibody or antigen-binding fragment thereof that specifically binds to a WT1 polypeptide; (iii) a T cell that specifically reacts with a WT1 polypeptide or (iv) an antigen-presenting cell that expresses a WT1 polypeptide, in combination with a pharmaceutically acceptable carrier or excipient. Vaccines comprise a polypeptide as described above and/or one or more of (i) a WT1 polynucleotide, (ii) an antigen-presenting cell that expresses a WT1 polypeptide or (iii) an anti-idiotypic antibody, and a non-specific immune response enhancer. Within certain embodiments, less than 23 consecutive amino acid residues, preferably less than 17 amino acid residues, of a native WT1 polypeptide are present within a WT1 polypeptide employed within such pharmaceutical compositions and vaccines. The

10

15

20

25

immune response enhancer may be an adjuvant. Preferably, an immune response enhancer enhances a T cell response.

The present invention further provides methods for enhancing or inducing an immune response in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above. In certain embodiments, the patient is a human.

The present invention further provides methods for inhibiting the development of a malignant disease in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as described above. Malignant diseases include, but are not limited to leukemias (e.g., acute myeloid, acute lymphocytic and chronic myeloid) and cancers (e.g., breast, lung, thyroid or gastrointestinal cancer or a melanoma). The patient may, but need not, be afflicted with the malignant disease, and the administration of the pharmaceutical composition or vaccine may inhibit the onset of such a disease, or may inhibit progression and/or metastasis of an existing disease.

The present invention further provides, within other aspects, methods for removing cells expressing WT1 from bone marrow and/or peripheral blood or fractions thereof, comprising contacting bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood with T cells that specifically react with a WT1 polypeptide, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of WT1 positive cells to less than 10%, preferably less than 5% and more preferably less than 1%, of the number of myeloid or lymphatic cells in the bone marrow, peripheral blood or fraction. Bone marrow, peripheral blood and fractions may be obtained from a patient afflicted with a disease associated with WT1 expression, or may be obtained from a human or non-human mammal not afflicted with such a disease.

Within related aspects, the present invention provides methods for inhibiting the development of a malignant disease in a patient, comprising administering to a patient bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood prepared as described above. Such bone marrow, peripheral blood or fractions may be autologous,

10

15

20

25

or may be derived from a related or unrelated human or non-human animal (e.g., syngeneic or allogeneic).

In other aspects, the present invention provides methods for stimulating (or priming) and/or expanding T cells, comprising contacting T cells with a WT1 polypeptide under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Such T cells may be autologous, allogeneic, syngeneic or unrelated WT1-specific T cells, and may be stimulated *in vitro* or *in vivo*. Expanded T cells may, within certain embodiments, be present within bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood, and may (but need not) be clonal. Within certain embodiments, T cells may be present in a mammal during stimulation and/or expansion. WT1-specific T cells may be used, for example, within donor lymphocyte infusions.

Within related aspects, methods are provided for inhibiting the development of a malignant disease in a patient, comprising administering to a patient T cells prepared as described above. Such T cells may, within certain embodiments, be autologous, syngeneic or allogeneic.

The present invention further provides, within other aspects, methods for monitoring the effectiveness of an immunization or therapy for a malignant disease associated with WT1 expression in a patient. Such methods are based on monitoring antibody, CD4+ T cell and/or CD8+ T cell responses in the patient. Within certain such aspects, a method may comprise the steps of: (a) incubating a first biological sample with one or more of: (i) a WT1 polypeptide; (ii) a polynucleotide encoding a WT1 polypeptide; or (iii) an antigen presenting cell that expresses a WT1 polypeptide, wherein the first biological sample is obtained from a patient prior to a therapy or immunization, and wherein the incubation is performed under conditions and for a time sufficient to allow immunocomplexes to form; (b) detecting immunocomplexes formed between the WT1 polypeptide and antibodies in the biological sample that specifically bind to the WT1 polypeptide; (c) repeating steps (a) and (b) using a second biological sample obtained from the same patient following therapy or immunization; and (d) comparing the number of

10

15

20

25

immunocomplexes detected in the first and second biological samples, and therefrom monitoring the effectiveness of the therapy or immunization in the patient.

Within certain embodiments of the above methods, the step of detecting comprises (a) incubating the immunocomplexes with a detection reagent that is capable of binding to the immunocomplexes, wherein the detection reagent comprises a reporter group, (b) removing unbound detection reagent, and (c) detecting the presence or absence of the reporter group. The detection reagent may comprise, for example, a second antibody, or antigen-binding fragment thereof, capable of binding to the antibodies that specifically bind to the WT1 polypeptide or a molecule such as Protein A. Within other embodiments, a reporter group is bound to the WT1 polypeptide, and the step of detecting comprises removing unbound WT1 polypeptide and subsequently detecting the presence or absence of the reporter group.

Within further aspects, methods for monitoring the effectiveness of an immunization or therapy for a malignant disease associated with WT1 expression in a patient may comprise the steps of: (a) incubating a first biological sample with one or more of: (i) a WT1 polypeptide; (ii) a polynucleotide encoding a WT1 polypeptide; or (iii) an antigen presenting cell that expresses a WT1 polypeptide, wherein the biological sample comprises CD4+ and/or CD8+ T cells and is obtained from a patient prior to a therapy or immunization, and wherein the incubation is performed under conditions and for a time sufficient to allow specific activation, proliferation and/or lysis of T cells; (b) detecting an amount of activation, proliferation and/or lysis of the T cells; (c) repeating steps (a) and (b) using a second biological sample comprising CD4+ and/or CD8+ T cells, wherein the second biological sample is obtained from the same patient following therapy or immunization; and (d) comparing the amount of activation, proliferation and/or lysis of T cells in the first and second biological samples, and therefrom monitoring the effectiveness of the therapy or immunization in the patient.

The present invention further provides methods for inhibiting the development of a malignant disease associated with WT1 expression in a patient,

10

15

20

25

comprising the steps of: (a) incubating CD4⁺ and/or CD8+ T cells isolated from a patient with one or more of: (i) a WT1 polypeptide; (ii) a polynucleotide encoding a WT1 polypeptide; or (iii) an antigen presenting cell that expresses a WT1 polypeptide, such that the T cells proliferate; and (b) administering to the patient an effective amount of the proliferated T cells, and therefrom inhibiting the development of a malignant disease in the patient. Within certain embodiments, the step of incubating the T cells may be repeated one or more times.

Within other aspects, the present invention provides methods for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising the steps of: (a) incubating CD4⁺ and/or CD8+ T cells isolated from a patient with one or more of: (i) a WT1 polypeptide; (ii) a polynucleotide encoding a WT1 polypeptide; or (iii) an antigen presenting cell that expresses a WT1 polypeptide, such that the T cells proliferate; (b) cloning one or more cells that proliferated; and (c) administering to the patient an effective amount of the cloned T cells.

Within other aspects, methods are provided for determining the presence or absence of a malignant disease associated with WT1 expression in a patient, comprising the steps of: (a) incubating CD4⁺ and/or CD8+ T cells isolated from a patient with one or more of: (i) a WT1 polypeptide; (ii) a polynucleotide encoding a WT1 polypeptide; or (iii) an antigen presenting cell that expresses a WT1 polypeptide; and (b) detecting the presence or absence of specific activation of the T cells, therefrom determining the presence or absence of a malignant disease associated with WT1 expression. Within certain embodiments, the step of detecting comprises detecting the presence or absence of proliferation of the T cells.

Within further aspects, the present invention provides methods for determining the presence or absence of a malignant disease associated with WT1 expression in a patient, comprising the steps of: (a) incubating a biological sample obtained from a patient with one or more of: (i) a WT1 polypeptide; (ii) a polynucleotide encoding a WT1 polypeptide; or (iii) an antigen presenting cell that expresses a WT1

15

20

25

polypeptide, wherein the incubation is performed under conditions and for a time sufficient to allow immunocomplexes to form; and (b) detecting immunocomplexes formed between the WT1 polypeptide and antibodies in the biological sample that specifically bind to the WT1 polypeptide; and therefrom determining the presence or absence of a malignant disease associated with WT1 expression.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a comparison of the mouse (MO) and human (HU) WT1 protein sequences (SEQ ID NOS: 320 and 319 respectively).

Figure 2 is a Western blot illustrating the detection of WT1 specific antibodies in patients with hematological malignancy (AML). Lane 1 shows molecular weight markers; lane 2 shows a positive control (WT1 positive human leukemia cell line immunoprecipitated with a WT1 specific antibody); lane 3 shows a negative control (WT1 positive cell line immunoprecipitated with mouse sera); and lane 4 shows a WT1 positive cell line immunoprecipitated with sera of a patient with AML. For lanes 2-4, the immunoprecipitate was separated by gel electrophoresis and probed with a WT1 specific antibody.

Figure 3 is a Western blot illustrating the detection of a WT1 specific antibody response in B6 mice immunized with TRAMP-C, a WT1 positive tumor cell line. Lanes 1, 3 and 5 show molecular weight markers, and lanes 2, 4 and 6 show a WT1 specific positive control (N180, Santa Cruz Biotechnology, polypeptide spanning 180 amino acids of the N-terminal region of the WT1 protein, migrating on the Western blot at 52 kD). The primary antibody used was WT180 in lane 2, sera of non-immunized B6 mice in lane 4 and sera of the immunized B6 mice in lane 6.

10

15

20

25

Figure 4 is a Western blot illustrating the detection of WT1 specific antibodies in mice immunized with representative WT1 peptides. Lanes 1, 3 and 5 show molecular weight markers and lanes 2, 4 and 6 show a WT1 specific positive control (N180, Santa Cruz Biotechnology, polypeptide spanning 180 amino acids of the N-terminal region of the WT1 protein, migrating on the Western blot at 52 kD). The primary antibody used was WT180 in lane 2, sera of non-immunized B6 mice in lane 4 and sera of the immunized B6 mice in lane 6.

Figures 5A to 5C are graphs illustrating the stimulation of proliferative T cell responses in mice immunized with representative WT1 peptides. Thymidine incorporation assays were performed using one T cell line and two different clones, as indicated, and results were expressed as cpm. Controls indicated on the x axis were no antigen (No Ag) and B6/media; antigens used were p6-22 human (p1), p117-139 (p2) or p244-262 human (p3).

Figure 6A and 6B are histograms illustrating the stimulation of proliferative T cell responses in mice immunized with representative WT1 peptides. Three weeks after the third immunization, spleen cells of mice that had been inoculated with Vaccine A or Vaccine B were cultured with medium alone (medium) or spleen cells and medium (B6/no antigen), B6 spleen cells pulsed with the peptides p6-22 (p6), p117-139 (p117), p244-262 (p244) (Vaccine A; Figure 6A) or p287-301 (p287), p299-313 (p299), p421-435 (p421) (Vaccine B; Figure 6B) and spleen cells pulsed with an irrelevant control peptide (irrelevant peptide) at 25ug/ml and were assayed after 96hr for proliferation by (³H) thymidine incorporation. Bars represent the stimulation index (SI), which is calculated as the mean of the experimental wells divided by the mean of the control (B6 spleen cells with no antigen).

Figures 7A-7D are histograms illustrating the generation of proliferative T-cell lines and clones specific for p117-139 and p6-22. Following *in vivo* immunization, the initial three *in vitro* stimulations (IVS) were carried out using all three peptides of Vaccine A or B, respectively. Subsequent IVS were carried out as single peptide stimulations using

10

20

25

only the two relevant peptides p117-139 and p6-22. Clones were derived from both the p6-22 and p117-139 specific T cell lines, as indicated. T cells were cultured with medium alone (medium) or spleen cells and medium (B6/no antigen), B6 spleen cells pulsed with the peptides p6-22 (p6), p117-139 (p117) or an irrelevant control peptide (irrelevant peptide) at 25ug/ml and were assayed after 96hr for proliferation by (3H) thymidine incorporation. Bars represent the stimulation index (SI), which is calculated as the mean of the experimental wells divided by the mean of the control (B6 spleen cells with no antigen).

Figures 8A and 8B present the results of TSITES Analysis of human WT1 (SEQ ID NO:319) for peptides that have the potential to elicit Th responses. Regions indicated by "A" are AMPHI midpoints of blocks, "R" indicates residues matching the Rothbard/Taylor motif, "D" indicates residues matching the IAd motif, and 'd' indicates residues matching the IEd motif.

Figures 9A and 9B are graphs illustrating the elicitation of WT1 peptidespecific CTL in mice immunized with WT1 peptides. Figure 9A illustrates the lysis of 15 target cells by allogeneic cell lines and Figure 9B shows the lysis of peptide coated cell lines. In each case, the % lysis (as determined by standard chromium release assays) is shown at three indicated effector:target ratios. Results are provided for lymphoma cells (LSTRA and E10), as well as E10 + p235-243 (E10+P235). E10 cells are also referred to herein as EL-4 cells.

Figures 10A-10D are graphs illustrating the elicitation of WT1 specific CTL, which kill WT1 positive tumor cell lines but do not kill WT1 negative cell lines, following vaccination of B6 mice with WT1 peptide P117. Figure 10A illustrates that Tcells of non-immunized B6 mice do not kill WT1 positive tumor cell lines. Figure 10B illustrates the lysis of the target cells by allogeneic cell lines. Figures 10C and 10D demonstrate the lysis of WT1 positive tumor cell lines, as compared to WT1 negative cell lines in two different experiments. In addition, Figures 10C and 10D show the lysis of peptide-coated cell lines (WT1 negative cell line E10 coated with the relevant WT1 peptide

10

15

20

25

P117) In each case, the % lysis (as determined by standard chromium release assays) is shown at three indicated effector:target ratios. Results are provided for lymphoma cells (E10), prostate cancer cells (TRAMP-C), a transformed fibroblast cell line (BLK-SV40), as well as E10+p117.

Figures 11A and 11B are histograms illustrating the ability of representative peptide P117-139 specific CTL to lyse WT1 positive tumor cells. Three weeks after the third immunization, spleen cells of mice that had been inoculated with the peptides p235-243 or p117-139 were stimulated in vitro with the relevant peptide and tested for ability to lyse targets incubated with WT1 peptides as well as WT1 positive and negative tumor cells. The bars represent the mean % specific lysis in chromium release assays performed in triplicate with an E:T ratio of 25:1. Figure 11A shows the cytotoxic activity of the p235-243 specific T cell line against the WT1 negative cell line EL-4 (EL-4, WT1 negative); EL-4 pulsed with the relevant (used for immunization as well as for restimulation) peptide p235-243 (EL-4+p235); EL-4 pulsed with the irrelevant peptides p117-139 (EL-4+p117), p126-134 (EL-4+p126) or p130-138 (EL-4+p130) and the WT1 positive tumor cells BLK-SV40 (BLK-SV40, WT1 positive) and TRAMP-C (TRAMP-C, WT1 positive), as indicated. Figure 11B shows cytotoxic activity of the p117-139 specific T cell line against EL-4; EL-4 pulsed with the relevant peptide P117-139 (EL-4+p117) and EL-4 pulsed with the irrelevant peptides p123-131 (EL-4+p123), or p128-136 (EL-4+p128); BLK-SV40 and TRAMP-C, as indicated.

Figures 12A and 12B are histograms illustrating the specificity of lysis of WT1 positive tumor cells, as demonstrated by cold target inhibition. The bars represent the mean % specific lysis in chromium release assays performed in triplicate with an E:T ratio of 25:1. Figure 12A shows the cytotoxic activity of the p117-139 specific T cell line against the WT1 negative cell line EL-4 (EL-4, WT1 negative); the WT1 positive tumor cell line TRAMP-C (TRAMP-C, WT1 positive); TRAMP-C cells incubated with a ten-fold excess (compared to the hot target) of EL-4 cells pulsed with the relevant peptide p117-139 (TRAMP-C + p117 cold target) without ⁵¹Cr labeling and TRAMP-C cells incubated with

10

15

20

25

EL-4 pulsed with an irrelevant peptide without ⁵¹Cr labeling (TRAMP-C + irrelevant cold target), as indicated. Figure 12B shows the cytotoxic activity of the p117-139 specific T cell line against the WT1 negative cell line EL-4 (EL-4, WT1 negative); the WT1 positive tumor cell line BLK-SV40 (BLK-SV40, WT1 positive); BLK-SV40 cells incubated with the relevant cold target (BLK-SV40 + p117 cold target) and BLK-SV40 cells incubated with the irrelevant cold target (BLK-SV40 + irrelevant cold target), as indicated.

Figures 13A-13C are histograms depicting an evaluation of the 9mer CTL epitope within p117-139. The p117-139 tumor specific CTL line was tested against peptides within aa117-139 containing or lacking an appropriate H-2^b class I binding motif and following restimulation with p126-134 or p130-138. The bars represent the mean % specific lysis in chromium release assays performed in triplicate with an E:T ratio of 25:1. Figure 13A shows the cytotoxic activity of the p117-139 specific T cell line against the WT1 negative cell line EL-4 (EL-4, WT1 negative) and EL-4 cells pulsed with the peptides p117-139 (EL-4 + p117), p119-127 (EL-4 + p119), p120-128 (EL-4 + p120), p123-131 (EL-4 + p123), p126-134 (EL-4 + p126), p128-136 (EL-4 + p128), and p130-138 (EL-4 + p130). Figure 13B shows the cytotoxic activity of the CTL line after restimulation with p126-134 against the WT1 negative cell line EL-4, EL-4 cells pulsed with p117-139 (EL-4 + p117), p126-134 (EL-4 + p126) and the WT1 positive tumor cell line TRAMP-C. Figure 13C shows the cytotoxic activity of the CTL line after restimulation with p130-138 against EL-4, EL-4 cells pulsed with p117-139 (EL-4 + p117), p130-138 (EL-4 + p130) and the WT1 positive tumor cell line TRAMP-C.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the immunotherapy and diagnosis of malignant diseases. The compositions described herein may include WT1 polypeptides, WT1 polypucleotides, antigen-presenting cells (APC, e.g., dendritic cells) that express a WT1 polypeptide, agents such as antibodies that bind to a WT1 polypeptide and/or immune system cells (e.g., T

10

15

20

25

cells) specific for WT1. WT1 Polypeptides of the present invention generally comprise at least a portion of a Wilms Tumor gene product (WT1) or a variant thereof. Nucleic acid sequences of the subject invention generally comprise a DNA or RNA sequence that encodes all or a portion of such a polypeptide, or that is complementary to such a sequence. Antibodies are generally immune system proteins, or antigen-binding fragments thereof, that are capable of binding to a portion of a WT1 polypeptide. T cells that may be employed within such compositions are generally T cells (e.g., CD4⁺ and/or CD8⁺) that are specific for a WT1 polypeptide. Certain methods described herein further employ antigen-presenting cells that express a WT1 polypeptide as provided herein.

The present invention is based on the discovery that an immune response raised against a Wilms Tumor (WT) gene product (e.g., WT1) can provide prophylactic and/or therapeutic benefit for patients afflicted with malignant diseases characterized by increased WT1 gene expression. Such diseases include, but are not limited to, leukemias (e.g., acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and childhood ALL), as well as many cancers such as lung, breast, thyroid and gastrointestinal cancers and melanomas. The WT1 gene was originally identified and isolated on the basis of a cytogenetic deletion at chromosome 11p13 in patients with Wilms' tumor (see Call et al., U.S. Patent No. 5,350,840). The gene consists of 10 exons and encodes a zinc finger transcription factor, and sequences of mouse and human WT1 proteins are provided in Figure 1 and SEQ ID NOs: 319 and 320.

WT1 POLYPEPTIDES

Within the context of the present invention, a WT1 polypeptide is a polypeptide that comprises at least an immunogenic portion of a native WT1 (i.e., a WT1 protein expressed by an organism that is not genetically modified), or a variant thereof, as described herein. A WT1 polypeptide may be of any length, provided that it comprises at least an immunogenic portion of a native protein or a variant thereof. In other words, a WT1 polypeptide may be an oligopeptide (i.e., consisting of a relatively small number of

10

15

20

25

amino acid residues, such as 8-10 residues, joined by peptide bonds), a full length WT1 protein (e.g., present within a human or non-human animal, such as a mouse) or a polypeptide of intermediate size. Within certain embodiments, the use of WT1 polypeptides that contain a small number of consecutive amino acid residues of a native WT1 polypeptide is preferred. Such polypeptides are preferred for certain uses in which the generation of a T cell response is desired. For example, such a WT1 polypeptide may contain less than 23, preferably no more than 18, and more preferably no more than 15 consecutive amino acid residues, of a native WT1 polypeptide. Polypeptides comprising nine consecutive amino acid residues of a native WT1 polypeptide are generally suitable for such purposes. Additional sequences derived from the native protein and/or heterologous sequences may be present within any WT1 polypeptide, and such sequences may (but need not) possess further immunogenic or antigenic properties. Polypeptides as provided herein may further be associated (covalently or noncovalently) with other polypeptide or non-polypeptide compounds.

An "immunogenic portion," as used herein is a portion of a polypeptide that is recognized (i.e., specifically bound) by a B-cell and/or T-cell surface antigen receptor. Certain preferred immunogenic portions bind to an MHC class I or class II molecule. As used herein, an immunogenic portion is said to "bind to" an MHC class I or class II molecule if such binding is detectable using any assay known in the art. For example, the ability of a polypeptide to bind to MHC class I may be evaluated indirectly by monitoring the ability to promote incorporation of ¹²⁵I labeled β2-microglobulin (β2m) into MHC class I/β2m/peptide heterotrimeric complexes (see Parker et al., J. Immunol. 152:163, 1994). Alternatively, functional peptide competition assays that are known in the art may be employed. Certain immunogenic portions have one or more of the sequences recited within one or more of Tables II - XIV. Representative immunogenic portions include, but are not limited to, RDLNALLPAVPSLGGGG (human WT1 residues 6-22; SEQ ID NO:1), PSQASSGQARMFPNAPYLPSCLE (human and mouse WT1 residues 117-139; SEQ ID NOs: 2 and 3 respectively), GATLKGVAAGSSSSVKWTE (human WT1 residues 244-

15

20

25

262; SEQ ID NO:4), GATLKGVAA (human WT1 residues 244-252; SEQ ID NO:88), CMTWNOMNL (human and mouse WT1 residues 235-243; SEQ ID NOs: 49 and 258 respectively), SCLESQPTI (mouse WT1 residues 136-144; SEQ ID NO:296), SCLESOPAI (human WT1 residues 136-144; SEQ ID NO:198), NLYOMTSQL (human and mouse WT1 residues 225-233; SEQ ID NOs: 147 and 284 respectively); ALLPAVSSL (mouse WT1 residues 10-18; SEO ID NO:255); or RMFPNAPYL (human and mouse WT1 residues 126-134; SEQ ID NOs: 185 and 293 respectively). Further immunogenic portions are provided herein, and others may generally be identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Representative techniques for identifying immunogenic portions include screening polypeptides for the ability to react with antigenspecific antisera and/or T-cell lines or clones. An immunogenic portion of a native WT1 polypeptide is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full length WT1 (e.g., in an ELISA and/or T-cell reactivity assay). In other words, an immunogenic portion may react within such assays at a level that is similar to or greater than the reactivity of the full length polypeptide. Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.

Alternatively, immunogenic portions may be identified using computer analysis, such as the Tsites program (see Rothbard and Taylor, EMBO J. 7:93-100, 1988; Deavin et al., Mol. Immunol. 33:145-155, 1996), which searches for peptide motifs that have the potential to elicit Th responses. CTL peptides with motifs appropriate for binding to murine and human class I or class II MHC may be identified according to BIMAS (Parker et al., J. Immunol. 152:163, 1994) and other HLA peptide binding prediction analyses. To confirm immunogenicity, a peptide may be tested using an HLA A2 transgenic mouse model and/or an in vitro stimulation assay using dendritic cells, fibroblasts or peripheral blood cells.

15

20

25

As noted above, a composition may comprise a variant of a native WT1 protein. A polypeptide "variant," as used herein, is a polypeptide that differs from a native polypeptide in one or more substitutions, deletions, additions and/or insertions, such that the immunogenicity of the polypeptide is retained (i.e., the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished relative to the native polypeptide). In other words, the ability of a variant to react with antigen-specific antisera and/or T-cell lines or clones may be enhanced or unchanged, relative to the native polypeptide, or may be diminished by less than 50%, and preferably less than 20%, relative to the native polypeptide. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antisera and/or T-cells as described herein. It has been found, within the context of the present invention, that a relatively small number of substitutions (e.g., 1 to 3) within an immunogenic portion of a WT1 polypeptide may serve to enhance the ability of the polypeptide to elicit an immune response. Suitable substitutions may generally be identified by using computer programs, as described above, and the effect confirmed based on the reactivity of the modified polypeptide with antisera and/or T-cells Accordingly, within certain preferred embodiments, a WT1 as described herein. polypeptide comprises a variant in which 1 to 3 amino acid resides within an immunogenic portion are substituted such that the ability to react with antigen-specific antisera and/or Tcell lines or clones is statistically greater than that for the unmodified polypeptide. Such substitutions are preferably located within an MHC binding site of the polypeptide, which may be identified as described above. Preferred substitutions allow increased binding to MHC class I or class II molecules.

Certain variants contain conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity in

10

15

20

25

polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.

As noted above, WT1 polypeptides may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. A polypeptide may also, or alternatively, be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

Within certain specific embodiments, a polypeptide may be a fusion protein that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired

10

15

20

25

intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the protein.

In certain embodiments, the present invention provides fusion proteins comprising a polypeptide disclosed herein together with at least one of the sequences disclosed in U.S. Patent Application No. 09/352,616, filed July 13, 1999, which is incorporated herein in its entirety. Preferably one or more of the following known prostate antigens may be employed in a fusion protein with WT1: prostate specific antigen (PSA); prostatic acid phosphatase (PAP); and prostate specific membrane antigen (PSMA). The protein sequences for PSMA, PAP and PSA are provided in SEQ ID NO: 327-329, respectively. In certain embodiments, the fusion proteins of the present invention comprise WT1, PSA, PAP and/or PSMA in combination with one or more of the following the inventive antigens: P501S (amino acid sequence provided in SEQ ID NO: 333); P703P (amino acid sequences provided in SEQ ID NO: 330-332); P704P (cDNA sequence provided in SEQ ID NO: 334); P712P (cDNA sequence provided in SEQ ID NO: 335); P775P (cDNA sequence provided in SEQ ID NO: 336); P776P (cDNA sequence provided in SEQ ID NO: 337); P790P (cDNA sequence provided in SEQ ID NO: 338). P711P (fulllength cDNA sequence provided in SEQ ID NO: 339, with the corresponding amino acid sequence provided in SEQ ID NO: 340); P710P (cDNA sequence provided in SEQ ID NO: 341-345); P714P (cDNA sequence provided in SEQ ID NO: 346); P510S (cDNA sequence provided in SEQ ID NO: 347); P774P (cDNA sequence provided in SEQ ID NO: 348); P705P (cDNA sequence provided in SEQ ID NO: 349, with the corresponding amino acid sequence provided in SEQ ID NO: 350); P503S (full-length cDNA sequence provided in SEQ ID NO: 351, with the corresponding amino acid sequence provided in SEO ID NO: 352); P713P (cDNA sequence provided in SEQ ID NO: 353); P780P (cDNA sequence provided in SEQ ID NO: 354); P788P (cDNA sequence provided in SEQ ID NO: 355);

The cDNA sequence of a fusion protein for WT1 and PSA is provided in SEQ ID NO: 356 with the corresponding amino acid provided in SEQ ID NO: 357. In preferred embodiments, the inventive fusion proteins comprise one of the following

10

15

20

25

combinations of antigens, or permutations: WT1 and PSA; WT1 and P703P; WT1 and P501S; WT1/P703P and P501S; WT1/PSA and P703P; WT1/PSA and P501S; WT1 and PAP; WT1/PAP and P703P; WT1/PAP and P501S; WT1 and PSMA; WT1/PSMA and P703P; WT1/PSMA and P501S; WT1/PSA/PAP and P703P; WT1/PSA/PAP and P501S; WT1/PSA/PAP and P501S; WT1/PSA/PSMA and P703P; WT1/PSA/PSMA and P501S; WT1/PSA/PSMA and P501S; WT1/PSA/PSMA and P501S; WT1/PSA/PAP/PSMA and P501S. One of skill in the art will appreciate that the order of polypeptides within a fusion protein can be altered without substantially changing the therapeutic, prophylactic or diagnostic properties of the fusion protein.

The fusion proteins described above are more immunogenic and will be effective in a greater number of prostate cancer patients than any of the individual components alone. The use of multiple antigens in the form of a fusion protein also lessens the likelihood of immunologic escape.

Fusion proteins may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion protein is expressed as a recombinant protein, allowing the production of increased levels, relative to a non-fused protein, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion protein that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary

10

15

20

25

structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., *Gene 40*:39-46, 1985; Murphy et al., *Proc. Natl. Acad. Sci. USA 83*:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided that comprise a polypeptide of the present invention together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (see, for example, Stoute et al. New Engl. J. Med., 336:86-91, 1997).

Within preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium Haemophilus influenza B (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in E. coli (thus

functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemaglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

5

10

15

20

25

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from Streptococcus pneumoniae, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; Gene 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see Biotechnology 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

WT1 polypeptides may be prepared using any of a variety of well known techniques. Recombinant polypeptides encoded by a WT1 polynucleotide as described herein may be readily prepared from the polynucleotide. In general, any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant WT1 polypeptides. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. The concentrate may then be applied to

10

15

20

25

a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide. Such techniques may be used to prepare native polypeptides or variants thereof. For example, polynucleotides that encode a variant of a native polypeptide may generally be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis, and sections of the DNA sequence may be removed to permit preparation of truncated polypeptides.

Certain portions and other variants may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, polypeptides having fewer than about 500 amino acids, preferably fewer than about 100 amino acids, and more preferably fewer than about 50 amino acids, may be synthesized. Polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Applied BioSystems, Inc. (Foster City, CA), and may be operated according to the manufacturer's instructions.

In general, polypeptides and polynucleotides as described herein are isolated. An "isolated" polypeptide or polynucleotide is one that is removed from its original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

Within further aspects, the present invention provides mimetics of WT1 polypeptides. Such mimetics may comprise amino acids linked to one or more amino acid mimetics (i.e., one or more amino acids within the WT1 protein may be replaced by an amino acid mimetic) or may be entirely nonpeptide mimetics. An amino acid mimetic is a

compound that is conformationally similar to an amino acid such that it can be substituted for an amino acid within a WT1 polypeptide without substantially diminishing the ability to react with antigen-specific antisera and/or T cell lines or clones. A nonpeptide mimetic is a compound that does not contain amino acids, and that has an overall conformation that is similar to a WT1 polypeptide such that the ability of the mimetic to react with WT1-specific antisera and/or T cell lines or clones is not substantially diminished relative to the ability of a WT1 polypeptide. Such mimetics may be designed based on standard techniques (e.g., nuclear magnetic resonance and computational techniques) that evaluate the three dimensional structure of a peptide sequence. Mimetics may be designed where one or more of the side chain functionalities of the WT1 polypeptide are replaced by groups that do not necessarily have the same size or volume, but have similar chemical and/or physical properties which produce similar biological responses. It should be understood that, within embodiments described herein, a mimetic may be substituted for a WT1 polypeptide.

15

20

25

5

10

WT1 POLYNUCLEOTIDES

Any polynucleotide that encodes a WT1 polypeptide as described herein is a WT1 polynucleotide encompassed by the present invention. Such polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

WT1 polynucleotides may encode a native WT1 protein, or may encode a variant of WT1 as described herein. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the immunogenicity of the encoded polypeptide is not diminished, relative to a native WT1 protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein. Preferred variants contain nucleotide substitutions, deletions, insertions and/or additions at

no more than 20%, preferably at no more than 10%, of the nucleotide positions that encode an immunogenic portion of a native WT1 sequence. Certain variants are substantially homologous to a native gene, or a portion thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding a WT1 polypeptide (or a complementary sequence). Suitable moderately stringent conditions include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5 X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS). Such hybridizing DNA sequences are also within the scope of this invention.

10

5

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a WT1 polypeptide. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention.

15

20

25

Once an immunogenic portion of WT1 is identified, as described above, a WT1 polynucleotide may be prepared using any of a variety of techniques. For example, a WT1 polynucleotide may be amplified from cDNA prepared from cells that express WT1. Such polynucleotides may be amplified via polymerase chain reaction (PCR). For this approach, sequence-specific primers may be designed based on the sequence of the immunogenic portion and may be purchased or synthesized. For example, suitable primers for PCR amplification of a human WT1 gene include: first step - P118: 1434-1414: 5' GAG AGT CAG ACT TGA AAG CAGT 3' (SEQ ID NO:5) and P135: 5' CTG AGC CTC AGC AAA TGG GC 3' (SEQ ID NO:6); second step - P136: 5' GAG CAT GCA TGG GCT CCG ACG TGC GGG 3' (SEQ ID NO:7) and P137: 5' GGG GTA CCC ACT GAA CGG TCC CCG A 3' (SEQ ID NO:8). Primers for PCR amplification of a mouse WT1 gene include: first step - P138: 5' TCC GAG CCG CAC CTC ATG 3' (SEQ ID NO:9) and P139: 5' GCC TGG GAT GCT GGA CTG 3' (SEQ ID NO:10), second step -

10

15

20

25

P140: 5' GAG CAT GCG ATG GGT TCC GAC GTG CGG 3' (SEQ ID NO:11) and P141: 5' GGG GTA CCT CAA AGC GCC ACG TGG AGT TT 3' (SEQ ID NO:12).

An amplified portion may then be used to isolate a full length gene from a human genomic DNA library or from a suitable cDNA library, using well known techniques. Alternatively, a full length gene can be constructed from multiple PCR fragments. WT1 polynucleotides may also be prepared by synthesizing oligonucleotide components, and ligating components together to generate the complete polynucleotide.

WT1 polynucleotides may also be synthesized by any method known in the art, including chemical synthesis (e.g., solid phase phosphoramidite chemical synthesis). Modifications in a polynucleotide sequence may also be introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis (see Adelman et al., DNA 2:183, 1983). Alternatively, RNA molecules may be generated by in vitro or in vivo transcription of DNA sequences encoding a WT1 polypeptide, provided that the DNA is incorporated into a vector with a suitable RNA polymerase promoter (such as T7 or SP6). Certain portions may be used to prepare an encoded polypeptide, as described herein. In addition, or alternatively, a portion may be administered to a patient such that the encoded polypeptide is generated in vivo (e.g., by transfecting antigen-presenting cells such as dendritic cells with, a cDNA construct encoding a WT1 polypeptide, and administering the transfected cells to the patient).

Polynucleotides that encode a WT1 polypeptide may generally be used for production of the polypeptide, in vitro or in vivo. WT1 polynucleotides that are complementary to a coding sequence (i.e., antisense polynucleotides) may also be used as a probe or to inhibit WT1 expression. cDNA constructs that can be transcribed into antisense RNA may also be introduced into cells of tissues to facilitate the production of antisense RNA.

Any polynucleotide may be further modified to increase stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than

10

15

20

25

phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Nucleotide sequences as described herein may be joined to a variety of other nucleotide sequences using established recombinant DNA techniques. For example, a polynucleotide may be cloned into any of a variety of cloning vectors, including plasmids, phagemids, lambda phage derivatives and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors. In general, a vector will contain an origin of replication functional in at least one organism, convenient restriction endonuclease sites and one or more selectable markers. Other elements will depend upon the desired use, and will be apparent to those of ordinary skill in the art.

Within certain embodiments, polynucleotides may be formulated so as to permit entry into a cell of a mammal, and expression therein. Such formulations are particularly useful for therapeutic purposes, as described below. Those of ordinary skill in the art will appreciate that there are many ways to achieve expression of a polynucleotide in a target cell, and any suitable method may be employed. For example, a polynucleotide may be incorporated into a viral vector such as, but not limited to, adenovirus, adeno-associated virus, retrovirus, or vaccinia or other pox virus (e.g., avian pox virus). Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a targeting moiety, such as a gene that encodes a ligand for a receptor on a specific target cell, to render the vector target specific. Targeting may also be accomplished using an antibody, by methods known to those of ordinary skill in the art. cDNA constructs within such a vector may be used, for example, to transfect human or animal cell lines for use in establishing WT1 positive tumor models which may be used to perform tumor protection

15

20

25

and adoptive immunotherapy experiments to demonstrate tumor or leukemia-growth inhibition or lysis of such cells.

Other therapeutic formulations for polynucleotides include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial membrane vesicle). The preparation and use of such systems is well known in the art.

10 Antibodies and Fragments Thereof

The present invention further provides binding agents, such as antibodies and antigen-binding fragments thereof, that specifically bind to a WT1 polypeptide. As used herein, an agent is said to "specifically bind" to a WT1 polypeptide if it reacts at a detectable level (within, for example, an ELISA) with a WT1 polypeptide, and does not react detectably with unrelated proteins under similar conditions. As used herein, "binding" refers to a noncovalent association between two separate molecules such that a "complex" is formed. The ability to bind may be evaluated by, for example, determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to "bind," in the context of the present invention, when the binding constant for complex formation exceeds about 10³ L/mol. The binding constant maybe determined using methods well known in the art.

Any agent that satisfies the above requirements may be a binding agent. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Certain antibodies are commercially available from, for example, Santa Cruz Biotechnology (Santa Cruz, CA). Alternatively, antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In

10

15

20

25

general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

10

15

20

25

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from rabbit serum by affinity chromatography on Protein A bead columns (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988) and digested by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by affinity chromatography on protein A bead columns.

Monoclonal antibodies and fragments thereof may be coupled to one or more therapeutic agents. Suitable agents in this regard include radioactive tracers and chemotherapeutic agents, which may be used, for example, to purge autologous bone marrow *in vitro*). Representative therapeutic agents include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein. For diagnostic purposes, coupling of radioactive agents may be used to facilitate tracing of metastases or to determine the location of WT1-positive tumors.

A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct

10

15

20

25

reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, e.g., U.S. Patent, No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Patent No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (e.g., U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Patent No. 4,569,789, to Blattler et al.).

10

15

20

25

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used. A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating For example, U.S. Patent No. 4,735,792 discloses representative compounds. radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

Also provided herein are anti-idiotypic antibodies that mimic an immunogenic portion of WT1. Such antibodies may be raised against an antibody, or antigen-binding fragment thereof, that specifically binds to an immunogenic portion of WT1, using well known techniques. Anti-idiotypic antibodies that mimic an immunogenic

portion of WT1 are those antibodies that bind to an antibody, or antigen-binding fragment thereof, that specifically binds to an immunogenic portion of WT1, as described herein.

T CELLS

5

10

15

20

25

Immunotherapeutic compositions may also, or alternatively, comprise T cells specific for WT1. Such cells may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be present within (or isolated from) bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood of a mammal, such as a patient, using a commercially available cell separation system, such as the CEPRATETM system, available from CellPro Inc., Bothell WA (see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human animals, cell lines or cultures.

T cells may be stimulated with WT1 polypeptide, polynucleotide encoding a WT1 polypeptide and/or an antigen presenting cell (APC) that expresses a WT1 polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the WT1 polypeptide. Preferably, a WT1 polypeptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of antigen-specific T cells. Briefly, T cells, which may be isolated from a patient or a related or unrelated donor by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes), are incubated with WT1 polypeptide. For example, T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with WT1 polypeptide (e.g., 5 to 25 μg/ml) or cells synthesizing a comparable amount of WT1 polypeptide. It may be desirable to incubate a separate aliquot of a T cell sample in the absence of WT1 polypeptide to serve as a control.

T cells are considered to be specific for a WT1 polypeptide if the T cells kill target cells coated with a WT1 polypeptide or expressing a gene encoding such a polypeptide. T cell specificity may be evaluated using any of a variety of standard

10

15

20

25

techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., Cancer Res. 54:1065-1070, 1994. Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Other ways to detect T cell proliferation include measuring increases in interleukin-2 (IL-2) production, Ca²⁺ flux, or dye uptake, such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium. Alternatively, synthesis of lymphokines (such as interferon-gamma) can be measured or the relative number of T cells that can respond to a WT1 polypeptide may be quantified. Contact with a WT1 polypeptide (200 ng/ml - 100 μg/ml, preferably 100 ng/ml - 25 μg/ml) for 3 - 7 days should result in at least a two fold increase in proliferation of the T cells and/or contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-y) is indicative of T cell activation (see Coligan et al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998). WT1 specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient or a related or unrelated donor and are administered to the patient following stimulation and expansion.

T cells that have been activated in response to a WT1 polypeptide, polynucleotide or WT1-expressing APC may be CD4⁺ and/or CD8⁺. Specific activation of CD4⁺ or CD8⁺ T cells may be detected in a variety of ways. Methods for detecting specific T cell activation include detecting the proliferation of T cells, the production of cytokines (e.g., lymphokines), or the generation of cytolytic activity (i.e., generation of cytotoxic T cells specific for WT1). For CD4⁺ T cells, a preferred method for detecting specific T cell activation is the detection of the proliferation of T cells. For CD8⁺ T cells, a

15

20

25

preferred method for detecting specific T cell activation is the detection of the generation of cytolytic activity.

For therapeutic purposes, CD4+ or CD8+ T cells that proliferate in response to the WT1 polypeptide, polynucleotide or APC can be expanded in number either in vitro or in vivo. Proliferation of such T cells in vitro may be accomplished in a variety of ways. For example, the T cells can be re-exposed to WT1 polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a WT1 polypeptide. The addition of stimulator cells is preferred where generating CD8+ T cell responses. T cells can be grown to large numbers in vitro with retention of specificity in response to intermittent restimulation with WT1 polypeptide. Briefly, for the primary in vitro stimulation (IVS), large numbers of lymphocytes (e.g., greater than 4 x 107) may be placed in flasks with media containing human serum. WT1 polypeptide (e.g., peptide at 10 µg/ml) may be added directly, along with tetanus toxoid (e.g., 5 µg/ml). The flasks may then be incubated (e.g., 37°C for 7 days). For a second IVS, T cells are then harvested and placed in new flasks with 2-3 x 10⁷ irradiated peripheral blood mononuclear cells. WT1 polypeptide (e.g., 10 µg/ml) is added directly. The flasks are incubated at 37°C for 7 days. On day 2 and day 4 after the second IVS, 2-5 units of interleukin-2 (IL-2) may be added. For a third IVS, the T cells may be placed in wells and stimulated with the individual's own EBV transformed B cells coated with the peptide. IL-2 may be added on days 2 and 4 of each cycle. As soon as the cells are shown to be specific cytotoxic T cells, they may be expanded using a 10 day stimulation cycle with higher IL-2 (20 units) on days 2, 4 and 6.

Alternatively, one or more T cells that proliferate in the presence of WT1 polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution. Responder T cells may be purified from the peripheral blood of sensitized patients by density gradient centrifugation and sheep red cell rosetting and established in culture by stimulating with the nominal antigen in the presence of irradiated autologous filler cells. In order to generate CD4⁺ T cell lines, WT1

10

15

20

polypeptide is used as the antigenic stimulus and autologous peripheral blood lymphocytes (PBL) or lymphoblastoid cell lines (LCL) immortalized by infection with Epstein Barr virus are used as antigen presenting cells. In order to generate CD8⁺ T cell lines, autologous antigen-presenting cells transfected with an expression vector which produces WT1 polypeptide may be used as stimulator cells. Established T cell lines may be cloned 2-4 days following antigen stimulation by plating stimulated T cells at a frequency of 0.5 cells per well in 96-well flat-bottom plates with 1 x 10⁶ irradiated PBL or LCL cells and recombinant interleukin-2 (rIL2) (50 U/ml). Wells with established clonal growth may be identified at approximately 2-3 weeks after initial plating and restimulated with appropriate antigen in the presence of autologous antigen-presenting cells, then subsequently expanded by the addition of low doses of rIL2 (10 U/ml) 2-3 days following antigen stimulation. T cell clones may be maintained in 24-well plates by periodic restimulation with antigen and rIL2 approximately every two weeks.

Within certain embodiments, allogeneic T-cells may be primed (i.e., sensitized to WT1) in vivo and/or in vitro. Such priming may be achieved by contacting T cells with a WT1 polypeptide, a polynucleotide encoding such a polypeptide or a cell producing such a polypeptide under conditions and for a time sufficient to permit the priming of T cells. In general, T cells are considered to be primed if, for example, contact with a WT1 polypeptide results in proliferation and/or activation of the T cells, as measured by standard proliferation, chromium release and/or cytokine release assays as described herein. A stimulation index of more than two fold increase in proliferation or lysis, and more than three fold increase in the level of cytokine, compared to negative controls, indicates T-cell specificity. Cells primed in vitro may be employed, for example, within a bone marrow transplantation or as donor lymphocyte infusion.

25

PHARMACEUTICAL COMPOSITIONS AND VACCINES

Within certain aspects, polypeptides, polynucleotides, antibodies and/or T cells may be incorporated into pharmaceutical compositions or vaccines. Alternatively, a

10

15

20

25

pharmaceutical composition may comprise an antigen-presenting cell (e.g., a dendritic cell) transfected with a WTl polynucleotide such that the antigen presenting cell expresses a WTl polypeptide. Pharmaceutical compositions comprise one or more such compounds or cells and a physiologically acceptable carrier or excipient. Certain vaccines may comprise one or more such compounds or cells and a non-specific immune response enhancer, such as an adjuvant or a liposome (into which the compound is incorporated). Pharmaceutical compositions and vaccines may additionally contain a delivery system, such as biodegradable microspheres which are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109. Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive.

Within certain embodiments, pharmaceutical compositions and vaccines are designed to elicit T cell responses specific for a WT1 polypeptide in a patient, such as a human. In general, T cell responses may be favored through the use of relatively short polypeptides (e.g., comprising less than 23 consecutive amino acid residues of a native WT1 polypeptide, preferably 4-16 consecutive residues, more preferably 8-16 consecutive residues and still more preferably 8-10 consecutive residues. Alternatively, or in addition, a vaccine may comprise a non-specific immune response enhancer that preferentially enhances a T cell response. In other words, the immune response enhancer may enhance the level of a T cell response to a WT1 polypeptide by an amount that is proportionally greater than the amount by which an antibody response is enhanced. For example, when compared to a standard oil based adjuvant, such as CFA, an immune response enhancer that preferentially enhances a T cell response may enhance a proliferative T cell response by at least two fold, a lytic response by at least 10%, and/or T cell activation by at least two fold compared to WT1-megative control cell lines, while not detectably enhancing an antibody response. The amount by which a T cell or antibody response to a WT1 polypeptide is enhanced may generally be determined using any representative technique known in the art, such as the techniques provided herein.

10

20

25

A pharmaceutical composition or vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems and mammalian expression systems. Appropriate nucleic acid expression systems contain the necessary DNA, cDNA or RNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a nonpathogenic (defective), replication competent virus. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in Ulmer et al., Science 259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

As noted above, a pharmaceutical composition or vaccine may comprise an antigen-presenting cell that expresses a WT1 polypeptide. For therapeutic purposes, as described herein, the antigen presenting cell is preferably an autologous dendritic cell. Such cells may be prepared and transfected using standard techniques, such as those described by Reeves et al., Cancer Res. 56:5672-5677, 1996; Tuting et al., J. Immunol. 160:1139-1147, 1998; and Nair et al., Nature Biotechnol. 16:364-369, 1998). Expression of a WT1 polypeptide on the surface of an antigen-presenting cell may be confirmed by in vitro stimulation and standard proliferation as well as chromium release assays, as described herein.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary

10

15

20

25

depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or intramuscular administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention. For certain topical applications, formulation as a cream or lotion, using well known components, is preferred.

Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.

Any of a variety of non-specific immune response enhancers, such as adjuvants, may be employed in the vaccines of this invention. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Suitable non-specific immune response enhancers include alum-based adjuvants (e.g., Alhydrogel, Rehydragel, aluminum phosphate, Algammulin, aluminum hydroxide); oil based adjuvants (Freund's adjuvant (FA), Specol, RIBI, TiterMax, Montanide ISA50 or Seppic MONTANIDE ISA 720; cytokines (e.g., GM-CSF or Flat3-ligand); microspheres; nonionic block copolymer-based adjuvants; dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants AS-1, AS-2

10

20

25

(Smith Kline Beecham); Ribi Adjuvant system based adjuvants; QS21 (Aquila); saponin based adjuvants (crude saponin, the saponin Quil A); muramyl dipeptide (MDP) based adjuvants such as SAF (Syntex adjuvant in its microfluidized form (SAF-m)); dimethyl-dioctadecyl ammonium bromide (DDA); human complement based adjuvants m. vaccae and derivatives; immune stimulating complex (iscom) based adjuvants; inactivated toxins; and attenuated infectious agents (such as M. tuberculosis).

As noted above, within certain embodiments, immune response enhancers are chosen for their ability to preferentially elicit or enhance a T cell response (e.g., CD4⁺ and/or CD8⁺) to a WT1 polypeptide. Such immune response enhancers are well known in the art, and include (but are not limited to) Montanide ISA50, Seppic MONTANIDE ISA 720, cytokines (e.g., GM-CSF, Flat3-ligand), microspheres, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1 (Smith Kline Beecham), AS-2 (Smith Kline Beecham), Ribi Adjuvant system based adjuvants, QS21 (Aquila), saponin based adjuvants (crude saponin, the saponin Quil A), Syntex adjuvant in its microfluidized form (SAF-m), MV, ddMV (Genesis), immune stimulating complex (iscom) based adjuvants and inactivated toxins.

The compositions and vaccines described herein may be administered as part of a sustained release formulation (i.e., a formulation such as a capsule or sponge that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide, antibody or cell dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

10

15

20

25

THERAPY OF MALIGNANT DISEASES

In further aspects of the present invention, the compositions and vaccines described herein may be used to inhibit the development of malignant diseases (e.g., progressive or metastatic diseases or diseases characterized by small tumor burden such as minimal residual disease). In general, such methods may be used to prevent, delay or treat a disease associated with WT1 expression. In other words, therapeutic methods provided herein may be used to treat an existing WT1-associated disease, or may be used to prevent or delay the onset of such a disease in a patient who is free of disease or who is afflicted with a disease that is not yet associated with WT1 expression.

As used herein, a disease is "associated with WT1 expression" if diseased cells (e.g., tumor cells) at some time during the course of the disease generate detectably higher levels of a WT1 polypeptide than normal cells of the same tissue. Association of WT1 expression with a malignant disease does not require that WT1 be present on a tumor. For example, overexpression of WT1 may be involved with initiation of a tumor, but the protein expression may subsequently be lost. Alternatively, a malignant disease that is not characterized by an increase in WT1 expression may, at a later time, progress to a disease that is characterized by increased WT1 expression. Accordingly, any malignant disease in which diseased cells formerly expressed, currently express or are expected to subsequently express increased levels of WT1 is considered to be "associated with WT1 expression."

Immunotherapy may be performed using any of a variety of techniques, in which compounds or cells provided herein function to remove WT1-expressing cells from a patient. Such removal may take place as a result of enhancing or inducing an immune response in a patient specific for WT1 or a cell expressing WT1. Alternatively, WT1-expressing cells may be removed ex vivo (e.g., by treatment of autologous bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood). Fractions of bone marrow or peripheral blood may be obtained using any standard technique in the art.

10

15

20

25

Within such methods, pharmaceutical compositions and vaccines may be administered to a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with a malignant disease. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the onset of a disease (i.e., prophylactically) or to treat a patient afflicted with a disease (e.g., to prevent or delay progression and/or metastasis of an existing disease). A patient afflicted with a disease may have a minimal residual disease (e.g., a low tumor burden in a leukemia patient in complete or partial remission or a cancer patient following reduction of the tumor burden after surgery radiotherapy and/or chemotherapy). Such a patient may be immunized to inhibit a relapse (i.e., prevent or delay the relapse, or decrease the severity of a relapse). Within certain preferred embodiments, the patient is afflicted with a leukemia (e.g., AML, CML, ALL or childhood ALL), a myelodysplastic syndrome (MDS) or a cancer (e.g., gastrointestinal, lung, thyroid or breast cancer or a melanoma), where the cancer or leukemia is WT1 positive (i.e., reacts detectably with an anti-WT1 antibody, as provided herein or expresses WT1 mRNA at a level detectable by RT-PCR, as described herein) or suffers from an autoimmune disease directed against WT1-expressing cells.

The compositions provided herein may be used alone or in combination with conventional therapeutic regimens such as surgery, irradiation, chemotherapy and/or bone marrow transplantation (autologous, syngeneic, allogeneic or unrelated). As discussed in greater detail below, binding agents and T cells as provided herein may be used for purging of autologous stem cells. Such purging may be beneficial prior to, for example, bone marrow transplantation or transfusion of blood or components thereof. Binding agents, T cells, antigen presenting cells (APC) and compositions provided herein may further be used for expanding and stimulating (or priming) autologous, allogeneic, syngeneic or unrelated WT1-specific T-cells *in vitro* and/or *in vivo*. Such WT1-specific T cells may be used, for example, within donor lymphocyte infusions.

Routes and frequency of administration, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In

10

15

20

general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. In some tumors, pharmaceutical compositions or vaccines may be administered locally (by, for example, rectocoloscopy, gastroscopy, videoendoscopy, angiography or other methods known in the art). Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an antitumor immune response that is at least 10-50% above the basal (i.e., untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells in vitro. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (e.g., more frequent complete or partial remissions, or longer disease-free and/or overall survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 100 µg to 5 mg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent complete or partial remissions, or longer disease-free and/or overall survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to WT1 generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after

In general, an appropriate dosage and treatment regimen provides the active

treatment.

10

20

25

er.

Within further aspects, methods for inhibiting the development of a malignant disease associated with WT1 expression involve the administration of autologous T cells that have been activated in response to a WT1 polypeptide or WT1-expressing APC, as described above. Such T cells may be CD4⁺ and/or CD8⁺, and may be proliferated as described above. The T cells may be administered to the individual in an amount effective to inhibit the development of a malignant disease. Typically, about 1×10^9 to 1×10^{11} T cells/M² are administered intravenously, intracavitary or in the bed of a resected tumor. It will be evident to those skilled in the art that the number of cells and the frequency of administration will be dependent upon the response of the patient.

Within certain embodiments, T cells may be stimulated prior to an autologous bone marrow transplantation. Such stimulation may take place *in vivo* or *in vitro*. For *in vitro* stimulation, bone marrow and/or peripheral blood (or a fraction of bone marrow or peripheral blood) obtained from a patient may be contacted with a WT1 polypeptide, a polynucleotide encoding a WT1 polypeptide and/or an APC that expresses a WT1 polypeptide under conditions and for a time sufficient to permit the stimulation of T cells as described above. Bone marrow, peripheral blood stem cells and/or WT1-specific T cells may then be administered to a patient using standard techniques.

Within related embodiments, T cells of a related or unrelated donor may be stimulated prior to a syngeneic or allogeneic (related or unrelated) bone marrow transplantation. Such stimulation may take place in vivo or in vitro. For in vitro stimulation, bone marrow and/or peripheral blood (or a fraction of bone marrow or peripheral blood) obtained from a related or unrelated donor may be contacted with a WT1 polypeptide, WT1 polypucleotide and/or APC that expresses a WT1 polypeptide under conditions and for a time sufficient to permit the stimulation of T cells as described above. Bone marrow, peripheral blood stem cells and/or WT1-specific T cells may then be administered to a patient using standard techniques.

Within other embodiments, WT1-specific T cells as described herein may be used to remove cells expressing WT1 from autologous bone marrow, peripheral blood or a

fraction of bone marrow or peripheral blood (e.g., CD34⁺ enriched peripheral blood (PB) prior to administration to a patient). Such methods may be performed by contacting bone marrow or PB with such T cells under conditions and for a time sufficient to permit the reduction of WT1 expressing cells to less than 10%, preferably less than 5% and more preferably less than 1%, of the total number of myeloid or lymphatic cells in the bone marrow or peripheral blood. The extent to which such cells have been removed may be readily determined by standard methods such as, for example, qualitative and quantitative PCR analysis, morphology, immunohistochemistry and FACS analysis. Bone marrow or PB (or a fraction thereof) may then be administered to a patient using standard techniques.

10

15

20

25

5

DIAGNOSTIC METHODS

The present invention further provides methods for detecting a malignant disease associated with WT1 expression, and for monitoring the effectiveness of an immunization or therapy for such a disease. Such methods are based on the discovery, within the present invention, that an immune response specific for WT1 protein can be detected in patients afflicted with such diseases, and that methods which enhance such immune responses may provide a preventive or therapeutic benefit.

To determine the presence or absence of a malignant disease associated with WT1 expression, a patient may be tested for the level of T cells specific for WT1. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with a WT1 polypeptide, a polynucleotide encoding a WT1 polypeptide and/or an APC that expresses a WT1 polypeptide, and the presence or absence of specific activation of the T cells is detected, as described herein. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with WT1 polypeptide (e.g., 5 - 25 μg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of WT1 polypeptide

to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a malignant disease associated with WT1 expression. Further correlation may be made, using methods well known in the art, between the level of proliferation and/or cytolytic activity and the predicted response to therapy. In particular, patients that display a higher antibody, proliferative and/or lytic response may be expected to show a greater response to therapy.

10

15

5

Within other methods, a biological sample obtained from a patient is tested for the level of antibody specific for WT1. The biological sample is incubated with a WT1 polypeptide, a polynucleotide encoding a WT1 polypeptide and/or an APC that expresses a WT1 polypeptide under conditions and for a time sufficient to allow immunocomplexes to form. Immunocomplexes formed between the WT1 polypeptide and antibodies in the biological sample that specifically bind to the WT1 polypeptide are then detected. A biological sample for use within such methods may be any sample obtained from a patient that would be expected to contain antibodies. Suitable biological samples include blood, sera, ascites, bone marrow, pleural effusion, and cerebrospinal fluid.

20

The biological sample is incubated with the WT1 polypeptide in a reaction mixture under conditions and for a time sufficient to permit immunocomplexes to form between the polypeptide and antibodies specific for WT1. For example, a biological sample and WT1 polypeptide may be incubated at 4°C for 24-48 hours.

25

Following the incubation, the reaction mixture is tested for the presence of immunocomplexes. Detection of immunocomplexes formed between the WT1 polypeptide and antibodies present in the biological sample may be accomplished by a variety of known techniques, such as radioimmunoassays (RIA) and enzyme linked immunosorbent assays (ELISA). Suitable assays are well known in the art and are amply described in the scientific and patent literature (e.g., Harlow and Lane, Antibodies: A Laboratory Manual,

10

15

20

25

Cold Spring Harbor Laboratory, 1988). Assays that may be used include, but are not limited to, the double monoclonal antibody sandwich immunoassay technique of David et al. (U.S. Patent 4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide et al., in Kirkham and Hunter, eds., *Radioimmunoassay Methods*, E. and S. Livingstone, Edinburgh, 1970); the "western blot" method of Gordon et al. (U.S. Patent 4,452,901); immunoprecipitation of labeled ligand (Brown et al., *J. Biol. Chem. 255*:4980-4983, 1980); enzyme-linked immunosorbent assays as described by, for example, Raines and Ross (*J. Biol. Chem. 257*:5154-5160, 1982); immunocytochemical techniques, including the use of fluorochromes (Brooks et al., *Clin. Exp. Immunol. 39*: 477, 1980); and neutralization of activity (Bowen-Pope et al., *Proc. Natl. Acad. Sci. USA 81*:2396-2400, 1984). Other immunoassays include, but are not limited to, those described in U.S. Patent Nos.: 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876.

For detection purposes, WT1 polypeptide may either be labeled or unlabeled. Unlabeled WT1 polypeptide may be used in agglutination assays or in combination with labeled detection reagents that bind to the immunocomplexes (e.g., anti-immunoglobulin, protein G, protein A or a lectin and secondary antibodies, or antigen-binding fragments thereof, capable of binding to the antibodies that specifically bind to the WT1 polypeptide). If the WT1 polypeptide is labeled, the reporter group may be any suitable reporter group known in the art, including radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

Within certain assays, unlabeled WT1 polypeptide is immobilized on a solid support. The solid support may be any material known to those of ordinary skill in the art to which the polypeptide may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The

10

15

20

25

polypeptide may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the WT1 polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of polypeptide ranging from about 10 ng to about 10 µg, and preferably about 100 ng to about 1 µg, is sufficient to immobilize an adequate amount of polypeptide.

Following immobilization, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin, Tween 20TM (Sigma Chemical Co., St. Louis, MO), heat-inactivated normal goat serum (NGS), or BLOTTO (buffered solution of nonfat dry milk which also contains a preservative, salts, and an antifoaming agent). The support is then incubated with a biological sample suspected of containing specific antibody. The sample can be applied neat, or, more often, it can be diluted, usually in a buffered solution which contains a small amount (0.1%-5.0% by weight) of protein, such as BSA, NGS, or BLOTTO. In general, an appropriate contact time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of antibody that specifically binds WT1 within a sample containing such an antibody. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound antibody. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of

10

15

20

25

binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. A detection reagent that binds to the immunocomplexes and that comprises a reporter group may then be added. The detection reagent is incubated with the immunocomplex for an amount of time sufficient to detect the bound antibody. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups (e.g., horseradish peroxidase, beta-galactosidase, alkaline phosphatase and glucose oxidase) may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products. Regardless of the specific method employed, a level of bound detection reagent that is at least two fold greater than background (i.e., the level observed for a biological sample obtained from a disease-free individual) indicates the presence of a malignant disease associated with WT1 expression.

In general, methods for monitoring the effectiveness of an immunization or therapy involve monitoring changes in the level of antibodies or T cells specific for WT1 in the patient. Methods in which antibody levels are monitored may comprise the steps of:

(a) incubating a first biological sample, obtained from a patient prior to a therapy or immunization, with a WT1 polypeptide, wherein the incubation is performed under conditions and for a time sufficient to allow immunocomplexes to form; (b) detecting immunocomplexes formed between the WT1 polypeptide and antibodies in the biological

10

15

20

25

sample that specifically bind to the WT1 polypeptide; (c) repeating steps (a) and (b) using a second biological sample taken from the patient following therapy or immunization; and (d) comparing the number of immunocomplexes detected in the first and second biological samples. Alternatively, a polynucleotide encoding a WT1 polypeptide, or an APC expressing a WT1 polypeptide may be employed in place of the WT1 polypeptide. Within such methods, immunocomplexes between the WT1 polypeptide encoded by the polynucleotide, or expressed by the APC, and antibodies in the biological sample are detected.

Methods in which T cell activation and/or the number of WT1 specific precursors are monitored may comprise the steps of: (a) incubating a first biological sample comprising CD4+ and/or CD8+ cells (e.g., bone marrow, peripheral blood or a fraction thereof), obtained from a patient prior to a therapy or immunization, with a WT1 polypeptide, wherein the incubation is performed under conditions and for a time sufficient to allow specific activation, proliferation and/or lysis of T cells; (b) detecting an amount of activation, proliferation and/or lysis of the T cells; (c) repeating steps (a) and (b) using a second biological sample comprising CD4+ and/or CD8+ T cells, and taken from the same patient following therapy or immunization; and (d) comparing the amount of activation, proliferation and/or lysis of T cells in the first and second biological samples. Alternatively, a polynucleotide encoding a WT1 polypeptide, or an APC expressing a WT1 polypeptide may be employed in place of the WT1 polypeptide.

A biological sample for use within such methods may be any sample obtained from a patient that would be expected to contain antibodies, CD4+ T cells and/or CD8+ T cells. Suitable biological samples include blood, sera, ascites, bone marrow, pleural effusion and cereprospinal fluid. A first biological sample may be obtained prior to initiation of therapy or immunization or part way through a therapy or vaccination regime. The second biological sample should be obtained in a similar manner, but at a time following additional therapy or immunization. The second biological sample may be obtained at the completion of, or part way through, therapy or immunization, provided that

at least a portion of therapy or immunization takes place between the isolation of the first and second biological samples.

Incubation and detection steps for both samples may generally be performed as described above. A statistically significant increase in the number of immunocomplexes in the second sample relative to the first sample reflects successful therapy or immunization.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 1

Identification of an Immune Response to WT1

in Patients with Hematological Malignancies

This Example illustrates the identification of an existent immune response in patients with a hematological malignancy.

To evaluate the presence of preexisting WT1 specific antibody responses in patients, sera of patients with AML, ALL, CML and severe aplastic anemia were analyzed using Western blot analysis. Sera were tested for the ability to immunoprecipitate WT1 from the human leukemic cell line K562 (American Type Culture Collection, Manassas, VA). In each case, immunoprecipitates were separated by gel electrophoresis, transferred to membrane and probed with the anti WT-1 antibody WT180 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). This Western blot analysis identified potential WT1 specific antibodies in patients with hematological malignancy. A representative Western blot showing the results for a patient with AML is shown in Figure 2. A 52 kD protein in the immunoprecipitate generated using the patient sera was recognized by the WT1 specific antibody. The 52 kD protein migrated at the same size as the positive control.

20

25

30

5

10

15

Example 2

Induction of Antibodies to WT1 in Mice Immunized with Cell Lines Expressing WT1

This Example illustrates the use of cells expressing WT1 to induce a WT1 specific antibody response in vivo.

Detection of existent antibodies to WT1 in patients with leukemia strongly implied that it is possible to immunize to WT1 protein to elicit immunity to WT1. To test whether immunity to WT1 can be generated by vaccination, mice were injected with TRAMP-C, a WT1 positive tumor cell line of B6 origin. Briefly, male B6 mice were

immunized with 5 x 10^6 TRAMP-C cells subcutaneously and boosted twice with 5 x 10^6 cells at three week intervals. Three weeks after the final immunization, sera were obtained and single cell suspensions of spleens were prepared in RPMI 1640 medium (GIBCO) with $25\mu M$ β -2-mercaptoethanol, 200 units of penicillin per ml, 10mM L-glutamine, and 10% fetal bovine serum.

Following immunization to TRAMP-C, a WT1 specific antibody response in the immunized animals was detectable. A representative Western blot is shown in Figure 3. These results show that immunization to WT1 protein can elicit an immune response to WT1 protein.

10

5

Example 3

Induction of Th and Antibody Responses in Mice Immunized with WT1 Peptides

This Example illustrates the ability of immunization with WT1 peptides to elicit an immune response specific for WT1.

Peptides suitable for eliciting Ab and proliferative T cell responses were identified according to the Tsites program (Rothbard and Taylor, *EMBO J.* 7:93-100, 1988; Deavin et al., *Mol. Immunol.* '33:145-155, 1996), which searches for peptide motifs that have the potential to elicit Th responses. Peptides shown in Table I were synthesized and sequenced.

<u>Table I</u> <u>WT1 Peptides</u>

25

Peptide	Sequence	Comments
Mouse: p6-22	RDLNALLPAVSSLGGGG (SEQ ID NO:13)	1 mismatch relative to human WT1 sequence
Human: p6-22	RDLNALLPAVPSLGGGG (SEQ ID NO:1)	
Human/mouse: p117-139	PSQASSGQARMFPNAPYLPSCLE (SEQ ID NOs: 2 and 3)	

20

25

Mouse: p244-262	GATLKGMAAGSSSSVKWTE	1 mismatch relative to
•	(SEQ ID NO:14)	human WT1 sequence
Human: p244-262	GATLKGVAAGSSSSVKWTE	
	(SEQ ID NO:4)	
Human/mouse:	RIHTHGVFRGIQDVR	
p287-301	(SEQ ID NOs: 15 and 16)	
Mouse: p299-313	VRRVSGVAPTLVRS	I mismatch relative to
	(SEQ ID NO:17)	human WT1 sequence
Human/mouse:	CQKKFARSDELVRHH	
p421-435	(SEQ ID NOs: 19 and 20)	

For immunization, peptides were grouped as follows:

5	Group A:	p6-22 human: 10.9mg in 1ml ($10\mu l = 100\mu g$) p117-139 human/mouse: 7.6mg in 1ml ($14\mu l = 100\mu g$) p244-262 human: 4.6.mg in 1ml ($22\mu l = 100\mu g$)
10	Group B:	p287-301 human/mouse: 7.2mg in 1ml ($14\mu l = 100\mu g$) mouse p299-313: 6.6.mg in 1ml ($15\mu l = 100\mu g$) p421-435 human/mouse: 3.3mg in 1ml ($30\mu l = 100\mu g$)
	Control:	(FBL peptide 100μg) + CFA/IFA

Control:

Group A contained peptides present within the amino terminus portion of WT1 (exon 1) and Group B contained peptides present within the carboxy terminus, which contains a four zinc finger region with sequence homology to other DNA-binding proteins. Within group B, p287-301 and p299-313 were derived from exon 7, zinc finger 1, and p421-435 was derived from exon 10, zinc finger IV.

(CD45 peptide 100µg) + CFA/IFA

B6 mice were immunized with a group of WT1 peptides or with a control peptide. Peptides were dissolved in 1ml sterile water for injection, and B6 mice were immunized 3 times at time intervals of three weeks. Adjuvants used were CFA/IFA, GM-CSF, and Montinide. The presence of antibodies specific for WT1 was then determined as

10

15

20

25

described in Examples 1 and 2, and proliferative T cell responses were evaluated using a standard thymidine incorporation assay, in which cells were cultured in the presence of antigen and proliferation was evaluated by measuring incorporated radioactivity (Chen et al., Cancer Res. 54:1065-1070, 1994). In particular, lymphocytes were cultured in 96-well plates at $2x10^5$ cells per well with $4x10^5$ irradiated (3000 rads) syngeneic spleen cells and the designated peptide.

Immunization of mice with the group of peptides designated as Group A elicited an antibody response to WT1 (Figure 4). No antibodies were detected following immunization to Vaccine B, which is consistent with a lack of helper T cell response from immunization with Vaccine B. P117-139 elicited proliferative T cell responses (Figures 5A-5C). The stimulation indices (SI) varied between 8 and 72. Other peptides (P6-22 and P299-313) also were shown to elicit proliferative T cell responses. Immunization with P6-22 resulted in a stimulation index (SI) of 2.3 and immunization with P299-313 resulted in a SI of 3.3. Positive controls included ConA stimulated T cells, as well as T cells stimulated with known antigens, such as CD45 and FBL, and allogeneic T cell lines (DeBruijn et al., Eur. J. Immunol. 21:2963-2970, 1991).

Figures 6A and 6B show the proliferative response observed for each of the three peptides within vaccine A (Figure 6A) and vaccine B (Figure 6B). Vaccine A elicited proliferative T cell responses to the immunizing peptides p6-22 and p117-139, with stimulation indices (SI) varying between 3 and 8 (bulk lines). No proliferative response to p244-262 was detected (Figure 6A).

Subsequent *in vitro* stimulations were carried out as single peptide stimulations using only p6-22 and p117-139. Stimulation of the Vaccine A specific T cell line with p117-139 resulted in proliferation to p117-139 with no response to p6-22 (Figure 7A). Clones derived from the line were specific for p117-139 (Figure 7B). By contrast, stimulation of the Vaccine A specific T cell line with p6-22 resulted in proliferation to p6-22 with no response to p117-139 (Figure 7C). Clones derived from the line were specific for p6-22 (Figure 7D).

These results show that vaccination with WT1 peptides can elicit antibody responses to WT1 protein and proliferative T cell responses to the immunizing peptides.

5

15

20

Example 4

Induction of CTL Responses in Mice Immunized with WT1 Peptides

This Example illustrates the ability of WT1 peptides to elicit CTL immunity.

Peptides (9-mers) with motifs appropriate for binding to class I MHC were identified using a BIMAS HLA peptide binding prediction analysis (Parker et al., J. Immunol. 152:163, 1994). Peptides identified within such analyses are shown in Tables II - XLIV. In each of these tables, the score reflects the theoretical binding affinity (half-time of dissociation) of the peptide to the MHC molecule indicated.

Peptides identified using the Tsites program (Rothbard and Taylor, *EMBO J.* 7:93-100, 1988; Deavin et al., *Mol. Immunol.* 33:145-155, 1996), which searches for peptide motifs that have the potential to elicit Th responses are further shown in Figures 8A and 8B, and Table XLV.

Table II

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A1

		Subsequence Residue	Score (Estimate of Half Time of Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	137	CLESQPAIR (SEQ ID NO:47)	18.000
2	80	GAEPHEEQC (SEQ ID NO:87)	9.000
3	40	FAPPGASAY (SEQ ID NO:74)	5.000
4	354	QCDFKDCER (SEQ ID NO:162)	5.000
5	2	GSDVRDLNA (SEQ	3.750

		ID NO:101)	
6	152	VTFDGTPSY (SEQ ID NO:244)	2.500
7	260	WTEGQSNHS (SEQ ID NO:247)	2.250
8	409	TSEKPFSCR (SEQ ID NO:232)	1.350
9	73	KQEPSWGGA (SEQ ID NO:125)	1.350
10	386	KTCQRKFSR (SEQ ID NO:128)	1.250
11	37	VLDFAPPGA (SEQ ID NO:241)	1.000
12	325	CAYPGCNKR (SEQ ID NO:44)	1.000
13	232	QLECMTWNQ (SEQ ID NO:167)	0.900
14	272	ESDNHTTPI (SEQ ID NO:71)	0.750
15	366	RSDQLKRHQ (SEQ ID NO:193)	0.750
16	222	SSDNLYQMT (SEQ ID NO:217)	0.750
17	427	RSDELVRHH (SEQ ID NO:191)	0.750
18	394	RSDHLKTHT (SEQ ID NO:192)	0.750
19	317	TSEKRPFMC (SEQ ID NO:233)	0.675
20	213	QALLLRTPY (SEQ ID NO:160)	0.500

Table III Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA A 0201

Rank I	Start Position	Subsequence Residue Listing RMFPNAPYL (SEO	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
	120	RMFPNAPYL (SEQ	313.968

	187 10 242 225 292	ID NO:185) SLGEQQYSV (SEQ ID NO:214) ALLPAVPSL (SEQ ID NO:34) NLGATLKGV (SEQ ID NO:146) NLYQMTSQL (SEQ ID NO:147)	285.163 181.794 159.970
3 . 4	10 242 225	ID NO:214) ALLPAVPSL (SEQ ID NO:34) NLGATLKGV (SEQ ID NO:146) NLYQMTSQL (SEQ	181.794
. 4	242 225	ALLPAVPSL (SEQ ID NO:34) NLGATLKGV (SEQ ID NO:146) NLYQMTSQL (SEQ	159.970
. 4	242 225	NO:34) NLGATLKGV (SEQ ID NO:146) NLYQMTSQL (SEQ	159.970
	225	NLGATLKGV (SEQ ID NO:146) NLYQMTSQL (SEQ	
	225	ID NO:146) NLYQMTSQL (SEQ	
5		NLYQMTSQL (SEQ	
5			40.040
	292	1 ID NO-147) 1	68.360
	292		
6	214	GVFRGIQDV (SEQ	51.790
		ID NO:103)	
7	191	QQYSVPPPV (SEQ	22.566
l		ID NO:171)	
8	280	ILCGAQYRI (SEQ ID	17.736
		NO:116)	
9	235	CMTWNQMNL (SEQ	15.428
İ		ID NO:49)	
10	441	NMTKLQLAL (SEQ	15.428
		ID NO:149)	_ ·
11	7	DLNALLPAV (SEQ	11.998
		ID NO:58)	•
12	227	YQMTSQLEC (SEQ	8.573
		ID NO:251)	
13	239	NQMNLGATL (SEQ	8.014
		ID NO:151)	
14	309	TLVRSASET (SEQ ID	7.452
		NO:226)	
15	408	KTSEKPFSC (SEQ ID	5.743
		NO:129)	
16	340	LQMHSRKHT (SEQ	4.752
		ID NO:139)	
17	228	QMTSQLECM (SEQ	4.044
		ID NO:169)	
18	93	TVHFSGQFT (SEQ ID	3.586
	-	NO:235)	
19	37	VLDFAPPGA (SEQ	3.378
-		ID NO:241)	
20	86	EQCLSAFTV (SEQ ID	3.068
		NO:69)	

Table IV

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A 0205

			Score (Estimate of Half Time of
		Subsequence Residue	
Dank	Camed Denisian	_	Disassociation of a Molecule Containing
Rank	Start Position	Listing	This Subsequence)
1	10	ALLPAVPSL (SEQ ID	42.000
		NO:34)	
2	292	GVFRGIQDV (SEQ ID	24.000
		NO:103)	
3	126	RMFPNAPYL (SEQ ID	21.000
		NO:185)	
4	225	NLYQMTSQL (SEQ	21.000
		ID NO:147)	
5	239	NQMNLGATL (SEQ	16.800
		ID NO:151)	
6	302	RVPGVAPTL (SEQ ID	14.000
		NO:195)	
7	441	NMTKLQLAL (SEQ	7.000
,		ID NO:149)	
8	235	CMTWNQMNL (SEQ	7.000
	255	ID NO:49)	7.000
9	187	SLGEQQYSV (SEQ ID	6.000
		NO:214)	3.000
10	191	QQYSVPPPV (SEQ ID	4.800
		NO:171)	1.000
11	340	LQMHSRKHT (SEQ	4.080
**	310	ID NO:139)	4.000
12	242	NLGATLKGV (SEQ	4,000
	212	ID NO:146)	4.000
13	227	YQMTSQLEC (SEQ ID	3.600
1.5	221	NO:251)	3.000
14	194	SVPPPVYGC (SEQ ID	2.000
14	154	, , ,	2.000
16	02	NO:218)	2 000
15	93	TVHFSGQFT (SEQ ID	2.000
		NO:235)	
16	280	ILCGAQYRI (SEQ ID	1.700
		NO:116)	
17	98	GQFTGTAGA (SEQ ID	1.200
		NO:99)	

18	309	TLVRSASET (SEQ ID NO:226)	1.000
19	81	AEPHEEQCL (SEQ ID NO:30)	0.980
20	· 73	KQEPSWGGA (SEQ ID NO:125)	0.960

Table V

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A24

		т	C CITACT: C
	-		Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	302	RVPGVAPTL (SEQ	16.800
		ID NO:195)	
2	218	RTPYSSDNL (SEQ ID	12.000
		NO:194)	
3	356	DFKDCERRF (SEQ	12.000
		ID NO:55)	
4	126	RMFPNAPYL (SEQ	9.600
		ID NO:185)	
5	326	AYPGCNKRY (SEQ	7.500
		ID NO:42)	
6	270	GYESDNHT (SEQ ID	7.500
		NO:106)T	
7	239.	NQMNLGATL (SEQ	7.200
		ID NO:151)	
8	10	ALLPAVPSL (SEQ ID	7.200
		NO:34)	
9	130	NAPYLPSCL (SEQ ID	7.200
,		NO:144)	
10	329	GCNKRYFKL (SEQ	6.600
		ID NO:90)	
11	417	RWPSCQKKF (SEQ	6.600
		ID NO:196)	
12	47	AYGSLGGPA (SEQ	6.000
		ID NO:41)	
13	180	DPMGQQGSL (SEQ	6.000
		ID NO:59)	

14	4 .	DVRDLNALL (SEQ ID NO:62)	5.760
15	285	QYRIHTHGV (SEQ ID NO:175)	5.000
16	192	QYSVPPPVY (SEQ ID NO:176)	5.000
17	207	DSCTGSQAL (SEQ ID NO:61)	4.800
18	441	NMTKLQLAL (SEQ ID NO:149)	4.800
19	225	NLYQMTSQL (SEQ ID NO:147)	4.000
20	235	CMTWNQMNL (SEQ ID NO:49)	4.000

Table VI
Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A3

			Score (Estimate of Half Time of
•		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	436	NMHQRNMTK (SEQ	40.000
		ID NO:148)	
2	240	QMNLGATLK (SEQ	20.000
		ID NO:168)	
3	88	CLSAFTVHF (SEQ ID	6.000
		NO:48)	•
4	126	RMFPNAPYL (SEQ	4.500
		ID NO:185)	, .
5	169	AQFPNHSFK (SEQ	4.500
		ID NO:36)	•
6	10	ALLPAVPSL (SEQ ID	4.050
		NO:34)	
7	137	CLESQPAIR (SEQ ID	4.000
		NO:47)	
8	225	NLYQMTSQL (SEQ	3.000
		ID NO:147)	
9	32	AQWAPVLDF (SEQ	2.700
		ID NO:37)	

10	280	ILCGAQYRI (SEQ ID NO:116)	2.700
11	386	KTCQRKFSR (SEQ ID NO:128)	1.800
12	235	CMTWNQMNL (SEQ ID NO:49)	1.200
13	441	NMTKLQLAL (SEQ ID NO:149)	1.200
14	152	VTFDGTPSY (SEQ ID NO:244)	1.000
15	187	SLGEQQYSV (SEQ ID NO:214)	0.900
16	383	FQCKTCQRK (SEQ. ID NO:80)	0.600
17	292	GVFRGIQDV (SEQ ID NO:103)	0.450
18	194	SVPPPVYGC (SEQ ID NO:218)	0.405
19	287	RIHTHGVFR (SEQ ID NO:182)	0.400
20	263	GQSNHSTGY (SEQ ID NO:100)	0.360

Table VII

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A68.1

		Subsequence Residue	Score (Estimate of Half Time of Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	100	FTGTAGACR (SEQ ID NO:84)	100.000
2	386	KTCQRKFSR (SEQ	50.000
		ID NO:128)	
3	368	DQLKRHQRR (SEQ ID NO:60)	30.000
4	312	RSASETSEK (SEQ ID NO:190)	18.000
. 5	337	LSHLQMHSR (SEQ ID NO:141)	15.000

6	364	FSRSDQLKR (SEQ ID	15.000
		NO:83)	15.000
7	409	TSEKPFSCR (SEQ ID	15.000
		NO:232)	13.000
8	299	DVRRVPGVA (SEQ	12.000
		ID NO:63)	
9	4	DVRDLNALL (SEQ	12.000
		ID NO:62)	12.000
10	118	SQASSGQAR (SEQ	10.000
		ID NO:216)	
11	343	HSRKHTGEK (SEQ	9.000
		ID NO:111)	
12	169	AQFPNHSFK (SEQ	9.000
		ID NO:36)	
13	292	GVFRGIQDV (SEQ	8.000
		ID NO:103)	
14	325	CAYPGCNKR (SEQ	7.500
		ID NO:44)	
15	425	FARSDELVR (SEQ	7.500
		ID NO:75)	
16	354	QCDFKDCER (SEQ	. 7.500
		ID NO:162)	
17	324	MCAYPGCNK (SEQ	6.000
		ID NO:142)	
18	251	AAGSSSSVK (SEQ	6.000
		' ID NO:28)	
19	379	GVKPFQCKT (SEQ	6.000
	100	ID NO:104)	
20	137	CLESQPAIR (SEQ ID	5.000
		NO:47)	

Table VIII Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA A 1101

Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
1	386	KTCQRKFSR (SEQ ID NO:128)	1.800

2	169	AQFPNHSFK (SEQ	1.200
		ID NO:36)	
3	436	NMHQRNMTK (SEQ	0.800
		ID NO:148)	
4	391	KFSRSDHLK (SEQ	0.600
		ID NO:120)	
5	373	HQRRHTGVK (SEQ	0.600
		ID NO:109)	
6	383	FQCKTCQRK (SEQ	0.600
		ID NO:80)	0.600
7	363	RFSRSDQLK (SEQ ID	0.600
		NO:178)	0.400
8	240	QMNLGATLK (SEQ	0.400
		ID NO:168)	0.240
9	287	RIHTHGVFR (SEQ ID	0.240
10	100	NO:182)	0.200
10	100	FTGTAGACR (SEQ ID NO:84)	0.200
	224	MCAYPGCNK (SEQ	0.200
11	324	ID NO:142)	0.200
12	251	AAGSSSSVK (SEQ	0.200
12	231	ID NO:28)	0.200
13	415	SCRWPSCQK (SEQ	0.200
13	713	ID NO:201)	
14	118	SQASSGQAR (SEQ	0.120
•	110	ÍD NO:216)	
15	292	GVFRGIQDV (SEQ	0.120
		ID NO:103)	•
16	137	CLESQPAIR (SEQ ID	0.080
	İ	NO:47)	
17	425	FARSDELVR (SEQ	0.080
		ID NO:75)	
18	325	CAYPGCNKR (SEQ	0.080
		ID NO:44)	
19	312	RSASETSEK (SEQ ID	0.060
		NO:190)	
20	65	PPPPHSFI (SEQ ID	0.060
		NO:156)K	

Table IX

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A 3101

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	386	KTCQRKFSR (SEQ	9.000
		ID NO:128)	
2	287	RIHTHGVFR (SEQ ID	6.000
		NO:182)	
3	137	CLESQPAIR (SEQ ID	2.000
		NO:47)	
4	118	SQASSGQAR (SEQ	2.000
		ID _' NO:216)	··· · · · · · · · · · · · · · · · · ·
- 5	368	DQLKRHQRR (SEQ	1.200
		ID NO:60)	
6	100	FTGTAGACR (SEQ	1.000
		ID NO:84)	
7	293	VFRGIQDVR (SEQ ID	0.600
		NO:238)	
8	325	CAYPGCNKR (SEQ	0.600
		ID NO:44)	·
9	169	AQFPNHSFK (SEQ	0.600
		ID NO:36)	
10	279	PILCGAQYR (SEQ ID	0.400
		NO:155)	
11	436	NMHQRNMTK (SEQ	0.400
		ID NO:148)	
12	425	FARSDELVR (SEQ	0.400
		ID NO:75)	
13	32	AQWAPVLDF (SEQ	0.240
		ID NO:37)	
14	240	QMNLGATLK (SEQ	0.200
		ID NO:168)	
15	354	QCDFKDCER (SEQ	0.200
		ID NO:162)	•
16	373	HQRRHTGVK (SEQ	0.200
		ID NO:109)	
17	383	FQCKTCQRK (SEQ	0.200
		ID NO:80)	

18	313	SASETSEKR (SEQ ID NO:197)	0.200
19	358	KDCERRFSR (SEQ ID NO:118)	0.180
20	391	KFSRSDHLK (SEQ ID NO:120)	0.180

Table X

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA A 3302

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	337	LSHLQMHSR (SEQ	15.000
		ID NO:141)	
2	409	TSEKPFSCR (SEQ ID	15.000
		NO:232)	
3	364	FSRSDQLKR (SEQ ID	15.000
		NO:83)	×
4	137	CLESQPAIR (SEQ ID	9.000
		NO:47)	
5	368	DQLKRHQRR (SEQ	9.000
		ID NO:60)	4.500
6	287	RIHŢHGVFR (SEQ ID	4.500
		NO:182)	3.000
7	210	TGSQALLLR (SEQ ID	3.000
	405	NO:223)	3,000
8	425	FARSDELVR (SEQ ID NO:75)	5.000
<u> </u>	212		3.000
9	313	SASETSEKR (SEQ ID NO:197)	3.000
10	293	VFRGIQDVR (SEQ ID	3.000
10	293	NO:238)	. 3.000
11	354	QCDFKDCER (SEQ	3.000
''	337	ID NO:162)	5.000
12	100	FTGTAGACR (SEQ	3.000
'~	100	ID NO:84)	
13	118	SOASSGOAR (SEQ	3.000
	***	ID NO:216)	

14	325	CAYPGCNKR (SEQ ID NO:44)	3.000
15	207	DSCTGSQAL (SEQ ID NO:61)	1.500
16	139	ESQPAIRNQ (SEQ ID NO:72)	1.500
17	299	DVRRVPGVA (SEQ ID NO:63)	1.500
18	419	PSCQKKFAR (SEQ ID NO:159)	1.500
19	272	ESDNHTTPI (SEQ ID NO:71)	1.500
20	4	DVRDLNALL (SEQ ID NO:62)	1.500

Table XI
Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B14

	<u> </u>		
			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	362	RRFSRSDQL (SEQ ID	1000.000
	4	NO:187)	
2	332	KRYFKLSHL (SEQ	300.000
		ID NO:127)	
3	423	KKFARSDEL (SEQ	150.000
		ID NO:122)	•
4	390	RKFSRSDHL (SEQ ID	150.000
		NO:183)	, ·
5	439	QRNMTKLQL (SEQ	20.000
		ID NO:173)	
6	329	GCNKRYFKL (SEQ	10.000
ĺ		ID NO:90)	
7	10	ALLPAVPSL (SEQ ID	10.000
		NO:34)	
8	180	DPMGQQGSL (SEQ	9.000
		ID NO:59)	
9	301	RRVPGVAPT (SEQ	6.000
		ID NO:189)	

10	126	RMFPNAPYL (SEQ ID NO:185)	5.000
11	371	KRHQRRHTG (SEQ	5.000
	225	ID NO:126)	5.000
12	225	NLYQMTSQL (SEQ ID NO:147)	3.000
13	144	IRNQGYSTV (SEQ ID NO:117)	4.000
14	429	DELVRHHNM (SEQ ID NO:53)	3.000
15	437	MHQRNMTKL (SEQ ID NO:143)	3.000
16	125	ARMFPNAPY (SEQ ID NO:38)	3.000
17	239	NQMNLGATL (SEQ ID NO:151)	3.000
18	286	YRIHTHGVF (SEQ ID NO:252)	3.000
19	174	HSFKHEDPM (SEQ ID NO:110)	3.000
20	372	RHQRRHTGV (SEQ ID NO:181)	3.000

Table XII

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B40

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	81	AEPHEEQCL (SEQ ID	40.000
		NO:30)	
2	429	DELVRHHNM (SEQ	24.000
		ID NO:53)	
3	410	SEKPFSCRW (SEQ	20.000
		ID NO:207)	
4	318	SEKRPFMCA (SEQ	15.000
I		ID NO:208)	
5	233	LECMTWNQM (SEQ	12.000
		ID NO:131)	

6	3	CDVDDINAL (CCO	
0	3	SDVRDLNAL (SEQ	10.000
		ID NO:206)	
7	349	GEKPYQCDF (SEQ	8.000
		ID NO:91)	
8	6	RDLNALLPA (SEQ	5.000
		ID NO:177)	
9	85	EEQCLSAFT (SEQ ID	4.000
		NO:65)	
10	315	SETSEKRPF (SEQ ID	4.000
	•	NO:209)	
11	261	TEGQSNHST (SEQ ID	4.000
	•	NO:221)	
12	23	GCALPVSGA (SEQ	3.000
		ID NO:89)	
13	38	LDFAPPGAS (SEQ ID	3.000
		NO:130)	
14	273	SDNHTTPIL (SEQ ID	2.500
		NO:204)	
15	206	TDSCTGSQA (SEQ	2.500
		ID NO:220)	
16	24	CALPVSGAA (SEQ	2.000
		ID NO:43)	
17	98	GQFTGTAGA (SEQ	2.000
		ID NO:99)	
18	30	GAAQWAPVL (SEQ	2.000
	•	'ID NO:86)	
19	84	HEEQCLSAF (SEQ ID	2.000
		NO:107)	
20	26	LPVSGAAQW (SEQ	2.000
		ID NO:138)	

Table XIII Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA B60

Pank	Start Position	Subsequence Residue	Score (Estimate of Half Time of Disassociation of a Molecule
1	81	Listing AEPHEEQCL (SEQ ID	Containing This Subsequence) 160.000
		NO:30)	

2	3	SDVRDLNAL (SEQ	40.000
		ID NO:206)	
3	429	DELVRHHNM (SEQ	40.000
	_	ID NO:53)	
4	233	LECMTWNQM (SEQ	22.000
		ID NO:131)	·
5	273	SDNHTTPIL (SEQ ID	20.000
		NO:204)	
6	209	CTGSQALLL (SEQ ID	8.000
		NO:52)	
7	30	GAAQWAPVL (SEQ	8.000
		ID NO:86)	
8	318	SEKRPFMCA (SEQ	8.000
		ID NO:208)	
9	180	DPMGQQGSL (SEQ	8.000
		ID NO:59)	
10	138	LESQPAIRN (SEQ ID	5.280
		NO:132)	
11	239	NQMNLGATL (SEQ	4.400
		ID NO:151)	
12	329	GCNKRYFKL (SEQ	4.400
		ID NO:90)	,
13	130	NAPYLPSCL (SEQ ID	4.400
		NO:144)	·
14	85	EEQCLSAFT (SEQ ID	4.400
		' NO:65)	
15	208	SCTGSQALL (SEQ ID	4.000
		NO:202)	· ·
16	207	DSCTGSQAL (SEQ	4.000
		ID NO:61)	
17	218	RTPYSSDNL (SEQ ID	4.000
]		NO:194)	
18	261	TEGQSNHST (SEQ ID	4.000
		NO:221)	
19	18	LGGGGGCAL (SEQ	4.000
		ID NO:134)	
20	221	YSSDNLYQM (SEQ	2.200
1		ID NO:253)	

Table XIV

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B61

			Constitution CIT-1070
		Cubacanana David	Score (Estimate of Half Time of
, ,	a	Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	318	SEKRPFMCA (SEQ	20.000
		ID NO:208)	
2	429	DELVRHHNM (SEQ	16.000
	·	ID NO:53)	
3	298	QDVRRVPGV (SEQ	10.000
		ID NO:164)	
4	81	AEPHEEQCL (SEQ ID	8.000
		NO:30)	
5	233	LECMTWNQM (SEQ	8.000
		ID NO:131)	
6	6	RDLNALLPA (SEQ	5.500
		ID NO:177)	
7	85	EEQCLSAFT (SEQ ID	4.000
		NO:65)	
8	261	TEGQSNHST (SEQ ID	4.000
		NO:221)	
9	206	TDSCTGSQA (SEQ	2.500
		ID NO:220)	
10	295	RGIQDVRRV (SEQ	2.200
		ID NO:179)	
11	3	SDVRDLNAL (SEQ	2.000
		ID NO:206)	
12	250	VAAGSSSSV (SEQ	2.000
		ID NO:236)	
13	29	SGAAQWAPV (SEQ	2.000
		ID NO:211)	
14	315	SETSEKRPF (SEQ ID	1.600
		NO:209)	
15	138	LESQPAIRN (SEQ ID	1.200
		NO:132)	1.200
16	244	GATLKGVAA (SEQ	1.100
		ID NO:88)	
17	20	GGGGCALPV (SEQ	1.100
1 1	20	ID NO:92)	. 1.100
	<u> </u>	10 140.72)	

18	440	RNMTKLQLA (SEQ ID NO:186)	1.100
- 19	23	GCALPVSGA (SEQ ID NO:89)	1.100
20	191	QQYSVPPPV (SEQ ID NO:171)	1.000

Table XV

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B62

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	146	NQGYSTVTF (SEQ	211.200
		ID NO:150)	
2	32	AQWAPVLDF (SEQ	96.000
		ID NO:37)	
3	263	GQSNHSTGY (SEQ	96.000
		ID NO:100)	
4	88	CLSAFTVHF (SEQ ID	96.000
		NO:48)	
5	17	SLGGGGGCA (SEQ	9.600
		ID NO:215)	0.000
6	239	NQMNLGATL (SEQ	8.800
		ID NO:151)	2.000
7	191	QQYSVPPPV (SEQ	8.000
		ID NO:171)	0.000
8	98	GQFTGTAGA (SEQ	8.000
		ID NO:99)	6.000
9	384	QCKTCQRKF (SEQ	6.000
		ID NO:163)	4 000
10	40	FAPPGASAY (SEQ	4.800
		ID NO:74)	
11	227	YQMTSQLEC (SEQ	4.800
<u> </u>		ID NO:251)	100
12	187	SLGEQQYSV (SEQ	4.400
<u></u>		ID NO:214)	
13	86	EQCLSAFTV (SEQ ID	4.400
ļ		NO:69)	

14	152	VTFDGTPSY (SEQ ID NO:244)	4.400
15	101	TGTAGACRY (SEQ ID NO:224)	4.000
16	242	NLGATLKGV (SEQ ID NO:146)	4.000
17	92	FTVHFSGQF (SEQ ID NO:85)	4.000
18	7	DLNALLPAV (SEQ ID NO:58)	4.000
19	123	GQARMFPNA (SEQ ID NO:98)	4.000
20	280	ILCGAQYRI (SEQ ID NO:116)	3.120

Table XVI
Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B7

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1			
1 1	180	DPMGQQGSL (SEQ	240.000
		ID NO:59)	
2	4	DVRDLNALL (SEQ	200.000
		ID NO:62)	
3	302	RVPGVAPTL (SEQ	20.000
	•	ID NO:195)	•
4	30	GAAQWAPVL (SEQ	12.000
		ID NO:86)	. *
5	239	NQMNLGATL (SEQ	12.000
		ID NO:151)	
6	130	NAPYLPSCL (SEQ ID	12.000
		NO:144)	
7	10	ALLPAVPSL (SEQ ID	12.000
		NO:34)	
.8	299	DVRRVPGVA (SEQ	5.000
		ID NO:63)	
9	208	SCTGSQALL (SEQ ID	4.000
		NO:202)	

10	303	VPGVAPTLV (SEQ ID NO:242)	4.000
11	18	LGGGGGCAL (SEQ ID NO:134)	4.000
12	218	RTPYSSDNL (SEQ ID NO:194)	4.000
13	207	DSCTGSQAL (SEQ ID NO:61)	4.000
14	209	CTGSQALLL (SEQ ID NO:52)	4.000
15	329	GCNKRYFKL (SEQ ID NO:90)	4.000
16	235	CMTWNQMNL (SEQ ID NO:49)	4.000
17	441	NMTKLQLAL (SEQ ID NO:149)	4.000
18	126	RMFPNAPYL (SEQ ID NO:185)	4.000
19	225	NLYQMTSQL (SEQ ID NO:147)	4.000
20	143	AIRNQGYST (SEQ ID NO:33)	3.000

Table XVII

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B8

		Subsequence Residue	Score (Estimate of Half Time of Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	329	GCNKRYFKL (SEQ ID NO:90)	16.000
2	4	DVRDLNALL (SEQ ID NO:62)	12.000
3	316	ETSEKRPFM (SEQ ID NO:73)	3.000
4	180	DPMGQQGSL (SEQ ID NO:59)	1.600
5	208	SCTGSQALL (SEQ ID NO:202)	0.800

· Down House

6	130	NAPYLPSCL (SEQ ID	0.800
<u></u>		NO:144)	0.000
7	244	GATLKGVAA (SEQ	0.800
		ID NO:88)	0.800
8	30	GAAQWAPVL (SEQ	0.800
		ID NO:86)	0.000
9	299	DVRRVPGVA (SEQ	0.400
		ID NO:63)	0.400
10	420	SCQKKFARS (SEQ	0.400
		ID NO:200)	. 0.100
11	387	TCQRKFSRS (SEQ ID	0.400
10		NO:219)	
12	225	NLYQMTSQL (SEQ	0.400
		ID NO:147)	
13	141	QPAIRNQGY (SEQ	0.400
14	10	ID NO:170)	
14	10	ALLPAVPSL (SEQ ID	0.400
15	202	NO:34)	
13	207	DSCTGSQAL (SEQ	0.400
16	204	ID NO:61)	
10	384	QCKTCQRKF (SEQ	0.400
17	136	ID NO:163)	
*/	130	SCLESQPAI (SEQ ID	0.300
18	347	NO:198)	
10	347	HTGEKPYQC (SEQ	0.300
19	401	ID NO:112)	
	701	HTRTHTGKT (SEQ	0.200
+	332	ID NO:114)	
ı	ے کے ک	KRYFKLSHL (SEQ ID NO:127)	0.200
		ID NO:127)	

Table XVIII 'ts of BIMAS HLA Peptide Binding Prediction Analysis for 'ing of Human WT1 Peptides to Human HLA B 2702

equence Residue	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
SHL (SEQ ?7)	900.000

2	362	RRFSRSDQL (SEQ ID	900.000
		NO:187)	
3	286	YRIHTHGVF (SEQ ID	200.000
		NO:252)	
4	125	ARMFPNAPY (SEQ	200.000
		ID NO:38)	
5	375	RRHTGVKPF (SEQ	180.000
		ID NO:188)	
6	32	AQWAPVLDF (SEQ	100.000
		ID NO:37)	
7	301	RRVPGVAPT (SEQ	60.000
1		ID NO:189)	
8	439	QRNMTKLQL (SEQ	60.000
		ID NO:173)	
9	126	RMFPNAPYL (SEQ	22.500
		ID NO:185)	
10	426	ARSDELVRH (SEQ	20.000
		ID NO:39)	
11	146	NQGYSTVTF (SEQ	20.000
1 1		ID NO:150)	
12	144	IRNQGYSTV (SEQ ID	20.000
1		NO:117)	
13	389	QRKFSRSDH (SEQ	20.000
1		ID NO:172)	
14	263	GQSNHSTGY (SEQ	20.000
		'ID NO:100)	
15	416	CRWPSCQKK (SEQ	20.000
11		ID NO:50)	
16	191	QQYSVPPPV (SEQ	10.000
		ID NO:171)	
17	217	LRTPYSSDN (SEQ ID	10.000
	,	NO:140)	
18	107	CRYGPFGPP (SEQ ID	10.000
		NO:51)	
19	98	GQFTGTAGA (SEQ	10.000
		ID NO:99)	
20	239	NQMNLGATL (SEQ	6.000
1		ID NO:151)	

Table XIX

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA B 2705

	 		0 00
		a	Score (Estimate of Half Time of
n .	G. (B.).	Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	332	KRYFKLSHL (SEQ	30000.000
		ID NO:127)	
2	362	RRFSRSDQL (SEQ ID	30000.000
		NO:187)	
3	416	CRWPSCQKK (SEQ	10000.000
_		ID NO:50)	
4	439	QRNMTKLQL (SEQ	2000.000
		ID NO:173)	· ••• ·
5	286	YRIHTHGVF (SEQ ID	1000.000
		NO:252)	
6	125	ARMFPNAPY (SEQ	1000.000
		ID NO:38)	
7	294	FRGIQDVRR (SEQ ID	1000,000
		NO:81)	
8	432	VRHHNMHQR (SEQ	1000.000
		ID NO:243)	
9	169	AQFPNHSFK (SEQ	1000.000
		ID NO:36)	
10	375	RRHTGVKPF (SEQ	900.000
		ID NO:188)	
11	126	RMFPNAPYL (SEQ	750.000
		ID NO:185)	
12	144	IRNQGYSTV (SEQ ID	600.000
		NO:117)	7
13	301	RRVPGVAPT (SEQ	600.000
		ID NO:189)	
14	32	AQWAPVLDF (SEQ	500.000
		ID NO:37)	
15	191	QQYSVPPPV (SEQ	300.000
		ID NO:171)	
16	373	HQRRHTGVK (SEQ	200.000
		ID NO:109)	
17	426	ARSDELVRH (SEQ	200.000
		ID NO:39)	243.300
L	L	10.00)	

18	383	FQCKTCQRK (SEQ ID NO:80)	200.000
19	239	NQMNLGATL (SEQ ID NO:151)	200.000
20	389	QRKFSRSDH (SEQ ID NO:172)	200.000

Table XX

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 3501

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	278	TPILCGAQY (SEQ ID	40.000
		NO:227)	
2	141	QPAIRNQGY (SEQ	40.000
		ID NO:170)	
3	219	TPYSSDNLY (SEQ ID	40.000
		. NO:231)	
4	327	YPGCNKRYF (SEQ	20.000
4		ID NO:250)	
5	163	TPSHHAAQF (SEQ	20.000
		ID NO:228)	•
6	180	DPMGQQGSL (SEQ	20.000
		ID NO:59)	
7	221	YSSDNLYQM (SEQ	20.000
		ID NO:253)	
8	26	LPVSGAAQW (SEQ	10.000
		ID NO:138)	/
9	174	HSFKHEDPM (SEQ	10.000
	<u> </u>	ID NO:110)	
10	82	EPHEEQCLS (SEQ ID	6.000
<u> </u>		NO:68)	
11	213	QALLLRTPY (SEQ ID	6.000
		NO:160)	
12	119	QASSGQARM (SEQ	6.000
		ID NO:161)	
13	4	DVRDLNALL (SEQ	6.000
		ID NO:62)	

. 5

14	40	FAPPGASAY (SEQ ID NO:74)	6.000
15	120	ASSGQARMF (SEQ	5.000
16	207	ID NO:40) DSCTGSQAL (SEQ	5.000
17	303	ID NO:61) VPGVAPTLV (SEQ	4.000
18	316	ID NO:242) ETSEKRPFM (SEQ ID	4.000
19	152	NO:73) VTFDGTPSY (SEQ ID	4.000
20	412	NO:244) KPFSCRWPS (SEQ ID	4.000
		NO:123)	

Table XXI

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 3701

	-	Subsequence Residue	Score (Estimate of Half Time of Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	3	SDVRDLNAL (SEQ	40.000
		ID NO:206)	
2	273	SDNHTTPIL (SEQ ID	40.000
<u> </u>		NO:204)	
3	81	AEPHEEQCL (SEQ ID	. 10.000
		NO:30)	
4	298	QDVRRVPGV (SEQ	8.000
		ID NO:164)	
5	428	SDELVRHHN (SEQ	6.000
		ID NO:203)	
6	85	EEQCLSAFT (SEQ ID	5.000
		NO:65)	
7	208	SCTGSQALL (SEQ ID	5.000
		NO:202)	
8	4	DVRDLNALL (SEQ	5.000
		ID NO:62)	
9	209	CTGSQALLL (SEQ ID	5.000
		NO:52)	

10	38	LDFAPPGAS (SEQ ID	4.000
		NO:130)	
11	223	SDNLYQMTS (SEQ	4.000
		ID NO:205)	•
12	179	EDPMGQQGS (SEQ	4.000
		ID NO:64)	
13	206	TDSCTGSQA (SEQ	4.000
		ID NO:220)	
14	6	RDLNALLPA (SEQ	4.000
		ID NO:177)	
15	84	HEEQCLSAF (SEQ ID	2.000
'		NO:107)	
16	233 .	LECMTWNQM (SEQ	2.000
		ID NO:131)	
17	429	DELVRHHNM (SEQ	2.000
		ID NO:53)	
18	315	SETSEKRPF (SEQ ID	2.000
		NO:209)	
19	349	GEKPYQCDF (SEQ	2.000
		ID NO:91)	
20	302	RVPGVAPTL (SEQ	1.500
-	•	ID NO:195)	

Table XXII

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 3801

		Cul Desidue	Score (Estimate of Half Time of Disassociation of a Molecule
		Subsequence Residue	
Rank	Start Position	Listing	Containing This Subsequence)
1	437	MHQRNMTKL (SEQ	36.000
		ID NO:143)	
2	434	HHNMHQRNM (SEQ	6.000
		ID NO:108)	
3	372	RHQRRHTGV (SEQ	6.000
		ID NO:181)	
4	180	DPMGQQGSL (SEQ	4.000
1		ID NO:59)	
5	433	RHHNMHQRN (SEQ	3.900
)	ID NO:180)	

6	165	SHHAAQFPN (SEQ	3.900
7	202	ID NO:213) CHTPTDSCT (SEQ ID	3.000
		NO:45)	
8	396	DHLKTHTRT (SEQ ID NO:57)	3.000
9	161	GHTPSHHAA (SEQ ID NO:94)	3.000
10	302	RVPGVAPTL (SEQ ID NO:195)	2.600
11	417	RWPSCQKKF (SEQ ID NO:196)	2.400
12	327	YPGCNKRYF (SEQ ID NO:250)	2.400
13	208	SCTGSQALL (SEQ ID NO:202)	2.000
14	163	TPSHHAAQF (SEQ ID NO:228)	2.000
15	120	ASSGQARMF (SEQ ID NO:40)	2.000
16	18	LGGGGGCAL (SEQ ID NO:134)	2.000
17	177	KHEDPMGQQ (SEQ ID NO:121)	1.800
18	83	PHEEQCLSA (SEQ ID 'NO:154)	1.800
19	10	ALLPAVPSL (SEQ ID NO:34)	1.300
20	225	NLYQMTSQL (SEQ ID NO:147)	1.300

Table XXIII Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA B 3901

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	437	MHQRNMTKL (SEQ	135.000
		ID NO:143)	·

2	332	KRYFKLSHL (SEQ ID NO:127)	45.000
3	434	HHNMHQRNM (SEQ	30.000
4	362	ID NO:108) RRFSRSDQL (SEQ ID NO:187)	30.000
5	372	RHQRRHTGV (SEQ ID NO:181)	30.000
6	10	ALLPAVPSL (SEQ ID NO:34)	9.000
7	439	QRNMTKLQL (SEQ ID NO:173)	7.500
8	390	RKFSRSDHL (SEQ ID NO:183)	6.000
9	396	DHLKTHTRT (SEQ ID NO:57)	6.000
10	239	NQMNLGATL (SEQ ID NO:151)	6.000
11	423	KKFARSDEL (SEQ ID NO:122)	6.000
12	126	RMFPNAPYL (SEQ ID NO:185)	6.000
13	225	NLYQMTSQL (SEQ ID NO:147)	6.000
14	180	DPMGQQGSL (SEQ 'ID NO:59)	6.000
15	144	IRNQGYSTV (SEQ ID NO:117)	5.000
16	136	SCLESQPAI (SEQ ID NO:198)	4.000
17	292	GVFRGIQDV (SEQ ID NO:103)	3.000
18	302	RVPGVAPTL (SEQ ID NO:195)	3.000
19	208	SCTGSQALL (SEQ ID NO:202)	3.000
20	207,	DSCTGSQAL (SEQ ID NO:61)	3.000

Table XXIV

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 3902

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	239	NQMNLGATL (SEQ	24.000
1	239	ID NO:151)	24.000
2	390		20.000
4	390	RKFSRSDHL (SEQ ID	20.000
	400	NO:183)	20.000
3	423	KKFARSDEL (SEQ	20.000
		ID NO:122)	
4	32	AQWAPVLDF (SEQ	5.000
		ID NO:37)	
5	146	NQGYSTVTF (SEQ	5.000
		ID NO:150)	
6	130	NAPYLPSCL (SEQ ID	2.400
		NO:144)	
7	225	NLYQMTSQL (SEQ	2.400
·		ID NO:147)	
8	30	GAAQWAPVL (SEQ	2.400
		ID NO:86)	
9	441	NMTKLQLAL (SEQ	2.400
		ID NO:149)	
10	302	RVPGVAPTL (SEQ	2.400
		ID NO:195)	
11	126	RMFPNAPYL (SEQ	2.000
		ID NO:185)	
12	218	RTPYSSDNL (SEQ ID	2.000
		NO:194)	2.000
13	209	CTGSQALLL (SEQ ID	2.000
		NO:52)	
14	332	KRYFKLSHL (SEQ	2.000
		ID NO:127)	
15	180	DPMGQQGSL (SEQ	2.000
-		ID NO:59)	2.000
16	437	MHQRNMTKL (SEQ	2.000
"		ID NO:143)	2.000
17	207	DSCTGSQAL (SEQ	2.000
1 '	207	ID NO:61)	2.000
L	L	ן (וס:טאיטו	

18	208	SCTGSQALL (SEQ ID NO:202)	2.000
19	329	GCNKRYFKL (SEQ ID NO:90)	2.000
20	10	ALLPAVPSL (SEQ ID NO:34)	2.000

Table XXV

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 4403

	<u></u>	· ·	Score (Estimate of Half Time of
		Calarana Darida	Disassociation of a Molecule
	a	Subsequence Residue	
Rank	Start Position	Listing	Containing This Subsequence)
1	315	SETSEKRPF (SEQ ID	80.000
		NO:209)	
2	349	GEKPYQCDF (SEQ	80.000
		ID NO:91)	
3	84	HEEQCLSAF (SEQ ID	60.000
		NO:107)	
4	410	SEKPFSCRW (SEQ	48.000
		ID NO:207)	
5	· 429	DELVRHHNM (SEQ	24.000
		ID NO:53)	
6	278	TPILCGAQY (SEQ ID	15.000
		NO:227)	
7	141	QPAIRNQGY (SEQ	9.000
		ID NO:170)	
8	40	FAPPGASAY (SEQ	9.000
		ID NO:74)	
9	213	QALLLRTPY (SEQ ID	9.000
		NO:160)	
10	318	SEKRPFMCA (SEQ	8.000
10		ID NO:208)	
11	81	AEPHEEQCL (SEQ ID	8.000
• • •	"	NO:30)	
12	152	VTFDGTPSY (SEQ ID	4.500
12	132	NO:244)	-1
13	101	TGTAGACRY (SEQ	4.500
כו	101	ID NO:224)	7.500
	1	ID NO.224)	l

14	120	ASSGQARMF (SEQ ID NO:40)	4.500
15	261	TEGQSNHST (SEQ ID NO:221)	4.000
16	85	EEQCLSAFT (SEQ ID NO:65)	4.000
17	233	LECMTWNQM (SEQ ID NO:131)	4.000
18	104	AGACRYGPF (SEQ ID NO:31)	4.000
19	3	SDVRDLNAL (SEQ ID NO:206)	3.000
20	185	QGSLGEQQY (SEQ ID NO:166)	3.000

Table XXVI

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA B 5101

	· · · · · · · · · · · · · · · · · · ·		·
			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	303	VPGVAPTLV (SEQ	314.600
		ID NO:242)	
2	180	DPMGQQGSL (SEQ	242,000
		ID NO:59)	
3	250	VAAGSSSSV (SEQ	157,300
		ID NO:236)	
4	130	NAPYLPSCL (SEQ ID	50.000
		NO:144)	/ *
5	30	GAAQWAPVL (SEQ	50.000
		ID NO:86)	•
6	20	GGGGCALPV (SEQ	44.000
		ID NO:92)	
7	64	PPPPPHSFI (SEQ ID	40.000
		NO:157)	
8	29	SGAAQWAPV (SEQ	40.000
		ID NO:211)	
9	18	LGGGGGCAL (SEQ	31.460
		ID NO:134)	

10	295	RGIQDVRRV (SEQ ID NO:179)	22.000
11	119	QASSGQARM (SEQ ID NO:161)	18.150
12	418	WPSCQKKFA (SEQ ID NO:246)	12.100
13	82	EPHEEQCLS (SEQ ID NO:68)	12.100
14	110	GPFGPPPPS (SEQ ID NO:96)	11.000
15	272	ESDNHTTPI (SEQ ID NO:71)	8.000
16	306	VAPTLVRSA (SEQ ID NO:237)	7.150
17	280	ILCGAQYRI (SEQ ID NO:116)	6.921
18	219	TPYSSDNLY (SEQ ID NO:231)	6.600
19	128	FPNAPYLPS (SEQ ID NO:79)	6.500
20	204	TPTDSCTGS (SEQ ID NO:230)	6.050

Table XXVII

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 5102

Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
1	295	RGIQDVRRV (SEQ ID NO:179)	290.400
2	303	VPGVAPTLV (SEQ ID NO:242)	200.000
3	180	DPMGQQGSL (SEQ ID NO:59)	133.100
4	250	VAAGSSSSV (SEQ ID NO:236)	110.000
5	30	GAAQWAPVL (SEQ ID NO:86)	55.000

6	130	NAPYLPSCL (SEQ ID	50.000
	150	NO:144)	50.000
7	20		
'	20	GGGGCALPV (SEQ	44.000
8		ID NO:92)	
l °	29	SGAAQWAPV (SEQ	44.000
		ID NO:211)	
9	64	PPPPPHSFI (SEQ ID	40.000
		NO:157)	
10	119	QASSGQARM (SEQ	36.300
		ID NO:161)	
11	110	GPFGPPPPS (SEQ ID	27.500
		NO:96)	
12	412	KPFSCRWPS (SEQ ID	25.000
		NO:123)	
13	18	LGGGGGCAL (SEQ	24.200
		ID NO:134)	
14	24	CALPVSGAA (SEQ	16.500
		ID NO:43)	
15	219	TPYSSDNLY (SEQ ID	15.000
		NO:231)	·
16	292	GVFRGIQDV (SEQ	14.641
		ID NO:103)	
17	136	SCLESQPAI (SEQ ID	14.520
		NO:198)	
18	418	WPSCQKKFA (SEQ	12.100
		ID NO:246)	
19	269	TGYESDNHT (SEQ	11.000
		ID NO:225)	
20	351	KPYQCDFKD (SEQ	11.000
		ID NO:124)	,

Table XXVIII Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA B 5201

Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
1	191	QQYSVPPPV (SEQ ID NO:171)	100.000

2	32	AQWAPVLDF (SEQ	30.000
		ID NO:37)	
3	243	LGATLKGVA (SEQ	16.500
		ID NO:133)	
4	303	VPGVAPTLV (SEQ	13.500
•	505	ID NO:242)	
5	86	EQCLSAFTV (SEQ ID	12.000
ا د	80	NO:69)	
	205	RGIQDVRRV (SEQ	10.000
6	295	, , ,	. 10.000
		ID NO:179)	8.250
7	98	GQFTGTAGA (SEQ	8.250
		ID NO:99)	
8	292	GVFRGIQDV (SEQ	8.250
		ID NO:103)	
9	29	SGAAQWAPV (SEQ	6.000
		ID NO:211)	
10	146	NQGYSTVTF (SEQ	5.500
		ID NO:150)	
11	20	GGGGCALPV (SEQ	5.000
		ID NO:92)	
12	239	NQMNLGATL (SEQ	4.000
~~		ID NO:151)	
13	64	PPPPPHSFI (SEQ ID	3.600
1 13	"	NO:157)	
14	273	SDNHTTPIL (SEQ ID	3.300
14	2/3	' NO:204)	3.500
15	286	YRIHTHGVF (SEQ ID	3.000
15	280	NO:252)	3.000
	260	TGYESDNHT (SEQ	3,000
16	269	, ,	3.000
		ID NO:225)	2.750
17	406	TGKTSEKPF (SEQ ID	2./30
L		NO:222)	0.050
18	327	YPGCNKRYF (SEQ	2.750
I		ID NO:250)	
19	7	DLNALLPAV (SEQ	2.640
		ID NO:58)	
20	104	AGACRYGPF (SEQ	2.500
		ID NO:31)	
L	<u> </u>		

Table XXIX

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA B 5801

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	230	TSQLECMTW (SEQ	96.800
		ID NO:234)	
2	92	FTVHFSGQF (SEQ ID	60.000
		NO:85)	
3	120	ASSGQARMF (SEQ	40.000
		ID NO:40)	
4	168	AAQFPNHSF (SEQ	20.000
		ID NO:29)	
5	408	KTSEKPFSC (SEQ ID	12.000
		NO:129)	
6	394	RSDHLKTHT (SEQ	9.900
		ID NO:192)	
7	276	HTTPILCGA (SEQ ID	7.200
		NO:115)	
8	218	RTPYSSDNL (SEQ ID	6.600
		NO:194)	
9	152	VTFDGTPSY (SEQ ID	6.000
		NO:244)	
10	40	FAPPGASAY (SEQ	6.000
		ID NO:74)	
11	213	QALLLRTPY (SEQ ID	4.500
		NO:160)	
12	347	HTGEKPYQC (SEQ	4.400
		ID NO:112)	
13	252	AGSSSSVKW (SEQ	4.400
		ID NO:32)	
14	211	GSQALLLRT (SEQ ID	4.356
		NO:102)	
15	174	HSFKHEDPM (SEQ	4.000
		ID NO:110)	
16	317	TSEKRPFMC (SEQ	4.000
		ID NO:233)	
17	26	LPVSGAAQW (SEQ	4.000
		ID NO:138)	

18	289	HTHGVFRGI (SEQ ID	3.600 .
		NO:113)	
19	222	SSDNLYQMT (SEQ ID NO:217)	3.300
20	96	FSGQFTGTA (SEQ ID NO:82)	3.300

Table XXX

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA CW0301

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	10	ALLPAVPSL (SEQ ID	100.000
		NO:34)	
2	332	KRYFKLSHL (SEQ	48.000
	.•	ID NO:127)	
3	126	RMFPNAPYL (SEQ	36.000
		ID NO:185)	
4	3	SDVRDLNAL (SEQ	30.000
	-	ID NO:206)	•
5	239	NQMNLGATL (SEQ	24.000
		ID NO:151)	
6	225	NLYQMTSQL (SEQ	24.000
		1D NO:147)	
7	180	DPMGQQGSL (SEQ	20.000
		ID NO:59)	
8	362	RRFSRSDQL (SEQ ID	12.000
		NO:187)	
9	329	GCNKRYFKL (SEQ	10.000
		ID NO:90)	
10	286	YRIHTHGVF (SEQ ID	10.000
		NO:252)	
11	301	RRVPGVAPT (SEQ	10.000
		ID NO:189)	
12	24	CALPVSGAA (SEQ	10.000
		ID NO:43)	
13	136	SCLESQPAI (SEQ ID	7.500
		NO:198)	
14	437	MHQRNMTKL (SEQ	7.200

		ID NO:143)	
15	390	RKFSRSDHL (SEQ ID	6.000
		NO:183)	
16	423	KKFARSDEL (SEQ	6.000
		ID NO:122)	
17	92	FTVHFSGQF (SEQ ID	5.000
		NO:85)	
18	429	DELVRHHNM (SEQ	5.000
		ID NO:53)	
19	130	NAPYLPSCL (SEQ ID	4.800
		NO:144)	
20	30	GAAQWAPVL (SEQ	4.000
		ID NO:86)	

Table XXXI

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Human HLA CW0401

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	356	DFKDCERRF (SEQ ID NO:55)	120.000
2	334	YFKLSHLQM (SEQ ID NO:248)	100.000
3	180	DPMGQQGSL (SEQ ID NO:59)	88.000
4	163	TPSHHAAQF (SEQ ID NO:228)	52.800
5	327	YPGCNKRYF (SEQ ID NO:250)	40.000
6	285.	QYRIHTHGV (SEQ ID NO:175)	27.500
7	424	KFARSDELV (SEQ ID NO:119)	25.000
8	326	AYPGCNKRY (SEQ ID NO:42)	25.000
9	192	QYSVPPPVY (SEQ ID NO:176)	25.000
10	417	RWPSCQKKF (SEQ ID NO:196)	22.000

11	278	TPILCGAQY (SEQ ID NO:227)	12.000
12	10	ALLPAVPSL (SEQ ID	11.616
		NO:34)	
13	141	QPAIRNQGY (SEQ	11.000
		ID NO:170)	
14	303	VPGVAPTLV (SEQ	11.000
		ID NO:242)	
15	219	TPYSSDNLY (SEQ ID	10.000
		NO:231)	
16	39	DFAPPGASA (SEQ	7.920
1 1		ID NO:54)	
17	99	QFTGTAGAC (SEQ	6.000
1 1		ID NO:165)	
18	4	DVRDLNALL (SEQ	5.760
		ID NO:62)	
19	70	SFIKQEPSW (SEQ ID	5.500
		NO:210)	
20	63	PPPPPPHSF (SEQ ID	5.280
		NO:158)	

Table XXXII

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA CW0602

		,	
			Score (Estimate of Half Time of
i		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	332	KRYFKLSHL (SEQ	9.680
		ID NO:127)	, <u>, , , , , , , , , , , , , , , , , , </u>
2	239	NQMNLGATL (SEQ	6.600
		ID NO:151)	
3	130	NAPYLPSCL (SEQ ID	6.600
		NO:144)	
4	7	DLNALLPAV (SEQ	6.000
		ID NO:58)	
5	441	NMTKLQLAL (SEQ	6.000
1		ID NO:149)	
6	225	NLYQMTSQL (SEQ	6.000
]		ID NO:147)	

7	4	DVRDLNALL (SEQ	6.000
'	4	ID NO:62)	0.000
8	3		4.400
8	3	SDVRDLNAL (SEQ	4.400
		ID NO:206)	1.000
9	10	ALLPAVPSL (SEQ ID	4.000
		NO:34)	
10	213	QALLLRTPY (SEQ ID	3.300
	· · · · · · · · · · · · · · · · · · ·	NO:160)	
11	319	EKRPFMCAY (SEQ	3.000
		ID NO:67)	
12	30	GAAQWAPVL (SEQ	2.200
		ID NO:86)	
13	242	NLGATLKGV (SEQ	2.200
	·	ID NO:146)	
14	292	GVFRGIQDV (SEQ	2.200
		ID NO:103)	
15	207	DSCTGSQAL (SEQ	2.200
		ID NO:61)	
16	362	RRFSRSDQL (SEQ ID	2.200
		NO:187)	
17	439	QRNMTKLQL (SEQ	2.200
		ID NO:173)	
18	295	RGIQDVRRV (SEQ	2.200
		ID NO:179)	
19	423	KKFARSDEL (SEQ	2.200
		1D NO:122)	·
20	180	DPMGQQGSL (SEQ	2.200
		ID NO:59)	

Table XXXIII Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Human HLA CW0702

Rank	Start Position	Subsequence Residue Listing	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence)
1	319	EKRPFMCAY (SEQ ID NO:67)	26.880
2	326	AYPGCNKRY (SEQ ID NO:42)	24.000

3				
192 QYSVPPPVY (SEQ 12.000 12.000 10 NO:176)	3	40		14.784
ID NO:176				
5 278 TPILCGAQY (SEQ ID NO:227) 12.000 6 219 TPYSSDNLY (SEQ ID NO:231) 12.000 7 213 QALLLRTPY (SEQ ID NO:160) 8.800 8 125 ARMFPNAPY (SEQ ID NO:38) 8.000 9 327 YPGCNKRYF (SEQ ID NO:250) 6.600 10 152 VTFDGTPSY (SEQ ID NO:244) 5.600 11 141 QPAIRNQGY (SEQ ID NO:170) 4.800 12 345 RKHTGEKPY (SEQ ID NO:184) 4.000 13 185 QGSLGEQQY (SEQ ID NO:166) 4.000 14 101 TGTAGACRY (SEQ ID NO:224) 4.000 15 375 RRHTGVKPF (SEQ ID NO:188) 4.000 16 263 GQSNHSTGY (SEQ ID NO:100) 3.000 17 163 TPSHHAAQF (SEQ ID NO:124) 3.000 18 33 QWAPVLDFA (SEQ ID NO:174) 2.640 19 130 NAPYLPSCL (SEQ ID NO:144) 2.640 20 84 HEEQCLSAF (SEQ ID D 2.400	4	192	, , , , ,	12.000
No:227 12.000 No:231 12.000 No:231 12.000 No:231 12.000 No:231 12.000		•		
6 219 TPYSSDNLY (SEQ ID NO:231) 7 213 QALLLRTPY (SEQ ID NO:160) 8 125 ARMFPNAPY (SEQ ID ID NO:38) 9 327 YPGCNKYF (SEQ ID ID NO:250) 10 152 VTFDGTPSY (SEQ ID NO:244) 11 141 QPAIRNQGY (SEQ ID NO:170) 12 345 RKHTGEKPY (SEQ ID NO:184) 13 185 QGSLGEQQY (SEQ ID NO:166) 14 101 TGTAGACRY (SEQ ID NO:224) 15 375 RRHTGVKPF (SEQ ID NO:188) 16 263 GQSNHSTGY (SEQ ID NO:100) 17 163 TPSHHAAQF (SEQ ID NO:228) 18 33 QWAPVLDFA (SEQ ID NO:174) 19 130 NAPYLPSCL (SEQ ID NO:144) 20 84 HEEQCLSAF (SEQ ID 2.400	5	278	TPILCGAQY (SEQ ID	12.000
NO:231 NO:231 R.800 NO:160 R.800 NO:160 R.800 NO:160 R.800 NO:160 R.800 NO:160 R.800 NO:38 R.800 ID NO:38 R.800 ID NO:250 ID NO:250 ID NO:250 ID NO:250 ID NO:170 ID NO:170 ID NO:170 ID NO:170 ID NO:184 ID NO:184 ID NO:166 ID NO:166 ID NO:224 ID NO:188 ID NO:188 ID NO:188 ID NO:100 ID NO:100 ID NO:100 ID NO:224 ID NO:100 ID NO:100 ID NO:228 ID NO:174 ID NO:228 ID NO:174 ID NO:174 ID NO:174 ID NO:174 ID NO:144 ID				
7 213 QALLLRTPY (SEQ ID NO:160) 8.800 8 125 ARMFPNAPY (SEQ ID NO:38) 8.000 9 327 YPGCNKRYF (SEQ ID NO:250) 6.600 10 152 VTFDGTPSY (SEQ ID NO:244) 5.600 11 141 QPAINQGY (SEQ ID NO:170) 4.800 12 345 RKHTGEKPY (SEQ ID NO:184) 4.000 13 185 QGSLGEQQY (SEQ ID NO:166) 4.000 14 101 TGTAGACRY (SEQ ID NO:224) 4.000 15 375 RRHTGVKPF (SEQ ID NO:100) 4.000 17 163 GQSNHSTGY (SEQ ID NO:228) 3.000 18 33 QWAPVLDFA (SEQ ID NO:174) 2.688 19 130 NAPYLPSCL (SEQ ID NO:144) 2.640 20 84 HEEQCLSAF (SEQ ID 2.400	6	219		12.000
NO:160 NO:160 NO:160 NO:160 NO:38 NO:00 NO:38 NO:00 NO:250 NO:250 NO:250 NO:244 NO:244 NO:244 NO:244 NO:244 NO:170 NO:170 NO:170 NO:170 NO:184 NO:184 NO:166 NO:166 NO:166 NO:224 NO:224 NO:166 NO:224 NO:166 NO:166 NO:224 NO:166 NO:166 NO:166 NO:224 NO:166 NO:166 NO:224 NO:166 NO:166 NO:166 NO:174 NO:166 NO:174 NO:166 NO:174 NO:166 NO:174 NO:174 NO:174 NO:174 NO:174 NO:174 NO:144 NO:140 NO:144				
8 125 ARMFPNAPY (SEQ ID NO:38) 8.000 9 327 YPGCNKRYF (SEQ ID NO:250) 6.600 10 152 VTFDGTPSY (SEQ ID NO:244) 5.600 11 141 QPAIRNQGY (SEQ ID NO:170) 4.800 12 345 RKHTGEKPY (SEQ ID NO:184) 4.000 13 185 QGSLGEQQY (SEQ ID NO:166) 4.000 14 101 TGTAGACRY (SEQ ID NO:224) 4.000 15 375 RRHTGVKPF (SEQ ID NO:100) 4.000 16 263 GQSNHSTGY (SEQ ID NO:100) 3.000 17 163 TPSHHAAQF (SEQ ID NO:174) 3.000 18 33 QWAPVLDFA (SEQ ID NO:174) 2.688 19 130 NAPYLPSCL (SEQ ID NO:144) 2.640 20 84 HEEQCLSAF (SEQ ID DO:100) 2.400	7	213	QALLLRTPY (SEQ ID	8.800
ID NO:38			NO:160)	
9 327 YPGCNKRYF (SEQ ID NO:250) 10 152 VTFDGTPSY (SEQ ID NO:244) 11 141 QPAIRNQGY (SEQ 4.800 ID NO:170) 12 345 RKHTGEKPY (SEQ 4.000 ID NO:184) 13 185 QGSLGEQQY (SEQ 1D NO:166) 14 101 TGTAGACRY (SEQ 1D NO:224) 15 375 RRHTGVKPF (SEQ 1D NO:188) 16 263 GQSNHSTGY (SEQ 1D NO:100) 17 163 TPSHHAAQF (SEQ 1D NO:228) 18 33 QWAPVLDFA (SEQ 1D NO:174) 19 130 NAPYLPSCL (SEQ ID NO:144) 20 84 HEEQCLSAF (SEQ ID 2.400	8	125	ARMFPNAPY (SEQ	8.000
ID NO:250) 10 152 VTFDGTPSY (SEQ ID NO:244) 5.600 11 141 QPAIRNQGY (SEQ ID NO:170) 12 345 RKHTGEKPY (SEQ ID NO:184) 13 185 QGSLGEQQY (SEQ ID NO:166) 14 101 TGTAGACRY (SEQ ID NO:224) 15 375 RRHTGVKPF (SEQ ID NO:188) 16 263 GQSNHSTGY (SEQ ID NO:100) 17 163 TPSHHAAQF (SEQ ID NO:228) 18 33 QWAPVLDFA (SEQ ID NO:174) 19 130 NAPYLPSCL (SEQ ID NO:144) 20 84 HEEQCLSAF (SEQ ID			ID NO:38)	
10	9	327	YPGCNKRYF (SEQ	6.600
NO:244 11			ID NO:250)	•
NO:244)	10	152	VTFDGTPSY (SEQ ID	5.600
ID NO:170)			NO:244)	
ID NO:170)	11	141	OPAIRNOGY (SEQ	4.800
12 345 RKHTGEKPY (SEQ 1.000				
13	12	345	RKHTGEKPY (SEQ	4.000
ID NO:166			ID NO:184)	
14 101 TGTAGACRY (SEQ ID NO:224) 4.000 15 375 RRHTGVKPF (SEQ ID NO:188) 4.000 16 263 GQSNHSTGY (SEQ ID NO:100) 4.000 17 163 TPSHHAAQF (SEQ ID NO:228) 3.000 18 33 QWAPVLDFA (SEQ ID NO:174) 2.688 19 130 NAPYLPSCL (SEQ ID NO:144) 2.640 20 84 HEEQCLSAF (SEQ ID DE C.400) 2.400	13	185	QGSLGEQQY (SEQ	4.000
ID NO:224			ID NO:166)	
15 375 RRHTGVKPF (SEQ 1.000 1.	14	101	TGTAGACRY (SEQ	4.000
ID NO:188			ID NO:224)	
ID NO:188	15	375	RRHTGVKPF (SEQ	4.000
ID NO:100) 17			ID NO:188)	
ID NO:100)	16	263	GQSNHSTGY (SEQ	4.000
ID NO:228) 18 33 QWAPVLDFA (SEQ 2.688 ID NO:174) 19 130 NAPYLPSCL (SEQ ID 2.640 NO:144) 20 84 HEEQCLSAF (SEQ ID 2.400			ID NO:100)	·
ID NO:228)	17	163	TPSHHAAQF (SEQ	3.000
ID NO:174) 19 130 NAPYLPSCL (SEQ ID NO:144) 20 84 HEEQCLSAF (SEQ ID 2.400			ID NO:228)	. · ·
ID NO:174) 19 130 NAPYLPSCL (SEQ ID NO:144) 20 84 HEEQCLSAF (SEQ ID 2.400	18	33	QWAPVLDFA (SEQ	2.688
NO:144) 20 84 HEEQCLSAF (SEQ ID 2.400			ID NO:174)	
20 84 HEEQCLSAF (SEQ ID 2.400	19	130	NAPYLPSCL (SEQ ID	2.640
20 01 1222 (323 121 (322 (322)			NO:144)	
	20	84	HEEQCLSAF (SEQ ID	2.400
110.107)			NO:107)	

Table XXXIV

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Mouse MHC Class I Db

	,	<u> </u>	
			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	235	CMTWNQMNL (SEQ	5255.712
		ID NO:49)	
2	126	RMFPNAPYL (SEQ	1990.800
		ID NO:185)	
3	221	YSSDNLYQM (SEQ	930.000
		ID NO:253)	
4	228	QMTSQLECM (SEQ	33.701
		ID NO:169)	
5	239	NQMNLGATL (SEQ	21.470
		ID NO:151)	
6	441	NMTKLQLAL (SEQ	19.908
		ID NO:149)	23.300
7	437	MHQRNMTKL (SEQ	. 19.837
		ID NO:143)	. 15.057
8	136	SCLESQPAI (SEQ ID	11.177
		NO:198)	**************************************
9	174	HSFKHEDPM (SEQ	10.800
		ID NO:110)	10.000
10	302	RVPGVAPTL (SEQ	10.088
-		ID NO:195)	101000
11	130	NAPYLPSCL (SEQ ID	8.400
		NO:144)	000
12	10	ALLPAVPSL (SEQ ID	5.988
	,	NO:34)	3.500
13	208	SCTGSQALL (SEQ ID	4.435
		NO:202)	1. 155
14	209	CTGSQALLL (SEQ ID	3.548
		NO:52)	3.3 10
15	238	WNQMNLGAT (SEQ	3.300
	,	ID NO:245)	3.300
16	218	RTPYSSDNL (SEQ ID	3.185
		NO:194)	3.103
17	24	CALPVSGAA (SEQ	2.851
		OTEL TOOTH (DEC	2.031

		ID NO:43)	
18	18	LGGGGGCAL (SEQ	2.177
	•	ID NO:134).	
19	142	PAIRNQGYS (SEQ ID	2.160
		NO:152)	
20	30	GAAQWAPVL (SEQ	1.680
1		ID NO:86)	

Table XXXV

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Mouse MHC Class I Dd

· · · · 		G.I. D.C.I.	Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	112	FGPPPPSQA (SEQ ID NO:76)	48.000
2	122	SGQARMFPN (SEQ ID NO:212)	36.000
3	104	AGACRYGPF (SEQ ID NO:31)	30.000
4	218	RTPYSSDNL (SEQ ID NO:194)	28.800
5	130	NAPYLPSCL (SEQ ID , NO:144)	20.000
6	302	RVPGVAPTL (SEQ ID NO:195)	20.000
7	18	LGGGGGCAL (SEQ ID NO:134)	20.000
8	81	AEPHEEQCL (SEQ ID NO:30)	10.000
9	29	SGAAQWAPV (SEQ ID NO:211)	7.200
10	423	KKFARSDEL (SEQ ID NO:122)	7.200
11	295	RGIQDVRRV (SEQ ID NO:179)	7.200
12	390	RKFSRSDHL (SEQ ID NO:183)	6.000
13	332	KRYFKLSHL (SEQ	6.000

		ID NO:127)	
14	362	RRFSRSDQL (SEQ ID NO:187)	6.000
15	417	RWPSCQKKF (SEQ ID NO:196)	6.000
16	160	YGHTPSHHA (SEQ ID NO:249)	6.000
17	20	GGGGCALPV (SEQ ID NO:92)	6.000
18	329	GCNKRYFKL (SEQ ID NO:90)	5.000
19	372	RHQRRHTGV (SEQ ID NO:181)	4.500
20	52	GGPAPPPAP (SEQ ID NO:93)	4.000

Table XXXVI

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Mouse MHC Class I Kb

Rank 1	Start Position 329	Subsequence Residue Listing GCNKRYFKL (SEQ ID NO:90)	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 24.000
2	225	NLYQMTSQL (SEQ ID NO:147)	10.000
3	420	SCQKKFARS (SEQ ID NO:200)	3.960
4	218	RTPYSSDNL (SEQ ID NO:194)	3.630
5	437	MHQRNMTKL (SEQ ID NO:143)	3.600
6	387	TCQRKFSRS (SEQ ID NO:219)	3.600
7	302	RVPGVAPTL (SEQ ID NO:195)	3.300
8	130	NAPYLPSCL (SEQ ID NO:144)	3.000
9	289	HTHGVFRGI (SEQ ID	3.000

		NO:113)	
10	43	PGASAYGSL (SEQ ID NO:153)	2.400
11	155	DGTPSYGHT (SEQ ID NO:56)	2.400
12	273	SDNHTTPIL (SEQ ID NO:204)	2.200
13	126	RMFPNAPYL (SEQ ID NO:185)	2.200
14	128	FPNAPYLPS (SEQ ID NO:79)	2.000
15	3	SDVRDLNAL (SEQ ID NO:206)	1.584
16	207	DSCTGSQAL (SEQ ID NO:61)	1.584
17	332	KRYFKLSHL (SEQ ID NO:127)	1.500
18	18	LGGGGGCAL (SEQ ID NO:134)	1.320
19	233	LECMTWNQM (SEQ ID NO:131)	1.320
20	441	NMTKLQLAL (SEQ ID NO:149)	1.200

Table XXXVII

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Mouse MHC Class I Kd

			Score (Estimate of Half Time of
Rank	Start Position	Subsequence Residue	Disassociation of a Molecule
Rank 1	1	Listing	Containing This Subsequence)
1	285	QYRIHTHGV (SEQ	600.000
2		ID NO:175)	
2	424	KFARSDELV (SEQ	288.000
		ID NO:119)	·
3	334	YFKLSHLQM (SEQ	120.000
		ID NO:248)	·
4	136	SCLESQPTI (SEQ ID	115.200
		NO:199)	• .
5 ·	239	NQMNLGATL (SEQ	115.200
		ID NO:151)	
6	10	ALLPAVSSL (SEQ ID	115.200
		NO:35)	
7	47	AYGSLGGPA (SEQ	86.400
		ID NO:41)	
8	180	DPMGQQGSL (SEQ	80.000
		ID NO:59)	
9	270	GYESDNHTA (SEQ	72.000
		ID NO:105)	. =
10	326	AYPGCNKRY (SEQ	60.000
	_	ID NO:42)	
11	192	QYSVPPPVY (SEQ	60.000
		' ID NO:176)	
12	272	ESDNHTAPI (SEQ ID	57.600
		NO:70)	, ·
13	289	HTHGVFRGI (SEQ ID	57.600
		NO:113)	
14	126	DVRDLNALL (SEQ	57.600
		ID NO:62)	2.1.550
15	4	CTGSQALLL (SEQ ID	57.600
		NO:52)	
16	208	SCTGSQALL (SEQ ID	48.000
		NO:202)	. 5.500
17	441	NMTKLQLAL (SEQ	48.000
1	1	ID NO:149)	10.000

18	207	DSCTGSQAL (SEQ ID NO:61)	48.000
19	130	NAPYLPSCL (SEQ ID NO:144)	48.000
20	235	CMTWNQMNL (SEQ ID NO:49)	48.000

Table XXXVIII Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Mouse MHC Class I Kk

Score (Estimate of Half Time of Disassociation of a Molecule Subsequence Residue Containing This Subsequence) **Start Position** Listing Rank 40.000 **AEPHEEQCL (SEQ ID** 81 NO:30) 40.000 2 EEQCLSAFT (SEQ ID 85 NO:65) 20.000 **DELVRHHNM (SEQ** 3 429 -- ID NO:53) 20.000 SETSEKRPF (SEQ ID 4 315 NO:209) 20.000 TEGQSNHST (SEQ ID 261 5 NO:221) 10.000 SEKPFSCRW (SEQ 6 410 ID NO:207) **ESDNHTTPI (SEQ ID** 10.000 7 272 NO:71) SEKRPFMCA (SEQ 10.000 318 8 ID NO:208) 10.000 LESQPAIRN (SEQ ID 9 138 NO:132) 10.000 LECMTWNQM (SEQ 10 233 ID NO:131) 10.000 **QDVRRVPGV (SEQ** 11 298 ID NO:164) 10.000 HEEQCLSAF (SEQ ID 84 12 NO:107) 10.000 **GEKPYQCDF (SEQ** 13 349 ID NO:91)

14	289	HTHGVFRGI (SEQ ID	10.000	
		NO:113)		
15	179	EDPMGQQGS (SEQ	8.000	
		ID NO:64)		
16	136	SCLESQPAI (SEQ ID	5.000	
		NO:198)		
17	· 280	ILCGAQYRI (SEQ ID	5.000	
		NO:116)		
18	273	SDNHTTPIL (SEQ ID	4.000	
		NO:204)		
19	428	SDELVRHHN (SEQ	4.000	
		ID NO:203)		
20	3	SDVRDLNAL (SEQ	4.000	
		ID NO:206)		

Table XXXIX

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Human WT1 Peptides to Mouse MHC Class I Ld

		.,,	C. CTT 1077
			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	163	TPSHHAAQF (SEQ	360.000
		ID NO:228)	
2	327	YPGCNKRYF (SEQ	300.000
		ÍD NO:250)	
3	180	DPMGQQGSL (SEQ	150.000
		ID NO:59)	
4	26	LPVSGAAQW (SEQ	93.600
		ID NO:138)	
5	278	TPILCGAQY (SEQ ID	72.000
		NO:227)	
6	141	QPAIRNQGY (SEQ	60.000
		ID NO:170)	
7	219	TPYSSDNLY (SEQ ID	60.000
		NO:231)	
8	303	VPGVAPTLV (SEQ	60.000
		ID NO:242)	
9	120	ASSGQARMF (SEQ	50.000
		ID NO:40)	

10	63	PPPPPPHSF (SEQ ID	45.000
l		NO:158)	
11	113	GPPPPSQAS (SEQ ID	45.000
		NO:97)	
12	157	TPSYGHTPS (SEQ ID	39.000
		NO:229)	<u> </u>
13	207	DSCTGSQAL (SEQ	32.500
		ID NO:61)	
14	110	GPFGPPPPS (SEQ ID	30.000
		NO:96)	
15	82	EPHEEQCLS (SEQ ID	30.000
		NO:68)	
16	412	KPFSCRWPS (SEQ ID	30.000
l		NO:123)	·
17	418	WPSCQKKFA (SEQ	30.000
		ID NO:246)	
18	. 221	YSSDNLYQM (SEQ	30.000
		ID NO:253)	
19	204	TPTDSCTGS (SEQ ID	30.000
		NO:230)	
20	128	FPNAPYLPS (SEQ ID	30.000
		NO:79)	

Table XL

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Human WT1 Peptides to Cattle HLA A20

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	350	EKPYQCDFK (SEQ	1000.00
		ID NO:66)	
2	319	EKRPFMCAY (SEQ	500.000
		ID NO:67)	
3	423	KKFARSDEL (SEQ	500.000
		ID NO:122)	•
4	345	RKHTGEKPY (SEQ	500.000
		ID NO:184)	
5	390	RKFSRSDHL (SEQ ID	500.000
		NO:183)	•
6	137	CLESQPAIR (SEQ ID	120.000

		NO:47)	
7	380	VKPFQCKTC (SEQ	100.000
		ID NO:239)	
8	407	GKTSEKPFS (SEQ ID	100.000
		NO:95)	
9	335	FKLSHLQMH (SEQ	100.000
		ID NO:78)	
10	247	LKGVAAGSS (SEQ	100.000
		ID NO:135)	
11	370	LKRHQRRHT (SEQ	100.000
		ID NO:136)	
12	258	VKWTEGQSN (SEQ	100.000
		ID NO:240)	
13	398	LKTHTRTHT (SEQ	100.000
		ID NO:137)	. :
14	331	NKRYFKLSH (SEQ	100.000
		ID NO:145)	
15	357	FKDCERRFS (SEQ ID	100.000
		NO:77)	
16	385	CKTCQRKFS (SEQ	100.000
		. ID NO:46)	
17	294	FRGIQDVRR (SEQ ID	80.000
		NO:81)	
18	368	DQLKRHQRR (SEQ	80.000
	·· · · · · · · · · · · · · · · · · · ·	ID NO:60)	
19	432	VRHHNMHQR (SEQ	80.000
		ID NO:243)	
20	118	SQASSGQAR (SEQ	80.000
		ID NO:216)	

Table XLI Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Mouse WT1 Peptides to Mouse MHC Class I A 0201

Rank 1	Start Position 126	Subsequence Residue Listing RMFPNAPYL (SEQ ID NO:293)	Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 313.968
2	187	SLGEQQYSV (SEQ ID NO:299)	285.163

3	10	ALLPAVSSL (SEQ ID NO:255)	181.794
4	225	NLYQMTSQL (SEQ ID NO:284)	68.360
5	292	GVFRGIQDV (SEQ ID NO:270)	51.790
6	93	TLHFSGQFT (SEQ ID NO:302)	40.986
7	191	QQYSVPPPV (SEQ ID NO:290)	22.566
8	280	ILCGAQYRI (SEQ ID NO:274)	17.736
9	441	NMTKLHVAL (SEQ ID NO:285)	15.428
10	235	CMTWNQMNL (SEQ ID NO:258)	15.428
11	7	DLNALLPAV (SEQ ID NO:261)	11.998
12	242	NLGATLKGM (SEQ ID NO:283)	11.426
13	227	YQMTSQLEC (SEQ ID NO:307)	8.573
14	239	NQMNLGATL (SEQ ID NO:286)	8.014
15	309	TLVRSASET (SEQ ID NO:303)	7.452
16	408	KTSEKPFSC (SEQ ID NO:277)	5.743
17	340	LQMHSRKHT (SEQ ID NO:280)	4.752
18	228	QMTSQLECM (SEQ ID NO:289)	4.044
19	37	VLDFAPPGA (SEQ ID NO:304)	3.378
20	302	RVSGVAPTL (SEQ ID NO:295)	1.869

Table XLII

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Mouse WT1 Peptides to Mouse MHC Class I Db

		<u> </u>	
		Cubanana	Score (Estimate of Half Time of
Rank	Start Position	Subsequence Residue	Disassociation of a Molecule
1	221	Listing	Containing This Subsequence)
1	221	YSSDNLYQM (SEQ	312.000
		ID NO:308)	
2	126	RMFPNAPYL (SEQ	260.000
		ID NO:293)	
3	235	CMTWNQMNL (SEQ	260.000
		ID NO:258)	
4	437	MHQRNMTKL (SEQ	200.000
		ID NO:281)	
5	238	WNQMNLGAT (SEQ	12.000
		ID NO:305)	12.000
6	130	NAPYLPSCL (SEQ ID	8.580
		NO:282)	
7	3	SDVRDLNAL (SEQ	7.920
		ID NO:298)	7.720
3	136	SCLESQPTI (SEQ ID	7.920
		NO:296)	7.520
9	81	AEPHEEQCL (SEQ ID	6.600
		NO:254)	
10	10	ALLPAVSSL (SEQ ID	6.600
		NO:255)	
11	218	RTPYSSDNL (SEQ ID	6.000
		NO:294)	0.000 , .
12	441	NMTKLHVAL (SEQ	3.432
		ID NO:285)	3.432
13	228	QMTSQLECM (SEQ	3.120
		ID NO:289)	5.120
14	174	HSFKHEDPM (SEQ	2 120
- 1	• • •	ID NO:272)	3.120
15	242	NLGATLKGM (SEQ	0.610
15	272		2.640
16	261	ID NO:283)	
10	201	TEGQSNHGI (SEQ ID	2.640
		NO:301)	

17	225	NLYQMTSQL (SEQ ID NO:284)	2.640
18	207	DSCTGSQAL (SEQ ID NO:263)	2.600
19	119	QASSGQARM (SEQ ID NO:288)	2.600
20	18	LGGGGGCGL (SEQ ID NO:279)	2.600

Table XLIII

Results of BIMAS HLA Peptide Binding Prediction Analysis for
Binding of Mouse WT1 Peptides to Mouse MHC Class I Kb

			Score (Estimate of Half Time of
		Subsequence Residue	Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
1	329	GCNKRYFKL (SEQ	24.000
		ID NO:268)	
2	225	NLYQMTSQL (SEQ	10.000
		ID NO:284)	
3	420	SCQKKFARS (SEQ	3.960
		ID NO:297)	
4	218	RTPYSSDNL (SEQ ID	3.630
		NO:294)	
5	437	MHQRNMTKL (SEQ	3.600
Ì		ID NO:281)	
6	387	TCQRKFSRS (SEQ ID	3.600
		NO:300)	
7	289	HTHGVFRGI (SEQ ID	3.000
		NO:273)	, , , , , , , , , , , , , , , , , , ,
8	130	NAPYLPSCL (SEQ ID	3.000
		NO:282)	
9	43	PGASAYGSL (SEQ	2.400
		ID NO:287)	
10	155	DGAPSYGHT (SEQ	2.400
		ID NO:260)	
11	126	RMFPNAPYL (SEQ	2.200
l		ID NO:293)	
12	128	FPNAPYLPS (SEQ ID	2.000
		NO:267)	

13	207	DSCTGSQAL (SEQ	1.604
'-	207		1.584
		ID NO:263)	
14	3	SDVRDLNAL (SEQ	1.584
		ID NO:298)	
15	. 332	KRYFKLSHL (SEQ	1.500
		ID NO:276)	
16	233	LECMTWNQM (SEQ	1.320
		ID NO:278)	
17	18	LGGGGGCGL (SEQ	1.320
		ID NO:279)	
18	242	NLGATLKGM (SEQ	1.200
		ID NO:283)	
19	123	GQARMFPN (SEQ ID	1.200
		NO:269)A	
20	441	NMTKLHVAL (SEQ	1.200
	·	ID NO:285)	

Table XLIV

Results of BIMAS HLA Peptide Binding Prediction Analysis for Binding of Mouse WT1 Peptides to Mouse MHC Class I Kd

		Г <u></u>	Score (Estimate of Holf Time of
		Subsequence Residue	Score (Estimate of Half Time of Disassociation of a Molecule
Rank	Start Position	Listing	Containing This Subsequence)
I	285	QYRIHTHGV (SEQ ID NO:291)	600.000
2	424	KFARSDELV (SEQ ID NO:275)	288.000
3	334	YFKLSHLQM (SEQ ID NO:306)	120.000
4	136	SCLESQPTI (SEQ ID NO:296)	115.200
5	239	NQMNLGATL (SEQ ID NO:286)	115.200
6	10	ALLPAVSSL (SEQ ID NO:255)	115.200
7	47	AYGSLGGPA (SEQ ID NO:256)	86.400
8	180	DPMGQQGSL (SEQ ID NO:262)	80.000

9	270	GYESDNHTA (SEQ ID NO:271)	72.000
10	192	QYSVPPPVY (SEQ ID NO:292)	60.000
11	326	AYPGCNKRY (SEQ ID NO:257)	60.000
12	289	HTHGVFRGI (SEQ ID NO:273)	57.600
13	4	DVRDLNALL (SEQ ID NO:264)	57.600
14	126	RMFPNAPYL (SEQ ID NO:293)	57.600
15	209	CTGSQALLL (SEQ ID NO:259)	48.000
16	86	EQCLSAFTL (SEQ ID NO:265)	48.000
17	302	RVSGVAPTL (SEQ ID NO:295)	48.000
18	218	RTPYSSDNL (SEQ ID NO:294)	48.000
19	272	ESDNHTAPI (SEQ ID NO:266)	48.000
20	225	NLYQMTSQL (SEQ ID NO:284)	48.000

Table XLV

Results of TSites Peptide Binding Prediction Analysis for

Human WT1 Peptides Capable of Eliciting a Helper T cell Response

Peptide	Sequence
p6-23	RDLNALLPAVPSLGGGG (SEQ ID NO:1)
p30-35	GAAQWA (SEQ ID NO:309)
p45-56	ASAYGSLGGPAP (SEQ ID NO:310)
p91-105	AFTVHFSGQFTGTAG (SEQ ID NO:311)
p117-139	PSQASSGQARMFPNAPYLPSCLE (SEQ ID NO:2)
p167-171	HAAQF (SEQ ID NO:312)
p202-233	CHTPTDSCTGSQALLLRTPYSSDNLYQMTSQL (SEQ ID NO:313)
p244-262	GATLKGVAAGSSSSVKWTE (SEQ ID NO:4)
p287-318	RIHTHGVFRGIQDVRRVPGVAPTLVRSASETS (SEQ ID NO:314)

p333-336	RYFK (SEQ ID NO:315)
p361-374	ERRFSRSDQLKRHO (SEO ID NO:316)
p389-410	QRKFSRSDHLKTHTRTHTGKTS (SEO ID NO.317)
p421-441	CQKKFARSDELVRHHNMHQRN (SEQ ID NO:318)

Certain CTL peptides (shown in Table XLVI) were selected for further study. For each peptide in Table XLVI, scores obtained using BIMAS HLA peptide binding prediction analysis are provided.

<u>Table XLVI</u>
WT1 Peptide Sequences and HLA Peptide Binding Predictions

Peptide	Sequence	Comments
p329-337	GCNKRYFKL	Score 24,000
	(SEQ ID NOs: 90 and	1,000
	268)	·
p225-233	NLYQMTSQL	binds also to class II and HLA A2, Kd,
	(SEQ ID NOs: 147 and	score 10,000
	284)	
p235-243	CMTWNQMNL	binds also to HLA A2, score 5,255,712
	(SEQ ID NOs: 49 and	
105.15	258)	
p126-134	RMFPNAPYL	binds also to Kd, class II and HLA A2,
	(SEQ ID NOs: 185 and	score 1,990,800
201 200	293)	
p221-229	YSSDNLYQM	binds also to Ld, score 312,000
	(SEQ ID NOs: 253 and	
-220 226	308)	
p228-236	QMTSQLECM	score 3,120
	(SEQ ID NOs: 169 and	÷
*220 247	289)	
p239-247	NQMNLGATL	binds also to HLA A 0201, Kd, score
	(SEQ ID NOs: 151 and	8,015
mouse n126 144	286)	
mouse p136-144	SCLESQPTI	binds also to Kd, 1 mismatch to human
human n126 144	(SEQ ID NO:296)	
human p136-144	SCLESQPAI	score 7,920
mouse =10 10	(SEQ ID NO:198)	
mouse p10-18	ALLPAVSSL	binds also to Kd, HLA A2, 1 mismatch

5

10

15

20

	(SEQ ID NO:255)	to human
human p10-18	ALLPAVPSL	score 6,600
	(SEQ ID NO:34)	

Peptide binding to C57Bl/6 murine MHC was confirmed using the leukemia cell line RMA-S, as described by Ljunggren et al., *Nature 346*:476-480, 1990. In brief, RMA-S cells were cultured for 7 hours at 26°C in complete medium supplemented with 1% FCS. A total of 10⁶ RMA-S cells were added into each well of a 24-well plate and incubated either alone or with the designated peptide (25ug/ml) for 16 hours at 26°C and additional 3 hours at 37°C in complete medium. Cells were then washed three times and stained with fluorescein isothiocyanate-conjugated anti D^b or anti-K^b antibody (PharMingen, San Diego, CA). Labeled cells were washed twice, resuspended and fixed in 500ul of PBS with 1% paraformaldehyde and analyzed for fluorescence intensity in a flow cytometer (Becton-Dickinson FACSCalibur®). The percentage of increase of D^b or K^b molecules on the surface of the RMA-S cells was measured by increased mean fluorescent intensity of cells incubated with peptide compared with that of cells incubated in medium alone.

Mice were immunized with the peptides capable of binding to murine class I MHC. Following immunization, spleen cells were stimulated *in vitro* and tested for the ability to lyse targets incubated with WT1 peptides. CTL were evaluated with a standard chromium release assay (Chen et al., Cancer Res. 54:1065-1070, 1994). 10⁶ target cells were incubated at 37°C with 150μCi of sodium ⁵¹Cr for 90 minutes, in the presence or absence of specific peptides. Cells were washed three times and resuspended in RPMI with 5% fetal bovine serum. For the assay, 10⁴ ⁵¹Cr-labeled target cells were incubated with different concentrations of effector cells in a final volume of 200μl in U-bottomed 96-well plates. Supernatants were removed after 4 to 7 hours at 37°C, and the percentage specific lysis was determined by the formula:

25 % specific lysis = 100 x (experimental release - spontaneous release)/(maximum release-spontaneous release).

10

15

The results, presented in Table XLVII, show that some WT1 peptides can bind to class I MHC molecules, which is essential for generating CTL. Moreover, several of the peptides were able to elicit peptide specific CTL (Figures 9A and 9B), as determined using chromium release assays. Following immunization to CTL peptides p10-18 human, p136-144 human, p136-144 mouse and p235-243, peptide specific CTL lines were generated and clones were established. These results indicate that peptide specific CTL can kill malignant cells expressing WT1.

Table XLVII
Binding of WT1 CTL Peptides to mouse B6 class I antigens

Peptide	Binding Affinity to Mouse MHC Class I
Positive control	91%
negative control	0.51.3%
p235-243	33.6%
p136-144 mouse	27.9%
p136-144 human	52%
p10-18: human	2.2%
p225-233	5.8%
p329-337	1.2%
p126-134	0.9%
p221-229	0.8%
p228-236	1.2%
p239-247	1%

Example 5 Use of a WT1 Polypeptide to Elicit WT1 Specific CTL in Mice

This Example illustrates the ability of a representative WT1 polypeptide to elicit CTL immunity capable of killing WT1 positive tumor cell lines.

P117-139, a peptide with motifs appropriate for binding to class I and class
20 II MHC, was identified as described above using TSITES and BIMAS HLA peptide
binding prediction analyses. Mice were immunized as described in Example 3. Following

10

15

20

25

immunization, spleen cells were stimulated *in vitro* and tested for the ability to lyse targets incubated with WT1 peptides, as well as WT1 positive and negative tumor cells. CTL were evaluated with a standard chromium release assay. The results, presented in Figures 10A-10D, show that P117 can elicit WT1 specific CTL capable of killing WT1 positive tumor cells, whereas no killing of WT1 negative cells was observed. These results demonstrate that peptide specific CTL in fact kill malignant cells expressing WT1 and that vaccine and T cell therapy are effective against malignancies that express WT1.

Similar immunizations were performed using the 9-mer class I MHC binding peptides p136-144, p225-233, p235-243 as well as the 23-mer peptide p117-139. Following immunization, spleen cells were stimulated *in vitro* with each of the 4 peptides and tested for ability to lyse targets incubated with WT1 peptides. CTL were generated specific for p136-144, p235-243 and p117-139, but not for p225-233. CTL data for p235-243 and p117-139 are presented in Figures 11A and 11B. Data for peptides p136-144 and p225-233 are not depicted.

CTL lysis demands that the target WT1 peptides are endogenously processed and presented in association with tumor cell class I MHC molecules. The above WT1 peptide specific CTL were tested for ability to lyse WT1 positive versus negative tumor cell lines. CTL specific for p235-243 lysed targets incubated with the p235-243 peptides, but failed to lyse cell lines that expressed WT1 proteins (Figure 11A). By marked contrast, CTL specific for p117-139 lysed targets incubated with p117-139 peptides and also lysed malignant cells expressing WT1 (Figure 11B). As a negative control, CTL specific for p117-139 did not lyse WT1 negative EL-4 (also referred to herein as E10).

Specificity of WT1 specific lysis was confirmed by cold target inhibition (Figures 12A-12B). Effector cells were plated for various effector: target ratios in 96-well U-bottom plates. A ten-fold excess (compared to hot target) of the indicated peptide-coated target without ⁵¹Cr labeling was added. Finally, 10^{4 51}Cr-labeled target cells per well were added and the plates incubated at 37°C for 4 hours. The total volume per well was 200µl.

10

15

20

Lysis of TRAMP-C by p117-139 specific CTL was blocked from 58% to 36% by EL-4 incubated with the relevant peptide p117-139, but not with EL-4 incubated with an irrelevant peptide (Figure 12A). Similarly, lysis of BLK-SV40 was blocked from 18% to 0% by EL-4 incubated with the relevant peptide p117-139 (Figure 12B). Results validate that WT1 peptide specific CTL specifically kill malignant cells by recognition of processed WT1.

Several segments with putative CTL motifs are contained within p117-139. To determine the precise sequence of the CTL epitope all potential 9-mer peptides within p117-139 were synthesized (Table XLVIII). Two of these peptides (p126-134 and p130-138) were shown to bind to H-2^b class I molecules (Table XLVIII). CTL generated by immunization with p117-139 lysed targets incubated with p126-134 and p130-138, but not the other 9-mer peptides within p117-139 (Figure 13A).

The p117-139 specific CTL line was restimulated with either p126-134 or p130-138. Following restimulation with p126-134 or p130-138, both T cell lines demonstrated peptide specific lysis, but only p130-138 specific CTL showed lysis of a WT1 positive tumor cell line (Figures 13B and 13C). Thus, p130-138 appears to be the naturally processed epitope.

<u>Table XLVIII</u>

<u>Binding of WT1 CTL 9mer Peptides within p117-139 to mouse B6 class I antigens</u>

Peptide				Binding Affinity to Mouse MHC Class I
P117-125	PSQASSGQA	(SEQ	ID	2%
NO:221)				
P118-126	SQASSGQAR	(SEQ	ID	2%
N'O:216)				
P119-127	QASSGQARM	(SEQ	ID	2%
NOs: 161 and	1 288)			
P120-128	ASSGQARMF	(SEQ	ID	1%
NO:40				
P121-129	SSGQARMFP	(SEQ	ID	1%
NO:222)				
P122-130	SGQARMFPN	(SEQ	ID	1%

10

15

Example 6 Identification of WT1 Specific mRNA in Mouse Tumor Cell Lines

This Example illustrates the use of RT-PCR to detect WT1 specific mRNA in cells and cell lines.

Mononuclear cells were isolated by density gradient centrifugation, and were immediately frozen and stored at -80°C until analyzed by RT-PCR for the presence of WT1 specific mRNA. RT-PCR was generally performed as described by Fraizer et al., Blood 86:4704-4706, 1995. Total RNA was extracted from 10⁷ cells according to standard procedures. RNA pellets were resuspended in 25 μL diethylpyrocarbonate treated water and used directly for reverse transcription. The zinc-finger region (exons 7 to 10) was amplified by PCR as a 330 bp mouse cDNA. Amplification was performed in a thermocycler during one or, when necessary, two sequential rounds of PCR. AmpliTaq

10

15

. 25

DNA Polymerase (Perkin Elmer Cetus, Norwalk, CT), 2.5 mM MgCl₂ and 20 pmol of each primer in a total reaction volume of 50μl were used. Twenty μL aliquots of the PCR products were electrophoresed on 2% agarose gels stained with ethidium bromide. The gels were photographed with Polaroid film (Polaroid 667, Polaroid Ltd., Hertfordshire, England). Precautions against cross contamination were taken following the recommendations of Kwok and Higuchi, *Nature 339*:237-238, 1989. Negative controls included the cDNA- and PCR-reagent mixes with water instead of cDNA in each experiment. To avoid false negatives, the presence of intact RNA and adequate cDNA generation was evaluated for each sample by a control PCR using β-actin primers. Samples that did not amplify with these primers were excluded from analysis.

Primers for amplification of WT1 in mouse cell lines were: P115: 1458-1478: 5' CCC AGG CTG CAA TAA GAG ATA 3' (forward primer; SEQ ID NO:21); and P116: 1767-1787: 5' ATG TTG TGA TGG CGG ACC AAT 3' (reverse primer; SEQ ID NO:22) (see Inoue et al, Blood 88:2267-2278, 1996; Fraizer et al., Blood 86:4704-4706, 1995).

Beta Actin primers used in the control reactions were: 5' GTG GGG CGC CCC AGG CAC CA 3' (sense primer; SEQ ID NO:23); and 5' GTC CTT AAT GTC ACG CAC GAT TTC 3' (antisense primer; SEQ ID NO:24)

Primers for use in amplifying human WT1 include: P117: 954-974: 5' GGC

20 ATC TGA GAC CAG TGA GAA 3' (SEQ ID NO:25); and P118: 1434-1414: 5' GAG

AGT CAG ACT TGA AAG CAGT 3' (SEQ ID NO:5). For nested RT-PCR, primers may

be: P119: 1023-1043: 5' GCT GTC CCA CTT ACA GAT GCA 3' (SEQ ID NO:26); and

P120: 1345-1365: 5' TCA AAG CGC CAG CTG GAG TTT 3' (SEQ ID NO:27).

Table XLVIII shows the results of WT1 PCR analysis of mouse tumor cell lines. Within Table IV, (+++) indicates a strong WT1 PCR amplification product in the first step RT PCR, (++) indicates a WT1 amplification product that is detectable by first step WT1 RT PCR, (+) indicates a product that is detectable only in the second step of WT1 RT PCR, and (-) indicates WT1 PCR negative.

<u>Table XLIX</u>
Detection of WT1 mRNA in Mouse Tumor Cell Lines

Cell Line	WT1 mRNA
K562 (human leukemia; ATCC): Positive control; (Lozzio and Lozzio, <i>Blood 45</i> :321-334, 1975)	+++
TRAMPC (SV40 transformed prostate, B6); Foster et al., Cancer Res. 57:3325-3330, 1997	+++
BLK-SV40 HD2 (SV40-transf. fibroblast, B6; ATCC); <i>Nature</i> 276:510-511, 1978	++
CTLL (T-cell, B6; ATCC); Gillis, Nature 268:154-156, 1977)	+
FM (FBL-3 subline, leukemia, B6); Glynn and Fefer, Cancer Res. 28:434-439, 1968	+
BALB 3T3 (ATCC); Aaroston and Todaro, J. Cell. Physiol. 72:141-148, 1968	+
S49.1 (Lymphoma, T-cell like, B/C; ATCC); Horibata and Harris, Exp. Cell. Res. 60:61, 1970	+
BNL CL.2 (embryonic liver, B/C; ATCC); <i>Nature</i> 276:510-511, 1978	+
MethA (sarcoma, B/C); Old et al., Ann. NY Acad. Sci. 101:80-106, 1962	-
P3.6.2.8.1 (myeloma, B/C; ATCC); Proc. Natl. Acad. Sci. USA 66:344, 1970	•
P2N (leukemia, DBA/2; ATCC); Melling et al., J. Immunol. 117:1267-1274, 1976	-
BCL1 (lymphoma, B/C; ATCC); Slavin and Strober, Nature 272:624-626, 1977	- 1
LSTRA (lymphoma, B/C); Glynn et al., Cancer Res. 28:434-439, 1968	- /
E10/EL-4 (lymphoma, B6); Glynn et al., Cancer Res. 28:434-439, 1968	-

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

- 1. A polypeptide comprising an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide comprises no more than 16 consecutive amino acid residues present within a native WT1 polypeptide.
- 2. A polypeptide according to claim 1, wherein the immunogenic portion binds to an MHC class I molecule.
- 3. A polypeptide according to claim 1, wherein the immunogenic portion binds to an MHC class II molecule.
- 4. A polypeptide according to claim 1, wherein the polypeptide comprises a sequence selected from the group consisting of:
 - (a) sequences recited in one or more of Tables II XLVI;
- (b) variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished; and
- (c) mimetics of the foregoing sequences, wherein the ability of the mimetic to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished.
- 5. A polypeptide according to claim 1, wherein the polypeptide comprises a sequence selected from the group consisting of:
- (a) ALLPAVPSL (SEQ ID NO:34), GATLKGVAA (SEQ ID NO:88), CMTWNQMNL (SEQ ID NOs: 49 and 258), SCLESQPTI (SEQ ID NOs: 199 and 296), SCLESQPAI (SEQ ID NO:198), NLYQMTSQL (SEQ ID NOs: 147 and

284); ALLPAVSSL (SEQ ID NOs: 35 and 255), RMFPNAPYL (SEQ ID NOs: 185 and 293);

- (b) variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished; and
- (c) mimetics of the foregoing sequences, wherein the ability of the mimetic to react with antigen-specific antisera and/or T-cell lines or clones is not substantially diminished.
- 6. A polypeptide according to claim 1, wherein the polypeptide comprises 4-16 consecutive amino acids of a native WT1 polypeptide.
- 7. A polypeptide according to claim 1, wherein the polypeptide comprises 8-10 consecutive amino acids of a native WT1 polypeptide.
- 8. A polypeptide comprising an immunogenic portion of amino acid residues 1 174 of a native WT1 polypeptide, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific T-cell lines or clones is not substantially diminished, wherein the polypeptide comprises no more than 16 consecutive amino acid residues present within amino acids 175 to 449 of the native WT1 polypeptide.
- 9. A polypeptide comprising a variant of an immunogenic portion of WT1 that differs in substitutions at between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.
- 10. A mimetic of an immunogenic portion of a WT1 polypeptide, wherein at least one amino acid residue is replaced by a compound that is not an amino

acid, such that the ability of the mimetic to react with antigen-specific antisera and/or T-cell lines or clones is not diminished.

- 11. A pharmaceutical composition comprising a polypeptide according to claim 1, in combination with a pharmaceutically acceptable carrier or excipient.
- 12. A pharmaceutical composition according to claim 11, wherein the polypeptide comprises 4-16 consecutive amino acids of a native WT1 polypeptide.
- 13. A pharmaceutical composition according to claim 11, wherein the polypeptide comprises 8-16 consecutive amino acids of a native WT1 polypeptide.
- 14. A pharmaceutical composition comprising a polypeptide according to claim 8, in combination with a pharmaceutically acceptable carrier or excipient.
- 15. A vaccine comprising a polypeptide according to claim 1, in combination with a non-specific immune response enhancer.
- 16. A vaccine according to claim 15, wherein the polypeptide comprises 4-16 consecutive amino acids of a native WT1 polypeptide.
- 17. A vaccine according to claim 15, wherein the polypeptide comprises 8-10 consecutive amino acids of a native WT1 polypeptide.
- 18. A vaccine according to claim 15, wherein the immune response enhancer is an adjuvant.
- 19. A vaccine comprising a polypeptide according to claim 8, in combination with a non-specific immune response enhancer.

- 20. A vaccine according to claim 19, wherein the immune response enhancer is an adjuvant.
 - 21. A vaccine comprising:
- (a) a WT1 polypeptide, wherein the polypeptide comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific T cell lines or clones is not substantially diminished; and
- (b) a non-specific immune response enhancer that preferentially enhances a T cell response in a patient.
- 22. A vaccine according to claim 21, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic MONTANIDE ISA 720, cytokines (e.g., GM-CSF, Flat3-ligand), microspheres, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvants, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants and inactivated toxins.
- 23. A pharmaceutical composition comprising a mimetic according to claim 10, in combination with a pharmaceutically acceptable carrier or excipient.
- 24. A vaccine compusing a mimetic according to claim 10, in combination with a non-specific immune response enhancer.
- 25. A polynucleotide encoding a polypeptide according to claim 1 or claim 8.
 - 26. A pharmaceutical composition, comprising:

- (a) a polynucleotide encoding a WT1 polypeptide, wherein the polypeptide comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished; and
 - (b) a pharmaceutically acceptable carrier or excipient.
 - 27. A pharmaceutical composition, comprising:
- (a) an antibody or antigen-binding fragment thereof that specifically binds to a WT1 polypeptide; and
 - (b) a pharmaceutically acceptable carrier or excipient.
 - 28. A pharmaceutical composition, comprising:
 - (a) a T cell that specifically reacts with a WT1 polypeptide; and
 - (b) a pharmaceutically acceptable carrier or excipient.
 - 29. A pharmaceutical composition, comprising:
 - (a) an antigen presenting cell that expresses
- (i) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished; and
 - (b) a pharmaceutically acceptable carrier or excipient.
 - 30. A vaccine, comprising:
- (a) a polynucleotide encoding a WT1 polypeptide, wherein the polypeptide comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished; and

- (b) a non-specific immune response enhancer.
- 31. A vaccine, comprising:
- (a) an antigen presenting cell that expresses:
- (i) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished; and
 - (b) a non-specific immune response enhancer.
 - 32. A vaccine comprising:
- (a) an anti-idiotypic antibody or antigen-binding fragment thereof that is specifically bound by an antibody that specifically binds to an immunogenic portion of WT1; and
 - (b) non-specific immune response enhancer.
- 33. A vaccine according to any one of claims 30-32, wherein the immune response enhancer is an adjuvant.
- 34. A vaccine according to any one of claims 30-32, wherein the immune response enhancer preferentially enhances a T cell response in a patient.
- 35. A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a pharmaceutical composition comprising:
- (a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigenspecific antibodies and/or T cell lines or clones is not substantially diminished; and
 - (b) a physiologically acceptable carrier or excipient;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

- 36. A method for enhancing or inducing an immune response in a patient, comprising administering to a patient a pharmaceutical composition according to any one of claims 11, 14, 23 or 26-29.
- 37. A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a vaccine comprising:
- (a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished; and
- (b) a non-specific immune response enhancer; and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.
- 38. A method for enhancing or inducing an immune response in a patient, comprising administering to a patient a vaccine according to any one of claims 15, 19, 21, 24 or 30-32, and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the patient.
- 39. A method for inhibiting the development of a malignant disease associated with WT1 expression in a human patient, comprising administering to a human patient a pharmaceutical composition comprising:
- (a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished; and
 - (b) a physiologically acceptable carrier or excipient;

and thereby inhibiting the development of a malignant disease associated with WT1 expression in the human patient.

- 40. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising administering to a patient a pharmaceutical composition according to any one of claims 11, 14, 23 or 26-29, and thereby inhibiting the development of a malignant disease in the patient.
- 41. A method for inhibiting the development of a malignant disease associated with WT1 expression in a human patient, comprising administering to a patient a vaccine comprising:
- (a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigenspecific antibodies and/or T cell lines or clones is not substantially diminished; and
- (b) a non-specific immune response enhancer; and thereby inhibiting the development of a malignant disease in the patient.
- 42. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising administering to a patient a vaccine according to any one of claims 15, 19, 21, 24 or 30-32, and thereby inhibiting the development of a malignant disease in the patient.
- 43. A method according to claim 39 or claim 41, wherein the malignant disease is a leukemia.
- 44. A method according to claim 43, wherein the leukemia is acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia.

- 45. A method according to claim 39 or claim 41, wherein the malignant disease is a cancer.
- 46. A method according to claim 45, wherein the cancer is breast, lung, thyroid or gastrointestinal cancer or a melanoma.
- 47. A method according to claim 40, wherein the malignant disease is a leukemia.
- 48. A method according to claim 47, wherein the leukemia is acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia.
- 49. A method according to claim 40, wherein the malignant disease is a cancer.
- 50. A method according to claim 49, wherein the cancer is breast, lung, thyroid or gastrointestinal cancer or a melanoma.
- 51. A méthod according to claim 42, wherein the malignant disease is a leukemia.
- 52. A method according to claim 51, wherein the leukemia is acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia.
- 53. A method according to claim 42, wherein the malignant disease is a cancer.
- 54. A method according to claim 53, wherein the cancer is breast, lung, thyroid or gastrointestinal cancer or a melanoma.
- 55. A method according to claim 39, wherein the pharmaceutical composition comprises a WT1 polypeptide that comprises a sequence selected from the

group consisting of sequences recited in one or more of Tables II - XLVI and variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not diminished.

- 56. A method according to claim 39, wherein the pharmaceutical composition comprises a WT1 polypeptide that comprises a sequence selected from the group consisting of ALLPAVPSL (SEQ ID NO:34), GATLKGVAA (SEQ ID NO:88), CMTWNQMNL (SEQ ID NOs: 49 and 258), SCLESQPTI (SEQ ID NOs: 199 and 296), SCLESQPAI (SEQ ID NO:198), NLYQMTSQL (SEQ ID NOs: 147 and 284), ALLPAVSSL (SEQ ID NOs: 35 and 255); RMFPNAPYL (SEQ ID NOs: 185 and 293) and variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not diminished.
- 57. A method according to claim 41, wherein the vaccine comprises a WT1 polypeptide that comprises a sequence selected from the group consisting of sequences recited in one or more of Tables II XLVI and variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not diminished.
- 58. A method according to claim 41, wherein the vaccine comprises a WT1 polypeptide that comprises a sequence selected from the group consisting of ALLPAVPSL (SEQ ID NO:34), GATLKGVAA (SEQ ID NO:88), CMTWNQMNL (SEQ ID NOs: 49 and 258), SCLESQPTI (SEQ ID NOs: 199 and 296), SCLESQPAI (SEQ ID NO:198), NLYQMTSQL (SEQ ID NOs: 147 and 284), ALLPAVSSL (SEQ ID NOs: 35 and 255), RMFPNAPYL (SEQ ID NOs: 185 and 293) and variants of the foregoing sequences that differ in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera and/or T-cell lines or clones is not diminished.

- 59. A method for removing cells expressing WT1 from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood, comprising contacting bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood with T cells that specifically react with a WT1 polypeptide, wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of WT1 positive cells to less than 10% of the number of myeloid or lymphatic cells in the bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood.
- 60. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising administering to a patient bone marrow, peripheral blood or a fraction or bone marrow or peripheral blood prepared according to the method of claim 59.
- 61. A method according to claim 60, wherein the bone marrow, peripheral blood or fraction is autologous.
- 62. A method according to claim 60, wherein the bone marrow, peripheral blood or fraction is syngeneic or allogeneic.
- 63. A method for stimulating and/or expanding T cells, comprising contacting T cells with a WT1 polypeptide, a polynucleotide encoding a WT1 polypeptide and/or an antigen presenting cell that expresses a WT1 polypeptide under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.
- 64. A method according to claim 63, wherein the T cells are present within bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood.

- 65. A method according to claim 63, wherein the bone marrow, peripheral blood or fraction is obtained from a patient afflicted with a malignant disease associated with WT1 expression.
- 66. A method according to claim 63, wherein the bone marrow, peripheral blood or fraction is obtained from a mammal that is not afflicted with a malignant disease associated with WT1 expression.
- 67. A method according to claim 63, wherein the T cells are cloned prior to expansion.
- 68. A method for stimulating and/or expanding T cells in a mammal; comprising administering to a mammal a pharmaceutical composition comprising:
 - (a) one or more of:
 - (i) a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
- (iii) an antigen-presenting cell that expresses a WT1 polypeptide; and
 - (b) a physiologically acceptable carrier or excipient; and thereby stimulating and/or expanding T cells in a mammal.
- 69. A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a vaccine comprising:
 - (a) one or more of:
 - (i) a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
- (iii) an antigen-presenting cell that expresses a WT1 polypeptide; and
 - (b) a non-specific immune response enhancer;and thereby stimulating and/or expanding T cells in a mammal.

- 70. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising administering to a patient T cells prepared according to the method of claim 63.
- 71. A method according to claim 70, wherein the bone marrow, peripheral blood or fraction is obtained from a patient afflicted with a malignant disease associated with WT1 expression.
- 72. A method according to claim 70, wherein the bone marrow, peripheral blood or fraction is obtained from a mammal that is not afflicted with a malignant disease associated with WT1 expression.
- 73. A method for monitoring the effectiveness of an immunization or therapy for a malignant disease associated with WT1 expression in a patient, comprising the steps of:
 - (a) incubating a first biological sample with one or more of:
 - (i) ' a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
- (iii) an antigen-presenting cell that expresses a WT polypeptide

wherein the first biological sample is obtained from a patient prior to a therapy or immunization, and wherein the incubation is performed under conditions and for a time sufficient to allow immunocomplexes to form;

- (b) detecting immunocomplexes formed between the WT1 polypeptide and antibodies in the biological sample that specifically bind to the WT1 polypeptide;
- (c) repeating steps (a) and (b) using a second biological sample obtained from the patient following therapy or immunization; and

- (d) comparing the number of immunocomplexes detected in the first and second biological samples, and therefrom monitoring the effectiveness of the therapy or immunization in the patient.
- 74. A method according to claim 73, wherein the step of detecting comprises (a) incubating the immunocomplexes with a detection reagent that is capable of binding to the immunocomplexes, wherein the detection reagent comprises a reporter group, (b) removing unbound detection reagent, and (c) detecting the presence or absence of the reporter group.
- 75. A method according to claim 74, wherein the detection reagent comprises a second antibody, or antigen-binding fragment thereof, capable of binding to the antibodies that specifically bind to the WT1 polypeptide.
- 76. A method according to claim 74, wherein the detection reagent comprises Protein A.
- 77. A method according to claim 74, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.
- 78. A method according to claim 73 wherein a reporter group is bound to the WT1 polypeptide, and wherein the step of detecting comprises removing unbound WT1 polypeptide and subsequently detecting the presence or absence of the reporter group.
- 79. A method for monitoring the effectiveness of an immunization or therapy for a malignant disease associated with WT1 expression in a patient, comprising the steps of:
 - (a) incubating a first biological sample with one or more of:

- (i) a WT1 polypeptide;
- (ii) a WT1 polynucleotide encoding a WT1 polypeptide; or
- (iii) an antigen-presenting cell that expresses a WT1 polypeptide;

wherein the biological sample comprises CD4+ and/or CD8+ T cells and is obtained from a patient prior to a therapy or immunization, and wherein the incubation is performed under conditions and for a time sufficient to allow specific activation, proliferation and/or lysis of T cells;

- (b) detecting an amount of activation, proliferation and/or lysis of the T cells;
- (c) repeating steps (a) and (b) using a second biological sample comprising CD4+ and/or CD8+ T cells, wherein the second biological sample is obtained from the same patient following therapy or immunization; and
- (d) comparing the amount of activation, proliferation and/or lysis of T cells in the first and second biological samples, and therefrom monitoring the effectiveness of the therapy or immunization in the patient.
- 80. A method according to claim 73 or claim 79, wherein the malignant disease is a cancer or a leukemia.
- 81. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising the steps of:
- (a) incubating CD4⁺ T cells isolated from a patient with one or more of:
 - (i) a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
- (iii) an antigen presenting cell that expresses a WT1 polypeptide;

such that the T cells proliferate; and

- (b) administering to the patient an effective amount of the proliferated T cells, and therefrom inhibiting the development of a malignant disease in the patient.
- 82. A method according to claim 81, wherein the malignant disease is a cancer or a leukemia.
- 83. A method according to claim 81, wherein the step of incubating the T cells is repeated one or more times.
- 84. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising the steps of:
- (a) incubating CD4⁺ T cells isolated from a patient with one or more of:
 - (i) a WT1 polypeptide;
 - (ii) a polynucleotide encoding a WT1 polypeptide; or
- (iii) an antigen presenting cell that expresses a WT1 polypeptide;

such that the T cells proliferate;

- (b) cloning one or more cells that proliferated in the presence of WT1 polypeptide; and
- (c) administering to the patient an effective amount of the cloned T cells.
- 85. A method according to claim 84, wherein the malignant disease is a cancer or a leukemia.
- 86. A method for inhibiting the development of a malignant disease associated with WT1 expression in a patient, comprising the steps of:




FIG. 4




FIG. 10B




FIG. 10C





FIG. 10D








FIG. 11A and 11B


BEST AVAILABLE COPY





BEST AVAILABLE COPY

FIG. 12A and 12B






FIG. 13A-13C

BEST AVAILABLE COPY

1

SEQUENCE LISTING

```
<110> Corixa Corporation et al.
     <120> COMPOSITIONS AND METHODS FOR WT1
       SPECIFIC IMMUNOTHERAPY
     <130> 210121.533PC
     <140> PCT
     <141> 2000-10-04
     <160> 357
     <170> FastSEQ for Windows Version 3.0
     <210> 1
     <211> 17
     <212> PRT
     <213> Homo sapien
     <400> 1
Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro Ser Leu Gly Gly Gly
Gly
     <210> 2
     <211> 23
     <212> PRT
     <213> Homo sapien
     <400> 2
Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe Pro Asn Ala Pro
               5
Tyr Leu Pro Ser Cys Leu Glu
            20
     <210> 3
      <211> 23
      <212> PRT
      <213> Mus musculus
      <400> 3
Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe Pro Asn Ala Pro
Tyr Leu Pro Ser Cys Leu Glu
           20
     <210> 4
      <211> 19
      <212> PRT
      <213> Homo sapien
Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser Val Lys
```

Trp Thr Glu		
<210> 5		
<211> 22		
<212> DNA		
<213> Homo sapien		
<400> 5		
gagagtcaga cttgaaagca gt	. 22	:
<210> 6		
<211> 20		
<212> DNA		
<213> Homo sapien		
<400> 6		
ctgagcctca gcaaatgggc	. 20)
<210> 7		1
<211> 27		•
<212> DNA		
<213> Homo sapien		
<400> 7		
gagcatgcat gggctccgac gtgcggg	27	1
<210> 8	•	
<211> 25		
<212> DNA		
<213> Homo sapien		
<400> 8		
ggggtaccca ctgaacggtc cccga	25	5
<210> 9		
<211> 18		
<211> 10 <212> DNA		
<213> Mus musculus	/	
<400> 9		_
teegageege aceteatg	18	3
<210> 10		
<211> 18		
<212> DNA	•	
<213> Mus musculus		
<400> 10		
gcctgggatg ctggactg	18	3
<210> 11		
	•	
<211> 27		
<212> DNA		
<213> Mus musculus		
<400> 11		
gagcatgcga tgggttccga cgtgcgg	27	7

3

```
<210> 12
       <211> 29
       <212> DNA
       <213> Mus musculus
       <400> 12
. ggggtacctc aaagcgccac gtggagttt
       <210> 13
       <211> 17
       <212> PRT
       <213> Mus musculus
       <400> 13
 Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Ser Ser Leu Gly Gly
                  5
                                     10
 1
 Gly
       <210> 14
       <211> 19
       <212> PRT
       <213> Mus musculus
       <400> 14
 Gly Ala Thr Leu Lys Gly Met Ala Ala Gly Ser Ser Ser Val Lys
 Trp Thr Glu
       <210> 15
       <211> 15
       <212> PRT
       <213> Homo sapien
       <400> 15
 Arg Ile His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg
                                     10
                  5
       <210> 16
       <211> 15
       <212> PRT
       <213> Mus musculus
       <400> 16
 Arg Ile His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg
                                     10
       <210> 17
       <211> 14
       <212> PRT
       <213> Mus musculus
       <400> 17
 Val Arg Arg Val Ser Gly Val Ala Pro Thr Leu Val Arg Ser
  1
```

```
<210> 18
      <211> 14
      <212> PRT
      <213> Homo sapien
      <400> 18
Val Arg Arg Val Pro Gly Val Ala Pro Thr Leu Val Arg Ser
      <210> 19
      <211> 15
<212> PRT
      <213> Homo sapien
      <400> 19
Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His His
                                     10
      <210> 20
      <211> 15
      <212> PRT
      <213> Mus musculus
      <400> 20
Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His His
      <210> 21
      <211> 21
      <212> DNA
      <213> Mus musculus
      <400> 21
cccaggctgc aataagagat a
                                                                         21
      <210> 22
      <211> 21
      <212> DNA
      <213> Mus musculus
      <400> 22
atgttgtgat ggcggaccaa t
                                                                         21
      <210> 23
      <211> 20
      <212> DNA
      <213> Homo sapien
      <400> 23
gtggggcgcc ccaggcacca
                                                                         20
      <210> 24
      <211> 24
      <212> DNA
      <213> Homo sapien
      <400> 24
gtccttaatg ctacgcacga tttc
                                                                         24
```

21

21

21

```
<210> 25
      <211> 21
      <212> DNA
      <213> Homo sapien
      <400> 25
ggcatctgag accagtgaga a
      <210> 26
      <211> 21
      <212> DNA
      <213> Homo sapien
      <400> 26
gctgtcccac ttacagatgc a
      <210> 27
      <211> 21
      <212> DNA
      <213> Homo sapien
      <400> 27
tcaaagcgcc agctggagtt t
      <210> 28
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 28
Ala Ala Gly Ser Ser Ser Ser Val Lys
      <210> 29
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 29
Ala Ala Gln Phe Pro Asn His Ser Phe
      <210> 30
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 30
Ala Glu Pro His Glu Glu Gln Cys Leu
                 5
 1
      <210> 31
      <211> 9
      <212> PRT
      <213> Homo sapien
```

<400> 31

```
Ala Gly Ala Cys Arg Tyr Gly Pro Phe
     <210> 32
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 32
Ala Gly Ser Ser Ser Ser Val Lys Trp
     <210> 33
     <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 33
Ala Ile Arg Asn Gln Gly Tyr Ser Thr
                 5
      <210> 34
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 34
Ala Leu Leu Pro Ala Val Pro Ser Leu
      <210> 35
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 35
Ala Leu Leu Pro Ala Val Ser Ser Leu
     <210> 36
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 36
Ala Gln Phe Pro Asn His Ser Phe Lys
      <210> 37
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 37
Ala Gln Trp Ala Pro Val Leu Asp Phe
```

<210> 38

```
<211> 9
     <212> PRT
     <213> Homo sapien
     <400> 38
Ala Arg Met Phe Pro Asn Ala Pro Tyr
1
                5
     <210> 39
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 39
Ala Arg Ser Asp Glu Leu Val Arg His
      <210> 40
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 40
Ala Ser Ser Gly Gln Ala Arg Met Phe
      <210> 41
      <211> 9
      <21.2> PRT
      <213> Homo sapien
      <400> 41
Ala Tyr Gly Ser Leu Gly Gly Pro Ala
      <210> 42
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 42
Ala Tyr Pro Gly Cys Asn Lys Arg Tyr
1
      <210> 43
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 43
Cys Ala Leu Pro Val Ser Gly Ala Ala
      <210> 44
      <211> 9
      <212> PRT
```

<213> Homo sapien

```
<400> 44
Cys Ala Tyr Pro Gly Cys Asn Lys Arg
      <210> 45
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 45
Cys His Thr Pro Thr Asp Ser Cys Thr
      <210> 46
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 46
Cys Lys Thr Cys Gln Arg Lys Phe Ser
      <210> 47
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 47
Cys Leu Glu Ser Gln Pro Ala Ile Arg
      <210> 48
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 48
Cys Leu Ser Ala Phe Thr Val His Phe
      <210> 49
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 49
Cys Met Thr Trp Asn Gln Met Asn Leu
      <210> 50
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 50
Cys Arg Trp Pro Ser Cys Gln Lys Lys
```

```
<210> 51
     <211> 9
     <212> PRT
      <213> Homo sapien
      <400> 51
Cys Arg Tyr Gly Pro Phe Gly Pro Pro
                5
     <210> 52
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 52
Cys Thr Gly Ser Gln Ala Leu Leu Leu
     <210> 53
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 53
Asp Glu Leu Val Arg His His Asn Met
     <210> 54
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 54
Asp Phe Ala Pro Pro Gly Ala Ser Ala
      <210> 55
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 55
Asp Phe Lys Asp Cys Glu Arg Arg Phe
      <210> 56
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 56
Asp Gly Thr Pro Ser Tyr Gly His Thr
      <210> 57
      <211> 9
      <212> PRT
      <213> Homo sapien
```

```
<400> 57
Asp His Leu Lys Thr His Thr Arg Thr
      <210> 58
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 58
Asp Leu Asn Ala Leu Leu Pro Ala Val
      <210> 59
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 59
Asp Pro Met Gly Gln Gln Gly Ser Leu
               5 ·
      <210> 60
      <211> 9
<212> PRT
      <213> Homo sapien
      <400> 60
Asp Gln Leu Lys Arg His Gln Arg Arg
      <210> 61
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 61
Asp Ser Cys Thr Gly Ser Gln Ala Leu
                5
      <210> 62
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 62
Asp Val Arg Asp Leu Asn Ala Leu Leu
      <210> 63
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 63
Asp Val Arg Arg Val Pro Gly Val Ala
```

```
<210> 64
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 64
Glu Asp Pro Met Gly Gln Gln Gly Ser
     <210> 65
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 65
Glu Glu Gln Cys Leu Ser Ala Phe Thr
     <210> 66
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 66
Glu Lys Pro Tyr Gln Cys Asp Phe Lys
     <210> 67
     <211> 9
     <212> PRT
     <213> Homo sapien
<400> 67
Glu Lys Arg Pro Phe Met Cys Ala Tyr
                5
1
     <210> 68
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 68
Glu Pro His Glu Glu Gln Cys Leu Ser
     <210> 69
      <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 69
Glu Gln Cys Leu Ser Ala Phe Thr Val
 1
     <210> 70.
     <211> 9
```

<212> PRT

```
<213> Homo sapien
      <400> 70
Glu Ser Asp Asn His Thr Ala Pro Ile
 1 5
      <210> 71
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 71
Glu Ser Asp Asn His Thr Thr Pro Ile
     <210> 72
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 72
Glu Ser Gln Pro Ala Ile Arg Asn Gln
   5
     <210> 73
     <211> 9
     <212> PRT
    <213> Homo sapien
     <400> 73
Glu Thr Ser Glu Lys Arg Pro Phe Met
     <210> 74
     <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 74
Phe Ala Pro Pro Gly Ala Ser Ala Tyr
     <210> 75
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 75
Phe Ala Arg Ser Asp Glu Leu Val Arg
     <210> 76
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 76
Phe Gly Pro Pro Pro Pro Ser Gln Ala
```

```
<210> 77
     <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 77
Phe Lys Asp Cys Glu Arg Arg Phe Ser
     <210> 78
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 78
Phe Lys Leu Ser His Leu Gln Met His
     <210> 79
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 79
Phe Pro Asn Ala Pro Tyr Leu Pro Ser
      <210> 80
      <211> 9
      <212> PRT
      <213> Homo sapien ,
      <400> 80
Phe Gln Cys Lys Thr Cys Gln Arg Lys
                5
      <210> 81
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 81
Phe Arg Gly Ile Gln Asp Val Arg Arg
      <210> 82
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 82
Phe Ser Gly Gln Phe Thr Gly Thr Ala
     <210> 83
      <211> 9
```

```
<212> PRT
      <213> Homo sapien
      <400> 83
Phe Ser Arg Ser Asp Gln Leu Lys Arg
      <210> 84
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 84
Phe Thr Gly Thr Ala Gly Ala Cys Arg
      <210> 85
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 85
Phe Thr Val His Phe Ser Gly Gln Phe
      <210> 86
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 86
Gly Ala Ala Gln Trp Ala Pro Val Leu
      <210> 87
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 87
Gly Ala Glu Pro His Glu Glu Gln Cys
                 5
      <210> 88
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 88
Gly Ala Thr Leu Lys Gly Val Ala Ala
      <210> 89
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 89
```

```
Gly Cys Ala Leu Pro Val Ser Gly Ala
     <210> 90
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 90
Gly Cys Asn Lys Arg Tyr Phe Lys Leu
     <210> 91
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 91
Gly Glu Lys Pro Tyr Gln Cys Asp Phe 1 5
     <210> 92
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 92
Gly Gly Gly Cys Ala Leu Pro Val
      <210> 93
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 93
Gly Gly Pro Ala Pro Pro Pro Ala Pro
      <210> 94
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 94
Gly His Thr Pro Ser His His Ala Ala
      <210> 95
      <211> 9
      <212> PRT
      <213> Homo sapien
<400> 95
Gly Lys Thr Ser Glu Lys Pro Phe Ser
                5
    <210> 96
```

```
<211> 9
      <212> PRT
      <213> Homo sapien
     <400> 96
Gly Pro Phe Gly Pro Pro Pro Ser
    5
      <210> 97
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 97
Gly Pro Pro Pro Pro Ser Gln Ala Ser
      <210> 98
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 98
Gly Gln Ala Arg Met Phe Pro Asn Ala
     <210> 99
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 99
Gly Gln Phe Thr Gly Thr Ala Gly Ala
     <210> 100
      <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 100
Gly Gln Ser Asn His Ser Thr Gly Tyr
        5
     <210> 101
     <211> 9
     <212> PRT
     <213> Homo sapien
   <400> 101
Gly Ser Asp Val Arg Asp Leu Asn Ala
     <210> 102
     <211> 9
     <212> PRT
```

<213> Homo sapien

```
<400> 102
Gly Ser Gln Ala Leu Leu Leu Arg Thr
     <210> 103
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 103
Gly Val Phe Arg Gly Ile Gln Asp Val
      <210> 104
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 104
Gly Val Lys Pro Phe Gln Cys Lys Thr
      5
      <210> 105
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 105
Gly Tyr Glu Ser Asp Asn His Thr Ala
      <210> 106
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 106
Gly Tyr Glu Ser Asp Asn His Thr Thr
      <210> 107
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 107
His Glu Glu Gln Cys Leu Ser Ala Phe
      <210> 108
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 108
 His His Asn Met His Gln Arg Asn Met
                5
 1
```

```
<210> 109
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 109
His Gln Arg Arg His Thr Gly Val Lys
      <210> 110
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 110
His Ser Phe Lys His Glu Asp Pro Met
      <210> 111
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 111
His Ser Arg Lys His Thr Gly Glu Lys
      <210> 112
     <211> 9
      <212> PRT
      <213> Homo sapien
    <400> 112
His Thr Gly Glu Lys Pro Tyr Gln Cys
      <210> 113
      <211> 9
      <212> PRT
      <213> Homo sapien
   <400> 113
His Thr His Gly Val Phe Arg Gly Ile
      <210> 114
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 114
His Thr Arg Thr His Thr Gly Lys Thr
                 5
      <210> 115
      <211> 9
      <212> PRT
      <213> Homo sapien
```

```
<400> 115
His Thr Thr Pro Ile Leu Cys Gly Ala
     <210> 116
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 116
Ile Leu Cys Gly Ala Gln Tyr Arg Ile
    5
     <210> 117
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 117
Ile Arg Asn Gln Gly Tyr Ser Thr Val
     <210> 118
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 118
Lys Asp Cys Glu Arg Arg Phe Ser Arg
     <210> 119
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 119
Lys Phe Ala Arg Ser Asp Glu Leu Val
     <210> 120
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 120
Lys Phe Ser Arg Ser Asp His Leu Lys
      <210> 121
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 121
Lys His Glu Asp Pro Met Gly Gln Gln
```

```
<210> 122
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 122
Lys Lys Phe Ala Arg Ser Asp Glu Leu
      <210> 123
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 123
Lys Pro Phe Ser Cys Arg Trp Pro Ser
      <210> 124
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 124
Lys Pro Tyr Gln Cys Asp Phe Lys Asp
      <210> 125
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 125
Lys Gln Glu Pro Ser Trp Gly Gly Ala
      <210> 126
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 126
Lys Arg His Gln Arg Arg His Thr Gly
      <210> 127
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 127
Lys Arg Tyr Phe Lys Leu Ser His Leu
     <210> 128
      <211> 9
```

<212> PRT

```
<213> Homo sapien
     <400> 128
Lys Thr Cys Gln Arg Lys Phe Ser Arg
     <210> 129
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 129
Lys Thr Ser Glu Lys Pro Phe Ser Cys
     <210> 130
     <211> 9
     <212> PRT
      <213> Homo sapien
     <400> 130
Leu Asp Phe Ala Pro Pro Gly Ala Ser
     5
1
     <210> 131
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 131
Leu Glu Cys Met Thr Trp Asn Gln Met
               5
     <210> 132
     <211> 9
     <212> PRT
     .<213> Homo sapien
     <400> 132
Leu Glu Ser Gln Pro Ala Ile Arg Asn
      <210> 133
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 133
Leu Gly Ala Thr Leu Lys Gly Val Ala
      <210> 134
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 134
Leu Gly Gly Gly Gly Cys Ala Leu
```

```
1
      <210> 135
<211> 9
<212> PRT
      <213> Homo sapien
      <400> 135
Leu Lys Gly Val Ala Ala Gly Ser Ser
      <210> 136
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 136
Leu Lys Arg His Gln Arg Arg His Thr
 1
                 5
      <210> 137
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 137
Leu Lys Thr His Thr Arg Thr His Thr .
      <210> 138
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 138
Leu Pro Val Ser Gly Ala Ala Gln Trp
      <210> 139
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 139
Leu Gln Met His Ser Arg Lys His Thr
      <210> 140
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 140
Leu Arg Thr Pro Tyr Ser Ser Asp Asn
     <210> 141
     <211> 9
```

```
<212> PRT
     <213> Homo sapien
     <400> 141
Leu Ser His Leu Gln Met His Ser Arg
               5
1
     <210> 142
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 142
Met Cys Ala Tyr Pro Gly Cys Asn Lys
     <210> 143
     <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 143
Met His Gln Arg Asn Met Thr Lys Leu
      <210> 144
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 144
Asn Ala Pro Tyr Leu Pro Ser Cys Leu
      <210> 145
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 145
Asn Lys Arg Tyr Phe Lys Leu Ser His
      <210> 146
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 146
Asn Leu Gly Ala Thr Leu Lys Gly Val
      <210> 147
      <211> 9
      <212> PRT
      <213> Homo sapien
```

<400> 147

```
Asn Leu Tyr Gln Met Thr Ser Gln Leu
     <210> 148
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 148
Asn Met His Gln Arg Asn Met Thr Lys
     <210> 149
     <211> 9
    <212> PRT
     <213> Homo sapien
     <400> 149
Asn Met Thr Lys Leu Gln Leu Ala Leu
1
     <210> 150
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 150
Asn Gln Gly Tyr Ser Thr Val Thr Phe
     <210> 151
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 151
Asn Gln Met Asn Leu Gly Ala Thr Leu
     <210> 152
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 152
Pro Ala Ile Arg Asn Gln Gly Tyr Ser
1
     <210> 153
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 153
Pro Gly Ala Ser Ala Tyr Gly Ser Leu
1
    <210> 154
```

PCT/US00/27465 WO 01/25273

25

```
<211> 9
     <212> PRT
     <213> Homo sapien
     <400> 154
Pro His Glu Glu Gln Cys Leu Ser Ala
     <210> 155
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 155
Pro Ile Leu Cys Gly Ala Gln Tyr Arg
     <210> 156
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 156
Pro Pro Pro Pro His Ser Phe Ile Lys
     <210> 157
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 157
Pro Pro Pro Pro Pro His Sep Phe Ile
       5
     <210> 158
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 158
Pro Pro Pro Pro Pro His Ser Phe
                5
     <210> 159
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 159
Pro Ser Cys Gln Lys Lys Phe Ala Arg
     <210> 160
     <211> 9
      <212> PRT
```

<213> Homo sapien

```
<400> 160
Gln Ala Leu Leu Leu Arg Thr Pro Tyr
      <210> 161
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 161
Gln Ala Ser Ser Gly Gln Ala Arg Met
     <210> 162
      <211> 9
     <212> PRT
      <213> Homo sapien
     <400> 162
Gln Cys Asp Phe Lys Asp Cys Glu Arg
 1
     <210> 163
    <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 163
Gln Cys Lys Thr Cys Gln Arg Lys Phe
    <210> 164
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 164
Gln Asp Val Arg Arg Val Pro Gly Val
     <210> 165
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 165
Gln Phe Thr Gly Thr Ala Gly Ala Cys
1
     <210> 166
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 166
Gln Gly Ser Leu Gly Glu Gln Gln Tyr
```

```
<210> 167
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 167
Gln Leu Glu Cys Met Thr Trp Asn Gln 1 5
      <210> 168
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 168
Gln Met Asn Leu Gly Ala Thr Leu Lys
               5
      <210> 169
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 169
Gln Met Thr Ser Gln Leu Glu Cys Met
      5
      <210> 170
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 170
Gln Pro Ala Ile Arg Asn Gln Gly Tyr
               5
    <210> 171
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 171
Gln Gln Tyr Ser Val Pro Pro Pro Val
 1
      <210> 172
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 172
Gln Arg Lys Phe Ser Arg Ser Asp His
      <210> 173
      <211> 9
      <212> PRT
     <213> Homo sapien
```

```
<400> 173
Gln Arg Asn Met Thr Lys Leu Gln Leu
     <210> 174
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 174
Gln Trp Ala Pro Val Leu Asp Phe Ala
     <210> 175
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 175
Gln Tyr Arg Ile His Thr His Gly Val
                5 ·
      <210> 176
     <211> 9
     <212> PRT
      <213> Homo sapien
     <400> 176
Gln Tyr Ser Val Pro Pro Pro Val Tyr
     <210> 177
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 177
Arg Asp Leu Asn Ala Leu Leu Pro Ala
     <210> 178
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 178
Arg Phe Ser Arg Ser Asp Gln Leu Lys
     <210> 179
      <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 179
Arg Gly Ile Gln Asp Val Arg Arg Val
```

```
<210> 180
       <211> 9
       <212> PRT
       <213> Homo sapien
       <400> 180
 Arg His His Asn Met His Gln Arg Asn
       <210> 181
       <211> 9
       <212> PRT
       <213> Homo sapien
       <400> 181
 Arg His Gln Arg Arg His Thr Gly Val
       <210> 182
       <211> 9
       <212> PRT
       <213> Homo sapien
      <400> 182
· Arg Ile His Thr His Gly Val Phe Arg
       <210> 183
       <211> 9
       <212> PRT
       <213> Homo sapien
      <400> 183
 Arg Lys Phe Ser Arg Ser Asp His Leu
       <210> 184
       <211> 9
       <212> PRT
       <213> Homo sapien
       <400> 184
 Arg Lys His Thr Gly Glu Lys Pro Tyr
       <210> 185
       <211> 9
       <212> PRT
       <213> Homo sapien
       <400> 185
 Arg Met Phe Pro Asn Ala Pro Tyr Leu
                  5
       <210> 186
       <211> 9
       <212> PRT
```

```
<213> Homo sapien
      <400> 186
Arg Asn Met Thr Lys Leu Gln Leu Ala
   5
      <210> 187
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 187
Arg Arg Phe Ser Arg Ser Asp Gln Leu
                5
     <210> 188
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 188
Arg Arg His Thr Gly Val Lys Pro Phe
     <210> 189
     <211> 9
     <212> PRT .
     <213> Homo sapien
     <400> 189
Arg Arg Val Pro Gly Val Ala Pro Thr
     <210> 190
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 190
Arg Ser Ala Ser Glu Thr Ser Glu Lys
1
     <210> 191
     <211> 9
    ' <212> PRT
     <213> Homo sapien
     <400> 191
Arg Ser Asp Glu Leu Val Arg His His
     <210> 192
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 192
Arg Ser Asp His Leu Lys Thr His Thr
```

```
1
      <210> 193
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 193
Arg Ser Asp Gln Leu Lys Arg His Gln
     <210> 194
<211> 9
    <212> PRT
     <213> Homo sapien
     <400> 194
Arg Thr Pro Tyr Ser Ser Asp Asn Leu
                5
      <210> 195
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 195
Arg Val Pro Gly Val Ala Pro Thr Leu
      5
      <210> 196
      <211> 9
      <212> PRT
      <213> Homo sapien .
      <400> 196
Arg Trp Pro Ser Cys Gln Lys Lys Phe
      <210> 197
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 197
Ser Ala Ser Glu Thr Ser Glu Lys Arg
                 5
      <210> 198
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 198
Ser Cys Leu Glu Ser Gln Pro Ala Ile
      <210> 199
      <211> 9
```

```
<212> PRT
      <213> Homo sapien
      <400> 199
Ser Cys Leu Glu Ser Gln Pro Thr Ile
      <210> 200
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 200
Ser Cys Gln Lys Lys Phe Ala Arg Ser
      <210> 201
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 201
Ser Cys Arg Trp Pro Ser Cys Gln Lys
      <210> 202
      <211> 9
      <212> PRT
     <213> Homo sapien
    <400> 202
Ser Cys Thr Gly Ser Gln Ala Leu Leu
     <210> 203
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 203
Ser Asp Glu Leu Val Arg His His Asn
1 5
     <210> 204
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 204
Ser Asp Asn His Thr Thr Pro Ile Leu
     <210> 205
     <211> 9
     <212> PRT
     <213> Homo sapien
    <400> 205
```

```
Ser Asp Asn Leu Tyr Gln Met Thr Ser
     <210> 206
     <211> 9
     <212> PRT ·
     <213> Homo sapien
     <400> 206
Ser Asp Val Arg Asp Leu Asn Ala Leu
                5
     <210> 207
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 207
Ser Glu Lys Pro Phe Ser Cys Arg Trp
     <210> 208
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 208
Ser Glu Lys Arg Pro Phe Met Cys Ala
     <210> 209
     <211> 9
     <212> PRT
      <213> Homo sapien
     <400> 209
Ser Glu Thr Ser Glu Lys Arg Pro Phe
     <210> 210
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 210
Ser Phe Ile Lys Gln Glu Pro Ser Trp
                5
      <210> 211
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 211
Ser Gly Ala Ala Gln Trp Ala Pro Val
1
 <210> 212
```

```
<211> 9
      <212> PRT
      <213> Homo sapien
      <400> 212
Ser Gly Gln Ala Arg Met Phe Pro Asn
      5
      <210> 213
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 213
Ser His His Ala Ala Gln Phe Pro Asn
 1
      <210> 214
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 214
Ser Leu Gly Glu Gln Gln Tyr Ser Val
 1
     <210> 215
     <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 215
Ser Leu Gly Gly Gly Gly Cys Ala
     <210> 216
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 216
Ser Gln Ala Ser Ser Gly Gln Ala Arg
1
               5
     <210> 217
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 217
Ser Ser Asp Asn Leu Tyr Gln Met Thr
     <210> 218
     <211> 9
     <212> PRT
     <213> Homo sapien
```

```
<400> 218
Ser Val Pro Pro Pro Val Tyr Gly Cys
     <210> 219
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 219
Thr Cys Gln Arg Lys Phe Ser Arg Ser
     <210> 220
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 220
Thr Asp Ser Cys Thr Gly Ser Gln Ala
     <210> 221
     <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 221
Thr Glu Gly Gln Ser Asn His Ser Thr
     <210> 222
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 222
Thr Gly Lys Thr Ser Glu Lys Pro Phe
      <210> 223
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 223
Thr Gly Ser Gln Ala Leu Leu Leu Arg
      <210> 224
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 224
Thr Gly Thr Ala Gly Ala Cys Arg Tyr
```

```
<210> 225
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 225
Thr Gly Tyr Glu Ser Asp Asn His Thr
     <210> 226
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 226
Thr Leu Val Arg Ser Ala Ser Glu Thr
     <210> 227
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 227
Thr Pro Ile Leu Cys Gly Ala Gln Tyr
     <210> 228
     .<211> 9
     <212> PRT
     <213> Homo sapien
    <400> 228
Thr Pro Ser His His Ala Ala Gln Phe
     <210> 229
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 229
Thr Pro Ser Tyr Gly His Thr Pro Ser
     5
     <210> 230
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 230
Thr Pro Thr Asp Ser Cys Thr Gly Ser
     <210> 231
     <211> 9
     <212> PRT
     <213> Homo sapien
```

PCT/US00/27465 WO 01/25273

37

```
<400> 231
Thr Pro Tyr Ser Ser Asp Asn Leu Tyr
     <210> 232
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 232
Thr Ser Glu Lys Pro Phe Ser Cys Arg
     <210> 233
     <211> 9
     <212> PRT
     <213> Homo sapien
     <400> 233
Thr Ser Glu Lys Arg Pro Phe Met Cys
     <210> 234
     <211> 9
      <212> PRT
     <213> Homo sapien
     <400> 234
Thr Ser Gln Leu Glu Cys Met Thr Trp
                5
     <210> 235
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 235
Thr Val His Phe Ser Gly Gln Phe Thr
     <210> 236
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 236
Val Ala Ala Gly Ser Ser Ser Ser Val
                5
     <210> 237
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 237
Val Ala Pro Thr Leu Val Arg Ser Ala
```

```
<210> 238
       <211> 9
       <212> PRT
       <213> Homo sapien
       <400> 238
 Val Phe Arg Gly Ile Gln Asp Val Arg
 1 5
      <210> 239
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 239
 Val Lys Pro Phe Gln Cys Lys Thr Cys
            5
      <210> 240
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 240
 Val Lys Trp Thr Glu Gly Gln Ser Asn
. 1
   <210> 241
<211> 9
      <212> PRT
      <213> Homo sapien
     <400> 241
 Val Leu Asp Phe Ala Pro Pro Gly Ala
     <210> 242
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 242
 Val Pro Gly Val Ala Pro Thr Leu Val
      <210> 243
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 243
Val Arg His His Asn Met His Gln Arg
     <210> 244
     <211> 9
     <212> PRT
```

```
<213> Homo sapien
      <400> 244
Val Thr Phe Asp Gly Thr Pro Ser Tyr
      <210> 245
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 245
Trp Asn Gln Met Asn Leu Gly Ala Thr
      <210> 246
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 246
Trp Pro Ser Cys Gln Lys Lys Phe Ala
      <210> 247
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 247
Trp Thr Glu Gly Gln Ser Asn His Ser
      <210> 248
      <211> 9
      <212> PRT
      <213> Homo sapien
     <400> 248
Tyr Phe Lys Leu Ser His Leu Gln Met
                 5
      <210> 249
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 249
Tyr Gly His Thr Pro Ser His His Ala
      <210> 250
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 250
Tyr Pro Gly Cys Asn Lys Arg Tyr Phe
```

```
1
      <210> 251
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 251
Tyr Gln Met Thr Ser Gln Leu Glu Cys
      <210> 252
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 252
Tyr Arg Ile His Thr His Gly Val Phe
                 5
      <210> 253
      <211> 9
      <212> PRT
      <213> Homo sapien
      <400> 253
Tyr Ser Ser Asp Asn Leu Tyr Gln Met
              5
      <210> 254
      <211> 9
      <212> PRT
      <213> Mus musculus .
      <400> 254
Ala Glu Pro His Glu Glu Gln Cys Leu
      <210> 255
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 255
Ala Leu Leu Pro Ala Val Ser Ser Leu
     5
1
      <210> 256
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 256
Ala Tyr Gly Ser Leu Gly Gly Pro Ala
     <210> 257
     <211> 9
```

```
<212> PRT
     <213> Mus musculus
     <400> 257
Ala Tyr Pro Gly Cys Asn Lys Arg Tyr
     <210> 258
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 258
Cys Met Thr Trp Asn Gln Met Asn Leu
     <210> 259
     <211> 9
     <212> PRT
     <213> Mus musculus
    <400> 259
Cys Thr Gly Ser Gln Ala Leu Leu Leu
    . <210> 260
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 260
Asp Gly Ala Pro Ser Tyr Gly His Thr
     <210> 261
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 261
Asp Leu Asn Ala Leu Leu Pro Ala Val
     <210> 262
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 262
Asp Pro Met Gly Gln Gln Gly Ser Leu
     <210> 263
      <211> 9
     <212> PRT
     <213> Mus musculus
  <400> 263
```

```
Asp Ser Cys Thr Gly Ser Gln Ala Leu
     <210> 264
      <211> 9
      <212> PRT
     <213> Mus musculus
    <400> 264
Asp Val Arg Asp Leu Asn Ala Leu Leu
     <210> 265
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 265
Glu Gln Cys Leu Ser Ala Phe Thr Leu
 1
     <210> 266
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 266
Glu Ser Asp Asn His Thr Ala Pro Ile
     <210> 267
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 267
Phe Pro Asn Ala Pro Tyr Leu Pro Ser
     <210> 268
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 268
Gly Cys Asn Lys Arg Tyr Phe Lys Leu
     <210> 269
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 269
Gly Gln Ala Arg Met Phe Pro Asn Ala
    <210> 270
```

```
<211> 9
     <212> PRT
     <213> Mus musculus
     <400> 270
Gly Val Phe Arg Gly Ile Gln Asp Val
1
     <210> 271
     <211> 9
     <212> PRT
     <213> Mus musculus
    <400> 271
Gly Tyr Glu Ser Asp Asn His Thr Ala
     <210> 272
     <211> 9
      <212> PRT
     <213> Mus musculus
     <400> 272
His Ser Phe Lys His Glu Asp Pro Met
     <210> 273
     <211> 9.
     <212> PRT
     <213> Mus musculus
     <400> 273
His Thr His Gly Val Phe Arg Gly Ile
                5
     <210> 274
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 274
Ile Leu Cys Gly Ala Gln Tyr Arg Ile
      <210> 275
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 275
Lys Phe Ala Arg Ser Asp Glu Leu Val
      <210> 276
      <211> 9
      <212> PRT
      <213> Mus musculus
```

```
<400> 276
Lys Arg Tyr Phe Lys Leu Ser His Leu
      <210> 277
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 277
Lys Thr Ser Glu Lys Pro Phe Ser Cys
      <210> 278
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 278
Leu Glu Cys Met Thr Trp Asn Gln Met
      <210> 279
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 279
Leu Gly Gly Gly Gly Cys Gly Leu
      <210> 280
      <211> 9
      <212> PRT
      <213> Mus musculus
    <400> 280
Leu Gln Met His Ser Arg Lys His Thr
                5
      <210> 281
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 281
Met His Gln Arg Asn Met Thr Lys Leu
     <210> 282
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 282
Asn Ala Pro Tyr Leu Pro Ser Cys Leu
```

```
<210> 283
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 283
Asn Leu Gly Ala Thr Leu Lys Gly Met
     <210> 284
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 284
Asn Leu Tyr Gln Met Thr Ser Gln Leu
1 5
     <210> 285
     <211> 9
     <212> PRT
     <213> Mus musculus
     <400> 285
Asn Met Thr Lys Leu His Val Ala Leu
     <210> 286
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 286
Asn Gln Met Asn Leu Gly Ala Thr Leu
     <210> 287
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 287
Pro Gly Ala Ser Ala Tyr Gly Ser Leu
      <210> 288
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 288
Gln Ala Ser Ser Gly Gln Ala Arg Met
 1
      <210> 289
      <211> 9
      <212> PRT
      <213> Mus musculus
```

```
<400> 289
Gln Met Thr Ser Gln Leu Glu Cys Met
      <210> 290
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 290
Gln Gln Tyr Ser Val Pro Pro Pro Val
      <210> 291
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 291
Gln Tyr Arg Ile His Thr His Gly Val
      <210> 292
      <211> 9
      <212> PRT
      <213> Mus musculus
    <400> 292
Gln Tyr Ser Val Pro Pro Pro Val Tyr
     <210> 293
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 293
Arg Met Phe Pro Asn Ala Pro Tyr Leu
      <210> 294
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 294
Arg Thr Pro Tyr Ser Ser Asp Asn Leu
     <210> 295
      <211> 9
      <212> PRT
     <213> Mus musculus
     <400> 295
Arg Val Ser Gly Val Ala Pro Thr Leu
```

```
<210> 296
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 296
 Ser Cys Leu Glu Ser Gln Pro Thr Ile
  1 5
      <210> 297
      <211> 9
       <212> PRT
       <213> Mus musculus
      <400> 297
 Ser Cys Gln Lys Lys Phe Ala Arg Ser
       <210> 298
       <211> 9
       <212> PRT
       <213> Mus musculus
      <400> 298
· Ser Asp Val Arg Asp Leu Asn Ala Leu
       <210> 299
       <211> 9
       <212> PRT
       <213> Mus musculus
      <400> 299
 Ser Leu Gly Glu Gln Gln Tyr Ser Val
  1 . 5
       <210> 300
       <211> 9
       <212> PRT
       <213> Mus musculus
      <400> 300
 Thr Cys Gln Arg Lys Phe Ser Arg Ser
       <210> 301
       <211> 9
       <212> PRT
       <213> Mus musculus
      <400> 301
 Thr Glu Gly Gln Ser Asn His Gly Ile
  1
       <210> 302
       <211> 9
```

<212> PRT

```
<213> Mus musculus
      <400> 302
Thr Leu His Phe Ser Gly Gln Phe Thr
      <210> 303
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 303
Thr Leu Val Arg Ser Ala Ser Glu Thr
 1
                5
      <210> 304
      <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 304
Val Leu Asp Phe Ala Pro Pro Gly Ala
      <210> 305
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 305
Trp Asn Gln Met Asn Leu Gly Ala Thr
     <210> 306
     <211> 9
      <212> PRT
      <213> Mus musculus
      <400> 306
Tyr Phe Lys Leu Ser His Leu Gln Met
                 5
      <210> 307
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 307
Tyr Gln Met Thr Ser Gln Leu Glu Cys
      <210> 308
      <211> 9
      <212> PRT
      <213> Mus musculus
     <400> 308
Tyr Ser Ser Asp Asn Leu Tyr Gln Met
```

WO 01/25273 PCT/US00/27465

49

```
1
     <210> 309
     <211> 6
     <212> PRT
     <213> Homo sapien
     <400> 309
Gly Ala Ala Gln Trp Ala
               5
     <210> 310
     <211> 12
     <212> PRT
     <213> Homo sapien
     <400> 310
Ala Ser Ala Tyr Gly Ser Leu Gly Gly Pro Ala Pro
              5
     <210> 311
     <211> 15
     <212> PRT
     <213> Homo sapien
     <400> 311
Ala Phe Thr Val His Phe Ser Gly Gln Phe Thr Gly Thr Ala Gly
       5
     <210> 312
     <211> 5
     <212> PRT
     <213> Homo sapien
     <400> 312
His Ala Ala Gln Phe
     <210> 313
     <211> 32
     <212> PRT
     <213> Homo sapien
     <400> 313
Cys His Thr Pro Thr Asp Ser Cys Thr Gly Ser Gln Ala Leu Leu Leu
1 5 10
Arg Thr Pro Tyr Ser Ser Asp Asn Leu Tyr Gln Met Thr Ser Gln Leu
           20
     <210> 314
     <211> 32
     <212> PRT
     <213> Homo sapien
     <400> 314
Arg Ile His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg
                                 10
       · 5
Val Pro Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser
```

```
20
                              25
                                                  30
     <210> 315
     <211> 4
     <212> PRT
     <213> Homo sapien
     <400> 315
Arg Tyr Phe Lys
     <210> 316
     <211> 14
     <212> PRT
     <213> Homo sapien
     <400> 316
Glu Arg Arg Phe Ser Arg Ser Asp Gln Leu Lys Arg His Gln
     <210> 317
     <211> 22
     <212> PRT
     <213> Homo sapien
     <400> 317
Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr His Thr Arg Thr
1 .
     5
                                  10
His Thr Gly Lys Thr Ser
       20
     <210> 318
     <211> 21
     <212> PRT
     <213> Homo sapien
     <400> 318
Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His His Asn
1
Met His Gln Arg Asn
           20
     <210> 319
     <211> 449
     <212> PRT
     <213> Homo sapien
     <400> 319
Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
                                  10
Ser Leu Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
                              25
Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
                         40
Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro
                   55
Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
```

```
Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
                                105
           100
Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
                           120
Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile
                       135
                                            140
Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr
                   150
                                        155
Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
                                   170
               165
Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln.
                                185
           180
Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser
                           200
                                                205
Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp
                       215
                                            220
Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln
                                        235
                   230
Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser
                                    250
               245
Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu
                                265
           260
Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile
                            280
His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro
                                            300
                       295
Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys
                                        315
                   310
Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys
               325
                                    330
Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro
                                345
Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp
                           360
Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln
                        375
Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr
                                        395
                   390
His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys
                                    410
Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val
                                425
Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala
                            440
Leu
```

<210> 320

<211> 449

<212> PRT

<213> Mus musculus

<400> 320

Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Ser 1 5 10 15 Ser Leu Gly Gly Gly Gly Cys Gly Leu Pro Val Ser Gly Ala Ala

			20					25					30		
Gln	Trp	Ala		Val	Leu	Asp	Phe		Pro	Pro	Glv	λla		Δla	Tur
		35					40					45			
	50					55			Pro		60				
65					70				Gln	75				_	80
				85					Ser 90					95	
			100					105	Ala				110		
		115			•		120		Ser	_		125	_		
	130					135			Leu		140	,			
Arg 145	Asn	Gln	Gly	Tyr	Ser 150	Thr	Val	Thr	Phe	Asp 155	Gly	Ala	Pro	Ser	Tyr 160
Gly	His	Thr	Pro	Ser 165	His	His	Ala	Ala	Gln 170	Phe	Pro	Asn	His	Ser 175	Phe
			180					185	Gly				190		
		195					200		Cys			205			
	210					215			Arg		220				
225					230				Glu	235					240
Met	Asn	Leu	Gly	Ala 245	Thr	Leu	Lys	Gly	Met 250	Ala	Ala	Gly	Ser	Ser 255	Ser
			260					265	Asn				270		
		275					280		Cys			285			
	290					295			Gln		300				
305					310				Ala	315					320
				325					Cys 330					335	_
			340					345	Lys				350		
		355					360		Arg			365			
	370					375			Thr		380				
385					390				Arg	395					400
				405					Ser 410					415	
			420					425	Ala				430		
	His	His 435	Asn	Met	His	Gln	Arg 440	Asn	Met	Thr	Lys	Leu 445	His	Val	Ala
Leu															

<210> 321 <211> 9

```
<212> PRT
      <213> Homo sapien and Mus musculus
      <400> 321
Pro Ser Gln Ala Ser Ser Gly Gln Ala
 1
                 5
      <210> 322
      <211> 9
      <212> PRT
      <213> Homo sapien and Mus. musculus
      <400> 322
Ser Ser Gly Gln Ala Arg Met Phe Pro
                5
      <210> 323
      <211> 9
      <212> PRT
      <213> Homo sapien and Mus musculus
      <400> 323
Gln Ala Arg Met Phe Pro Asn Ala Pro
      <210> 324
      <211> 9
      <212> PRT
      <213> Homo sapien and Mus musculus
      <400> 324
Met Phe Pro Asn Ala Pro Tyr Leu Pro
      <210> 325
      <211> 9
      <212> PRT
      <213> Homo sapien and Mus musculus
      <400> 325
Pro Asn Ala Pro Tyr Leu Pro Ser Cys
 1
                 5
      <210> 326
      <211> 9
       <212> PRT
      <213> Homo sapien and Mus musculus
      <400> 326
Ala Pro Tyr Leu Pro Ser Cys Leu Glu
<210> 327
<211> 261
<212> PRT
<213> Homo sapiens
```

<400> 327

Met Trp Val Pro Val Val Phe Leu Thr Leu Ser Val Thr Trp Ile Gly
5 10 15

Ala Ala Pro Leu Ile Leu Ser Arg Ile Val Gly Gly Trp Glu Cys Glu 20 25 30

Lys His Ser Gln Pro Trp Gln Val Leu Val Ala Ser Arg Gly Arg Ala 35 40 45

Val Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala Ala
50 55 60

His Cys Ile Arg Asn Lys Ser Val Ile Leu Leu Gly Arg His Ser Leu 65 70 75 80

Phe His Pro Glu Asp Thr Gly Gln Val Phe Gln Val Ser His Ser Phe 85 90 95

Pro His Pro Leu Tyr Asp Met Ser Leu Leu Lys Asn Arg Phe Leu Arg 100 105 110

Pro Gly Asp Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu 115 120 125

Pro Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr Gln 130 135 140

Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile 145 150 155 160

Glu Pro Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu 165 , 170 175

His Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val 180 185 190

Thr Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys Ser Thr 195 200 205

Cys Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gln 210 215 220

Gly Ile .hr Ser Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro 225 230 235 240

Ser Leu Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr 245 250 255

Ile Val Ala Asn Pro 260

<210> 328

<211> 386

<212> PRT

<213> Homo sapiens

<400> 328

Met Arg Ala Ala Pro Leu Leu Leu Ala Arg Ala Ala Ser Leu Ser Leu
5 10 15

Gly Phe Leu Phe Leu Leu Phe Phe Trp Leu Asp Arg Ser Val Leu Ala 20 25 30

Lys Glu Leu Lys Phe Val Thr Leu Val Phe Arg His Gly Asp Arg Ser 35 40 45

Pro Ile Asp Thr Phe Pro Thr Asp Pro Ile Lys Glu Ser Ser Trp Pro 50 55 60

Gln Gly Phe Gly Gln Leu Thr Gln Leu Gly Met Glu Gln His Tyr Glu 65 70 75 80

Leu Gly Glu Tyr Ile Arg Lys Arg Tyr Arg Lys Phe Leu Asn Glu Ser 85 90 95

Tyr Lys His Glu Gln Val Tyr Ile Arg Ser Thr Asp Val Asp Arg Thr 100 105 110

Leu Met Ser Ala Met Thr Asn Leu Ala Ala Leu Phe Pro Pro Glu Gly
115 120 125

Val Ser Ile Trp Asn Pro Ile Leu Leu Trp Gln Pro Ile Pro Val His 130 135 140

Thr Val Pro Leu Ser Glu Asp Gln Leu Leu Tyr Leu Pro Phe Arg Asn 145 150 155 160

Cys Pro Arg Phe Gln Glu Leu Glu Ser Glu Thr Leu Lys Ser Glu Glu 165 170 175

Phe Gln Lys Arg Leu His Pro Tyr Lys Asp Phe Ile Ala Thr Leu Gly
180 185 190

Lys Leu Ser Gly Leu His Gly Gln Asp Leu Phe Gly Ile Trp Ser Lys 195 200 205

Val Tyr Asp Pro Leu Tyr Cys Glu Ser Val His Asn Phe Thr Leu Pro 210 215 220

Ser Trp Ala Thr Glu Asp Thr Met Thr Lys Leu Arg Glu Leu Ser Glu 225 230 235 240

Leu Ser Leu Eur Ser Leu Tyr Gly Ile His Lys Gln Lys Glu Lys Ser 245 250 255

Arg Leu Gln Gly Gly Val Leu Val Asn Glu Ile Leu Asn His Met Lys 260 265 270

Arg Ala Thr Gln Ile Pro Ser Tyr Lys Lys Leu Ile Met Tyr Ser Ala 275 280 285

His Asp Thr Thr Val Ser Gly Leu Gln Met Ala Leu Asp Val Tyr Asn

	290					295					300				
Gly 305	Leu	Leu	Pro	Pro	Туг 310	Ala	Ser	Cys	His	Leu 315	Thr	Glu	Leu	Tyr	Phe 320
Glu	Lys	Gly	Glu	Tyr 325	Phe	Val	Glu	Met	Tyr 330	Tyr	Arg	Asn	Glu	Thr 335	Gln
His	Glų	Pro	Tyr 340	Pro	Leu	Met	Leu	Pro 345	Gly	Cys	Ser	Pro	Ser 350	Суѕ	Pro
Leu	Glu	Arg 355	Phe	Ala	Glu	Leu	Val 360	Gly	Pro	Val	Ile	Pro 365	Gln	Asp	Trp
Ser	Thr 370	Glu	Суз	Met	Thr	Thr 375	Asn	Ser	His	Gln	Gly 380	Thr	Glu	Asp	Ser
Thr 385	Asp														
<212 <212	0> 3; l> 2(2> PI B> Ho	61 RT	sapie	ens											
<400)> 32	29.									•				
			Pro	Val 5	Val	Phe	Leu	Thr	Leu 10	Ser	Val	Thr	Trp	Ile 15	Gly
Ala	Ala	Pro	Leu 20	Ile	Leu	Ser	Arg	Ile 25	Val	Gly	Gly	Trp	Glu 30	Cys	Glu
Lys	His	Ser 35	Gln	Pro	Trp	Gln	Val 40	Leu	Val	Ala	Ser	Arg 45	Gly	Arg	Ala
Val	Cys 50	Gly	Gly	Val	Leu	Val 55	His	Pro	Gln	Trp	Val 60	Leu	Thr	Ala	Ala
His 65	Cys	Ile	Arg	Asn	Lys 70	Ser	Val	Ile	Leu	Leu 75	Gly	Arg	His	Ser	Leu 80
Phe	His	Pro	Glu	Asp 85	Thr	Gly	Gln	Val	Phe 90	Gln	Val	Ser	His	Ser 95	Phe
Pro	His	Pro	Leu 100	Tyr	Asp	Met	Ser	Leu 105	Leu	Lys	Asn	Arg	Phe 110	Leu	Arg
Pro	Gly	Asp 115	Asp	Ser	Ser	His	Asp 120	Leu	Met	Leu	Leu	Arg 125	Leu	Ser	Glu
Pro	Ala 130	Glu	Leu	Thr	Asp	Ala 135	Val	Lys	Val	Met	Asp 140	Leu	Pro	Thr	Gln
Glu 145	Pro	Ala	Leu	Gly	Thr 150	Thr	Cys	Tyr	Ala	Ser 155	Gly	Trp	Gly	Ser	Ile 160
Glu	Pro	Glu	Glu	Phe	Leu	Thr	Pro	Lys	Lys	Leu	Gln	Cys	Val	Asp	Leu

PCT/US00/27465 WO 01/25273

57

175 170 165

His Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val 185

Thr Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys Ser Thr

Cys Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gln

Gly Ile Thr Ser Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro 230

Ser Leu Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr

Ile Val Ala Asn Pro 260

<210> 330

<211> 220

<212> PRT

<213> Homo sapien

<400> 330

Glu Asp Cys Ser Pro His Ser Gln Pro Trp Gln Ala Ala Leu Val Met 10

Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp Val 25

Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu Gly , 40

Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val Glu 55 60

Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu Ala 70

Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser Asp 90 85

Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly Asn 105

Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met Pro 120 125

Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val Cys 135 140

Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala Gly 155 150

Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly Pro 165 170

Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys Ala 185 180

Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys Lys 195 200

Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser 215

<210> 331

<211> 77

<212> PRT <213> Homo sapien

<400> 331

 Leu Val
 Ser Gly
 Ser Cys
 Ser Gln
 Ile Ile Asn Gly
 Glu Asp Cys
 Ser 15

 Pro His Ser Gln
 Fro Trp
 Gln Ala Ala Leu
 Val
 Met Glu Asn Glu Leu 30

 Phe Cys
 Ser Gly
 Val
 Leu Val
 His Pro Gln Trp
 Val
 Leu Ser Ala Thr 45

 His Cys
 Phe Gln Asn Ser Tyr
 Thr Ile Gly
 Leu Gly
 Leu His Ser Leu 50

 Glu Ala Asp Gln Glu
 Pro Gly
 Ser Gln Met Val
 Glu Ala Glu
 Ala Fro Gly

<210> 332

<211> 22

<212> PRT

<213> Homo sapien

<400> 332

Gln His Asn Gly Pro Ile Pro Ser Leu Thr Pro Pro Ser Gly Ser Leu

1 5 10 15

Val Ser Gly Ser Cys Ser
20

<210> 333

<211> 553

<212> PRT

<213> Homo sapien

<400> 333

Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala Gln Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu 25 Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val 40 Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly 55 Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly 70 75 Arg Tyr Gly Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile 85 90 Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu 100 105 Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly 120 125 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu 135 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala 150 155 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr 170 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu 185

Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu

•		195					200					205			
Thr	Cys 210	Val	Ala	Ala	Thr	Leu 215	Leu	Val	Ala	Glu	Glu 220	Ala	Ala	Leu	Gly
Pro 225		Glu	Pro	Ala	Glu 230	Gly	Leu	Ser	Ala	Pro 235	Ser	Leu	Ser	Pro	His 240
	Cys	Pro	Cys	Arg 245		Arg	Leu	Ala	Phe 250	Arg	Asn	Leu	Gly	Ala 255	Leu
Leu	Pro	Arg	Leu 260		Gln	Leu	Суз	Cys 265		Met	Pro	Arg	Thr 270	Leu	Arg
Arg	Leu	Phe 275		Ala	Glu	Leu	Cys 280		Trp	Met	Ala	Leu 285		Thr	Phe
Thr	Leu 290		Tyr	Thr	Asp	Phe 295		Gly	Glu	Gly	Leu 300	Tyr	Gln	Gly	Val
Pro 305		Ala	Glu	Pro	Gly 310		Glu	Ala	Arg	Arg 315		Tyr	Asp	Glu	Gly 320
	Arg	Met	Gly	Ser 325		Gly	Leu	Phe	Leu 330	Gln	Cys	Ala	Ile	Ser 335	Leu
Val	Phe	Ser	Leu 340		Met	Asp	Arg	Leu 345		Gln	Arg	Phe	Gly 350	Thr	Arg
Ala	Val	Tyr 355		Ala	Ser	Val	Ala 360	Ala	Phe	Pro	Val	Ala 365	Ala	Gly	Ala
Thr	Cys 370		Ser	His	Ser	Val 375	Ala	Val	Val	Thr	Ala 380	Ser	Ala	Ala	Leu
Thr 385		Phe	Thr	Phe	Ser 390	Ala	Leu	Gln	Ile	Leu 395	Pro	Tyr	Thr	Leu	Ala 400
	Leu	Tyr	His	Arg 405	Glu	Lys	Gln	Val	Phe 410	Leu	Pro	Lys	Tyr	Arg 415	Gly
Asp	Thr	Gly	Gly 420	Ala	Ser	Ser	Glu	Asp 425		Leu	Met	Thr	Ser 430	Phe	Leu
Pro	Gly	Pro 435	Lys	Pro	Gly	Ala	Pro 440	Phe	Pro	Asn	Gly	His 445	Val	Gly	Ala
Gly	Gly 450	Ser	Gly	Leu	Leu	Pro 455		Pro	Pro	Ala	Leu 460	Суз	Gly	Ala	Ser
Ala 465	Cys	Asp	Val	Ser	Val 470	Arg	Val	Val	Val	Gly 475		Pro	Thr	Glu	Ala 480
Arg	Val	Val	Pro	Gly 485	Arg	Gly	Ile	Суз	Leu 490	Asp	Leu	Ala	Ile	Leu 495	Asp
Ser	Ala	Phe	Leu 500	Leu	Ser	Gln	Val	Ala 505		Ser	Leu	Phe	Met 510		Ser
		515					520			Tyr		525			
Gly	Leu 530	Gly	Leu	Val	Ala	Ile 535		Phe	Ala	Thr	Gln 540	Val	Val	Phe	Asp
Lys 545	Ser	Asp	Leu	Ala	Lys 550	Tyr	Ser	Ala							

<210> 334

<211> 385

<212> DNA

<213> Homo sapien

<400> 334

actacacaca ctccacttgc ccttgtgaga cactttgtcc cagcacttta ggaatgctga 60 ggtcggacca gccacatctc atgtgcaaga ttgcccagca gacatcaggt ctgagagttc 120 cccttttaaa aaaggggact tgcttaaaaa agaagtctag ccacgattgt gtagagcagc 180 ctgggcagtc ttgcacatga gatggggctg gtctgatctc agcactcat agtctgcttg 300

```
ceteteccag ggccccagee tggccacace tgettacagg geacteteag atgeccatae
                                                                       360
catagittet gigetagigg accgi
                                                                       385
      <210> 335
      <211> 647
      <212> DNA
      <213> Homo sapien
      <220>
      <221> misc feature
      <222> (1)...(647)
      <223> n = A, T, C or G
      <400> 335
acgattttca ttatcatgta aatcgggtca ctcaaggggc caaccacagc tgggagccac
                                                                        60
tgctcagggg aaggttcata tgggactttc tactgcccaa ggttctatac aggatataaa
                                                                       120
ggngcctcac agtatagatc tggtagcaaa gaagaagaaa caaacactga tctctttctg
                                                                       180
ccacccctct gaccctttgg aactcctctg accctttaga acaagcctac ctaatatctg
                                                                      . 240...
ctagagaaaa gaccaacaac ggcctcaaag gatctcttac catgaaggtc tcagctaatt
                                                                       300
cttggctaag atgtgggttc cacattaggt tctgaatatg gggggaaggg tcaatttgct
                                                                       360
cattttgtgt gtggataaag tcaggatgcc caggggccag agcagggggc tgcttgcttt
                                                                       420
gggaacaatg gctgagcata taaccatagg ttatggggaa caaaacaaca tcaaagtcac
                                                                       480
tgtatcaatt gccatgaaga cttgagggac ctgaatctac cgattcatct taaggcagca
                                                                       540
ggaccagttt gagtggcaac aatgcagcag cagaatcaat ggaaacaaca gaatgattgc
                                                                       600
aatgtccttt tttttctcct gcttctgact tgataaaagg ggaccgt
                                                                       647
      <210> 336
<211>.526
      <212> DNA
      <213> Homo sapien
      <220>
      <221> misc feature
      <222> (1)...(526)
      <223> n = A, T, C or G
      <400> 336
caaatttgag ccaatgacat agaattttac aaatcaagaa gcttattctg gggccatttc
                                                                        60
ttttgacgtt ttctctaaac tactaaagag gcattaatga tccataaatt atattatcta
                                                                       120
catttacagc atttaaaatg tgttcagcat gaaatattag ctacagggga agctaaataa
                                                                       180
attaaacatg gaataaagat ttgtccttaa atataatcta caagaagact ttgatatttg
                                                                       240
tttttcacaa gtgaagcatt cttataaagt gtcataacct ttttggggaa actatgggaa
                                                                       300
aaaatgggga aactctgaag ggttttaagt atcttacctg aagctacaga ctccataacc
                                                                       360
tctctttaca gggagctcct gcagccccta cagaaatgag tggctgagat tcttgattgc
                                                                       420
acagcaagag cttctcatct aaaccctttc cctttttagt atctgtgtat caagtataaa
                                                                       480
agttctataa actgtagtnt acttatttta atccccaaag cacagt
                                                                       526
      <210> 337
<211> 854
      <212> DNA
      <213> Homo sapien
      <400> 337
ccttttctag ttcaccagtt ttctgcaagg atgctggtta gggagtgtct gcaggaggag
                                                                        60
caagtetgaa accaaateta ggaaacatag gaaacgagee aggeacaggg etggtgggee
                                                                       120
atcagggacc accetttggg ttgatatttt gettaatetg catettttga gtaagateat
                                                                       180
```

```
240
 ctqqcaqtaq aagctgttct ccaggtacat ttctctagct catgtacaaa aacatcctga
 aggactttgt caggtgcctt gctaaaagcc agatgcgttc ggcacttcct tggtctgagg
                                                                       300
 ttaattgcac acctacaggc actgggctca tgctttcaag tattttgtcc tcactttagg
                                                                       360
 gtgagtgaaa gatccccatt ataggagcac ttgggagaga tcatataaaa gctgactctt
                                                                       420
 gagtacatgc agtaatgggg tagatgtgtg tggtgtgtct tcattcctgc aagggtgctt
                                                                       480
 qttaqqqaqt gtttccagga ggaacaagtc tgaaaccaat catgaaataa atggtaggtg
                                                                       540
 tgaactggaa aactaattca aaagagagat cgtgatatca gtgtggttga tacaccttgg
                                                                       600
 caatatggaa ggctctaatt tgcccatatt tgaaataata attcagcttt ttgtaataca
                                                                       660
 aaataacaaa ggattgagaa tcatggtgtc taatgtataa aagacccagg aaacataaat
                                                                       720
                                                                       780
 atatcaactq cataaatqta aaatqcatqt gacccaaqaa ggccccaaaq tggcagacaa
 cattqtaccc attttccctt ccaaaatgtg agcggcgggc ctgctgcttt caaggctgtc
                                                                       840
 acacgggatg tcag
                                                                       854
       <210> 338
       <211> 251
       <212> DNA
       <213> Homo sapien
       <400> 338
 ctcaaagcta atctctcggg aatcaaacca gaaaagggca aggatcttag gcatggtgga
                                                                        60
 tqtqqataaq gccaggtcaa tggctgcaag catgcagaga aagaggtaca tcggagcgtg
                                                                       120
                                                                       180
 caqqctqcqt tccqtcctta cqatqaagac cacqatqcag tttccaaaca ttgccactac
                                                                       240
 atacatggaa aggagggga agccaaccca gaaatgggct ttctctaatc ctgggatacc
                                                                       251
 aataagcaca a
<210> 339
<211> 3279
<212> DNA
<213> Homo sapiens
<400> 339
cttcctgcag cccccatgct ggtgaggggc acgggcagga acagtggacc caacatggaa 60
atgctggagg gtgtcaggaa gtgatcgggc tctggggcag ggaggagggg tggggagtgt 120
cactgggagg ggacatcctg cagaaggtag gagtgagcaa acacccgctg caggggaggg 180
qaqaqcctq cqqcacctgg gggagcagag ggagcagcac ctgcccaggc ctgggaggag 240
gggcctggag ggcgtgagga ggagcgaggg ggctgcatgg ctggagtgag ggatcagggg 300
cagggegega gatggeetea cacagggaag agagggeeee teetgeaggg ceteacetgg 360
gccacaggag gacactgctt ttcctctgag gagtcaggag ctgtggatgg tgctggacag 420
aagaaggaca gggcctggct caggtgtcca gaggctgtcg ctggcttccc tttgggatca 480
gactgcaggg agggagggcg gcagggttgt ggggggagtg acgatgagga tgacctgggg 540
gtggetecag gcettgeece tgeetgggee etcacceage etceetcaca gteteetgge 600
ceteagtete teceeteeae tecateetee atetggeete agtgggteat tetgateaet 660
quactracca tacccarece tecccarege ectecatege tecccaatee cetegagage 720
qqacatctaq tcaqaqaqta gtcctqaaqa ggtggcctct qcgatgtgcc tgtgggggca 780
quatectqca qatqqtcccq qccctcatcc tgctgacctg tctgcaggga ctgtcctcct 840
ggaccttgcc ccttgtgcag gagctggacc ctgaagtccc ctccccatag gccaagactg 900
gagcettgtt ccctctgttg gactccctgc ccatattctt gtgggagtgg gttctggaga 960
cattletqte tqtteetgag agetgggaat tgeteteagt catetgeetg egeggttetg 1020
agagatggag ttgcctaggc agttattggg gccaatcttt ctcactgtgt ctctcctcct 1080
ttaccettaq qqtqattctq qqqqtecact tqtctqtaat qqtqtqcttc aaggtatcac 1140
atcatqqqqc cctqaqccat gtgccctqcc tgaaaagcct gctgtgtaca ccaaggtggt 1200
qcattaccqq aagtqqatca aggacaccat cgcagccaac ccctgagtgc ccctgtccca 1260
cccctacctc tagtaaattt aagtccacct cacgttctgg catcacttgg cctttctgga 1320
tgctggacac ctgaagcttg gaactcacct ggccgaagct cgagcctcct gagtcctact 1380
gacctgtgct ttctggtgtg gagtccaggg ctgctaggaa aaggaatggg cagacacagg 1440
tqtatqccaa tqtttctqaa atgggtataa tttcgtcctc tccttcggaa cactggctgt 1500
```

ctctgaaqac ttctcgctca gtttcagtga ggacacacac aaagacgtgg gtgaccatgt 1560

```
tgtttgtggg gtgcagagat gggaggggtg gggcccaccc tggaagagtg gacagtgaca 1620
caaggtggac actctctaca gatcactgag gataagctgg agccacaatg catgaggcac 1680
acacacagca aggttgacgc tgtaaacata gcccacgctg tcctgggggc actgggaagc 1740
ctagataagg ccgtgagcag aaagaagggg aggatcctcc tatqttqttq aaggagggac 1800
tagggggaga aactgaaagc tgattaatta caggaggttt gttcaggtcc cccaaaccac 1860
cgtcagattt gatgatttcc tagcaggact tacagaaata aagagctatc atgctgtggt 1920
ttattatggt ttgttacatt gataggatac atactgaaat cagcaaacaa aacagatgta 1980
tagattagag tgtggagaaa acagaggaaa acttgcagtt acgaagactg gcaacttggc 2040
tttactaagt tttcagactg gcaggaagtc aaacctatta ggctgaggac cttgtggagt 2100
gtagctgatc cagctgatag aggaactagc caggtggggg cctttccctt tggatggggg 2160
gcatatccga cagttattct ctccaagtgg agacttacgg acagcatata attctccctg 2220
caaggatgta tgataatatg tacaaagtaa ttccaactga ggaagctcac ctgatcctta 2280
gtgtccaggg tttttactgg gggtctgtag gacgagtatg gagtacttga ataattgacc 2340
tgaagtcctc agacctgagg ttccctagag ttcaaacaga tacagcatgg tccagagtcc 2400
cagatgtaca aaaacaggga ttcatcacaa atcccatctt tagcatgaag ggtctggcat 2460
ggcccaaggc cccaagtata tcaaggcact tgggcagaac atgccaagga atcaaatgtc 2520
atctcccagg agttattcaa gggtgagccc tttacttggg atgtacaggc tttgagcagt 2580
gcagggctgc tgagtcaacc ttttattgta caggggatga gggaaaggga gaggatgagg 2640.
aagcccccct ggggatttgg tttggtcttg tgatcaggtg gtctatgggg ctatccctac 2700
aaagaagaat ccagaaatag gggcacattg aggaatgata ctgagcccaa agagcattca 2760
atcattgttt tatttgcctt cttttcacac cattggtgag ggagggatta ccaccctggg 2820
gttatgaaga tggttgaaca ccccacacat agcaccggag atatgagatc aacagtttct 2880
tagccataga gattcacagc ccagagcagg aggacgctgc acaccatgca ggatgacatg 2940
ggggatgcgc tcgggattgg tgtgaagaag caaggactgt tagaggcagg ctttatagta 3000
acaagacggt ggggcaaact ctgatttccg tgggggaatg tcatggtctt gctttactaa 3060
gttttgagac tggcaggtag tgaaactcat taggctgaga accttgtgga atgcagctga 3120
cccagctgat agaggaagta gccaggtggg agcctttccc agtgggtgtg ggacatatct 3180
ggcaagattt tgtggcactc ctggttacag atactggggc agcaaataaa actgaatctt 3240
gttttcagac cttaaaaaaa aaaaaaaaaa aaaagtttt
<210> 340
<211> 154
<212> PRT
<213> Homo sapiens
<400> 340
Met Ala Gly Val Arg Asp Gln Gly Gln Gly Ala Arg Trp Pro His Thr
Gly Lys Arg Gly Pro Leu Leu Gln Gly Leu Thr Trp Ala Thr Gly Gly
His Cys Phe Ser Ser Glu Glu Ser Gly Ala Val Asp Gly Ala Gly Gln
                             40
Lys Lys Asp Arg Ala Trp Leu Arg Cys Pro Glu Ala Val Ala Gly Phe
Pro Leu Gly Ser Asp Cys Arg Glu Gly Gly Arg Gln Gly Cys Gly Gly
```

Trp Ala Leu Thr Gln Pro Pro Ser Gln Ser Pro Gly Pro Gln Ser Leu 100 105 110

Ser Asp Asp Glu Asp Asp Leu Gly Val Ala Pro Gly Leu Ala Pro Ala

90

Pro Ser Thr Pro Ser Ser Ile Trp Pro Gln Trp Val Ile Leu Ile Thr

63

```
115
                           120
                                               125
Glu Leu Thr Ile Pro Ser Pro Ala His Gly Pro Pro Trp Leu Pro Asn
                                           140
Ala Leu Glu Arg Gly His Leu Val Arg Glu
                   150
       <210> 341
 <211> 718
       <212> DNA
       <213> Homo sapien
       <220>
       <221> misc feature
       <222> (1) ... (718)
       \langle 223 \rangle n = A, T, C or G
       <400> 341
                                                                       60
 qqaqatttqt qtqqtttqca gccqaqgqaq accaggaaga tctgcatggt gggaaggacc
 tgatgataca gaggtgagaa ataagaaagg ctgctgactt taccatctga ggccacacat
                                                                      120
 ctgctgaaat ggagataatt aacatcacta gaaacagcaa gatgacaata taatgtctaa
                                                                      180
 gtagtgacat gtttttgcac atttccagcc cttttaaata tccacacaca caggaagcac
                                                                      240
                                                                      300
 aaaaggaage acagagatee etqqqagaaa tgeeeggeeg eeatettggg teategatga
 gcctcgccct gtgcctgntc ccgcttgtga gggaaggaca ttagaaaatg aattgatgtg
                                                                      360
 ttccttaaag gatggcagga aaacagatcc tgttgtggat atttatttga acgggattac
                                                                      420
 agatttgaaa tgaagtcaca aagtgagcat taccaatgag aggaaaacag acgagaaaat
                                                                      480
 cttgatggtt cacaagacat gcaacaaaca aaatggaata ctgtgatgac acgagcagcc
                                                                      540
                                                                      600
 aactggggag gagataccac ggggcagagg tcaggattct ggccctgctg cctaactgtg
 cgttatacca atcatttcta tttctaccct caaacaagct gtngaatatc tgacttacgg
                                                                      660
 ttcttntggc ccacattttc atnatccacc ccntcntttt aannttantc caaantgt
                                                                      718
<210> 342
<211> 3112
<212> DNA
<213> Homo sapiens
<400> 342
cattgtgttg ggagaaaaac agaggggaga tttgtgtggc tgcagccgag ggagaccagg 60
aaqatctqca tqqtqqqaag gacctgatga tacagagttt gataggagac aattaaaggc 120
tggaaggcac tggatgcctg atgatgaagt ggactttcaa actggggcac tactgaaacg 180
atgggatggc cagagacaca ggagatgagt tggagcaagc tcaataacaa agtggttcaa 240
cgaggacttg gaattgcatg gagctggagc tgaagtttag cccaattgtt tactagttga 300
gtgaatgtgg atgattggat gatcatttct catctctgag cctcaggttc cccatccata 360
aaatgggata cacagtatga totataaagt gggatatagt atgatotact toactgggtt 420
atttgaagga tgaattgaga taatttattt caggtgccta gaacaatgcc cagattagta 480
catttggtgg aactgagaaa tggcataaca ccaaatttaa tatatgtcag atgttactat 540
gattateatt caateteata gttttgteat ggeecaattt ateeteactt gtgeeteaac 600
aaattgaact gttaacaaag gaatctctgg tcctgggtaa tggctgagca ccactgagca 660
tttccattcc agttggcttc ttgggtttgc tagctgcatc actagtcatc ttaaataaat 720
gattaaataa agaacttgag aagaacaggt ttcattaaac ataaaatcaa tgtagacgca 840
aattttctgg atgggcaata cttatgttca caggaaatgc tttaaaatat gcagaagata 900
attaaatggc aatggacaaa gtgaaaaact tagacttttt ttttttttt ggaagtatct 960
ggatgttcct tagtcactta aaggagaact gaaaaatagc agtgagttcc acataatcca 1020
acctgtgaga ttaaggctct ttgtggggaa ggacaaagat ctgtaaattt acagtttcct 1080
tccaaagcca acgtcgaatt ttgaaacata tcaaagctct tcttcaagac aaataatcta 1140
tagtacatct ttcttatggg atgcacttat gaaaaatggt ggctgtcaac atctagtcac 1200
```

```
tttagctctc aaaatggttc attttaagag aaagttttag aatctcatat ttattcctgt 1260
 ggaaggacag cattgtgget tggactttat aaggtcttta ttcaactaaa taggtgagaa 1320
 ataagaaagg ctgctgactt taccatctga ggccacacat ctgctgaaat ggagataatt 1380
 aacatcacta gaaacagcaa gatgacaata taatgtctaa gtagtgacat gtttttgcac 1440
 atttccagcc cetttaaata tecacacaca caggaagcac aaaaggaagc acagagatec 1500
 ctgggagaaa tgcccggccg ccatcttggg tcatcgatga gcctcgccct gtgcctggtc 1560
 ccgcttgtga gggaaggaca ttagaaaatg aattgatgtg ttccttaaag gatgggcagg 1620
 aaaacagate etgttgtgga tatttatttg aacgggatta cagatttgaa atgaagtcae 1680
 aaagtgagca ttaccaatga gaggaaaaca gacgagaaaa tcttgatggc ttcacaagac 1740
 atgcaacaaa caaaatggaa tactgtgatg acatgaggca gccaagctgg ggaggagata 1800
 accaegggge agagggteag gattetggee etgetgeeta aactgtgegt teataaceaa 1860
 atcatttcat atttctaacc ctcaaaacaa agctgttgta atatctgatc tctacggttc 1920
 cttctgggcc caacattctc catatatcca gccacactca tttttaatat ttagttccca 1980
 gatctgtact gtgacctttc tacactgtag aataacatta ctcattttgt tcaaagaccc 2040
 ttcgtgttgc tgcctaatat gtagctgact gtttttccta aggagtgttc tggcccaggg 2100
 gatctgtgaa caggctggga agcatctcaa gatctttcca gggttatact tactagcaca 2160
 cagcatgate attacggagt gaattateta atcaacatca teetcagtgt etttgeceat 2220
 actgaaattc atttcccact tttgtgccca ttctcaagac ctcaaaatgt cattccatta 2280.
 atatcacagg attaactttt ttttttaacc tggaagaatt caatgttaca tgcagctatg 2340
 ggaatttaat tacatatttt gttttccagt gcaaagatga ctaagtcctt tatccctccc 2400
ctttgtttga tttttttcc agtataaagt taaaatgctt agccttgtac tgaggctgta 2460
tacagecaca geeteteeec atceetecag cettatetgt cateaceate aacecetece 2520
atgeacctaa acaaaatcta acttgtaatt ccttgaacat gteaggeata cattatteet 2580
tetgeetgag aagetettee ttgtetetta aatetagaat gatgtaaagt tttgaataag 2640
ttgactatet taetteatge aaagaaggga cacatatgag atteateate acatgagaea 2700
gcaaatacta aaagtgtaat ttgattataa gagtttagat aaatatatga aatgcaagag 2760
ccacagaggg aatgtttatg gggcacgttt gtaagcctgg gatgtgaagc aaaggcaggg 2820
aacctcatag tatcttatat aatatacttc atttctctat ctctatcaca atatccaaca 2880
agettttcac agaattcatg cagtgcaaat ccccaaaggt aacetttate catttcatgg 2940
tgagtgcgct ttagaatttt ggcaaatcat actggtcact tatctcaact ttgagatgtg 3000
tttgtccttg tagttaattg aaagaaatag ggcactcttg tgagccactt tagggttcac 3060
3112
<210> 343
<211> 2229
<212> DNA
<213> Homo sapiens
<400> 343
agetetttgt aaattettta ttgecaggag tgaaccetaa agtggeteae aagagtgeee 60
tatttctttc aattaactac aaggacaaac acatctcaaa gttgagataa gtgaccagta 120
tgatttgcca aaattctaaa gcgcactcac catgaaatgg ataaaggtta cctttgggga 180
titgcactgc atgaattctg tgaaaagctt gttggatatt gtgatagaga tagagaaatg 240
aagtatatta tataagatac tatgaggttc cctgcctttg cttcacatcc caggcttaca 300
aacgtgcccc ataaacattc cctctgtggc tcttgcattt catatattta tctaaactct 360
tataatcaaa tacactttta gtattigcig tctcatgtga tgatgaatct catatgtgtc 420
cettetttge atgaagtaag atagteaact tatteaaaac titacateat tetagattta 480
agagacaagg aagagcttct caggcagaag gaataatgta tgcctgacat gttcaaggaa 540
ttacaagtta gattttgttt aggtgcatgg gaggggttga tggtgatgac agataaggct 600
ggagggatgg ggagaggctg tggctgtata cagcctcagt acaaggctaa gcattttaac 660
tttatactgg aaaaaaatc aaacaaaggg gagggataaa ggacttagtc atctttgcac 720
tggaaaacaa aatatgtaat taaattccca tagctgcatg taacattgaa ttcttccagg 780
ttaaaaaaaa agttaatcct gtgatattaa tggaatgaca ttttgaggtc ttgagaatgg 840
gcacaaaagt gggaaatgaa tttcagtatg ggcaaagaca ctgaggatga tgttgattag 900
ataattcact ccgtaatgat catgctgtgt gctagtaagt ataaccctgg aaagatcttg 960
agatgettee cageetgtte acagateece tgggccagaa cacteettag gaaaaacagt 1020
cagctacata ttaggcagca acacgaaggg tctttgaaca aaatgagtaa tgttattcta 1080
cagtgtagaa aggtcacagt acagatctgg gaactaaata ttaaaaatga gtgtggctgg 1140
```

```
atatatggag aatgttgggc ccagaaggaa ccgtagagat cagatattac aacagctttg 1200
ttttgagggt tagaaatatg aaatgatttg gttatgaacg cacagtttag gcagcagggc 1260
cagaatcetg accetetgee cegtggttat etecteecea gettggetge eteatgteat 1320
cacagtattc cattttgttt gttgcatgtc ttgtgaagcc atcaagattt tctcgtctgt 1380
tttcctctca ttggtaatgc tcactttgtg acttcatttc aaatctgtaa tcccgttcaa 1440
ataaatatcc acaacaggat ctgttttcct gcccatcctt taaggaacac atcaattcat 1500
tttctaatgt ccttccctca caagcgggac caggcacagg gcgaggctca tcgatgaccc 1560
aagatggcgg ccgggcattt ctcccaggga tctctgtgct tccttttgtg cttcctgtgt 1620
gtgtggatat ttaaaggggc tggaaatgtg caaaaacatg tcactactta gacattatat 1680
tgtcatcttg ctgtttctag tgatgttaat tatctccatt tcagcagatg tgtggcctca 1740
gatggtaaag tcagcagcct ttcttatttc tcacctggaa atacatacga ccatttgagg 1800
agacaaatgg caaggtgtca gcataccctg aacttgagtt gagagctaca cacaatatta 1860
ttggtttccg agcatcacaa acaccctctc tgtttcttca ctgggcacag aattttaata 1920
cttatttcag tgggctgttg gcaggaacaa atgaagcaat ctacataaag tcactagtgc 1980
agtgcctgac acacaccatt ctcttgaggt cccctctaga gatcccacag gtcatatgac 2040
ttcttqqqqa qcaqtqqctc acacctqtaa tcccaqcact ttgggaggct gaggcaggtg 2100
ggtcacctga ggtcaggagt tcaagaccag cctggccaat atggtgaaac cccatctcta 2160
ctaaaaatac aaaaattagc tgggcgtgct ggtgcatgcc tgtaatccca gccccaacac 2220
                                                                  2229
aatggaatt
<210> 344
```

<210> 344 <211> 2426 <212> DNA <213> Homo sapiens

<400> 344

gtaaattett tattgecagg agtgaaceet aaagtggete acaagagtge ectattett 60 tcaattaact acaaggacaa acacatctca aagttgagat aagtgaccag tatgatttgc 120 caaaattcta aagcgcactc accatgaaat ggataaaggt tacctttggg gatttgcact 180 gcatgaattc tgtgaaaagc ttgttggata ttgtgataga gatagagaaa tgaagtatat 240 tatataagat actatgaggt tecetgeett tgetteacat eecaggetta caaacgtgee 300 ccataaacat tccctctgtg gctcttgcat ttcatatatt tatctaaact cttataatca 360 aattacactt ttagtatttg ctgtctcatg tgatgatgaa tctcatatgt gtcccttctt 420 tgcatgaagt aagatagtca acttattcaa aactttacat cattctagat ttaagagaca 480 aggaagaget teteaggeag aaggaataat gtatgeetga catgtteaag gaattacaag 540 ttagattitg tttaggtgca tgggaggggt tgatggtgat gacagataag gctggaggga 600 tggggagagg ctgtggctgt atacagcctc agtacaaggc taagcatttt aactttatac 660 tggaaaaaaa atcaaacaaa ggggagggat aaaggactta gtcatctttg cactggaaaa 720 caaaatatgt aattaaattc ccatagctgc atgtaacatt gaattcttcc aggttaaaaa 780 aaaaagttaa teetgtgata ttaatggaat gacattttga ggtettgaga atgggcacaa 840 aagtgggaaa tgaatttcag tatgggcaaa gacactgagg atgatgttga ttagataatt 900 cactccgtaa tgatcatgct gtgtgctagt aagtataacc ctggaaagat cttgagatgc 960 ttcccagcct gttcacagat cccctgggcc agaacactcc ttaggaaaaa cagtcagcta 1020 catattaggc agcaacacga agggtctttg aacaaaatga gtaatgttat tctacagtgt 1080 agaaaggtca cagtacagat ctgggaacta aatattaaaa atgagtgtgg ctggatatat 1140 ggagaatgtt gggcccagaa ggaaccqtaq aqatcagata ttacaacaqc tttgttttqa 1200 gggttagaaa tatgaaatga tttggttatg aacgcacagt ttaggcagca gggccagaat 1260 cctqaccetc tgcccqtgg ttatctcctc cccaqcttgg ctgcctcatg tcatcacagt 1320 attccatttt gtttgttgca tgtcttgtga agccatcaag attttctcgt ctgttttcct 1380 ctcattggta atgctcactt tgtgacttca tttcaaatct gtaatcccgt tcaaataaat 1440 atccacaaca ggatctgttt tcctgcccat cctttaagga acacatcaat tcattttcta 1500 atgtccttcc ctcacaagcg ggaccaggca cagggcgagg ctcatcgatg acccaagatg 1560 geggeeggge attteteeca gggatetetg tgetteettt tgtgetteet gtgtgtgtgg 1620 atatttaaag gggctggaaa tgtgcaaaaa catgtcacta cttagacatt atattgtcat 1680 cttqctqttt ctaqtqatqt taattatctc catttcaqca qatqtqtqqc ctcaqatqgt 1740 aaagtcagca geetttetta ttteteacet ggaaatacat acgaecattt gaggagacaa 1800 atggcaaggt gtcagcatac cctgaacttg agttgagagc tacacacaat attattggtt 1860 tecgageate acaaacacee tetetgttte tteaetggge acagaatttt aataettatt 1920

```
tcagtggget gttggcagga acaaatgaag caatctacat aaagtcacta gtgcagtgcc 1980
tgacacacac cattetettg aggteeecte tagagateee acaggteata tgaettettg 2040
gggagcagtg gctcacacct gtaatcccag cactttggga ggctgaggca ggtgggtcac 2100
ctgaggtcag gagttcaaga ccagcctggc caatatggtg aaaccccatc tctactaaaa 2160
atacaaaaat tagctgggcg tgctggtgca tgcctgtaat cccagctact tgggaggctg 2220
aggcaggaga attgctggaa catgggaggc ggaggttgca gtgagctgta attgtgccat 2280
tgcactcgaa cctgggcgac agagtggaac tctgtttcca aaaaacaaac aaacaaaaa 2340
ggcatagtca gatacaacgt gggtgggatg tgtaaataga agcaggatat aaagggcatg 2400
gggtgacggt tttgcccaac acaatg
<210> 345
<211> 812
<212> DNA
<213> Homo sapiens
<400> 345
gaacaaaatg agtaatgtta ttctacagtg tagaaaggtc acagtacaga tctgggaact 60
aaatattaaa aatgagtgtg gctggatata tggagaatgt tgggcccaga aggaaccgta 120
gagatcagat attacaacag ctttgttttg agggttagaa atatgaaatg atttggttat 180
gaacgcacag tttaggcagc agggccagaa tcctgaccct ctgccccgtg gttatctcct 240
ccccagettg gctgcctcat gtcatcacag tattccattt tgtttgttgc atgtcttgtg 300
aagccatcaa gattttctcg tctgttttcc tctcattggt aatgctcact ttgtgacttc 360
atttcaaatc tgtaatcccg ttcaaataaa tatccacaac aggatctgtt ttcctgccca 420
teetttaagg aacacateaa tteatttet aatgteette eeteacaage gggaceagge 480
acagggcgag geteategat gacceaagat ggcggccggg cattteteec agggatetet 540
gtgcttcctt ttgtgcttcc tgtgtgtgtg gatatttaaa ggggctggaa atgtgcaaaa 600
acatgtcact acttagacat tatattgtca tettgetgtt tetagtgatg ttaattatet 660
ccatttcage agatgtgtgg cctcagatgg taaagtcage agcctttctt atttctcace 720
tetgtateat caggicette ceaccatgea gatetteetg gieteeeteg getgeageea 780
cacaaatctc ccctctgttt ttctgatgcc ag
       <210> 346
<211> 2417
       <212> DNA
       <213> Homo sapien
       <400> 346
ggcggccgct ctagagctag tgggatcccc cgggctgcac gaattcggca cgagtgagtt
                                                                        60
ggagttttac ctgtattgtt ttaatttcaa caagcctgag gactagccac aaatgtaccc
                                                                       120
agtttacaaa tgaggaaaca ggtgcaaaaa ggttgttacc tgtcaaaggt cgtatgtggc
                                                                       180
agagccaaga tttgagccca gttatgtctg atgaacttag cctatgctct ttaaacttct
                                                                       240
gaatgetgae cattgaggat atetaaaett agateaattg catttteeet eeaagaetat
                                                                       300
ttacttatca atacaataat accaccttta ccaatctatt gttttgatac gagactcaaa
                                                                       360
tatgccagat atatgtaaaa gcaacctaca agctctctaa tcatgctcac ctaaaagatt
                                                                       420
eccgggatet aataggetea aagaaactte tietagaaat ataaaagaga aaattggatt
atgcaaaaat tcattattaa ttttttcat ccatccttta attcagcaaa catttatctg
                                                                       480
                                                                       540
ttgttgactt tatgcagtat ggccttttaa ggattggggg acaggtgaag aacggggtgc
                                                                       600
cagaatgcat cetectaeta atgaggteag tacacatttg cattttaaaa tgeeetgtee
                                                                       660
agctgggcat ggtggatcat gcctgtaatc tcaacattgg aaggccaagg caggaggatt
                                                                       720
getteagece aggagtteaa gaccageetg ggeaacatag aaagaceeca teteteaate
                                                                       780
aatcaatcaa tgccctgtct ttgaaaataa aactctttaa gaaaggttta atgggcaggg
                                                                       840
tgtggtagct catgcctata atacagcact ttgggaggct gaggcaggag gatcacttta
                                                                       900
geceagaagt teaagaceag cetgggeaac aagtgacace teateteaat tttttaataa
                                                                       960
aatgaataca tacataagga aagataaaaa gaaaagttta atgaaagaat acagtataaa
                                                                      1020
acaaatctet tggacctaaa agtatttttg ttcaagccaa atattgtgaa tcacctetet
                                                                      1080
gtgttgagga tacagaatat ctaagcccag gaaactgagc agaaagttca tgtactaact
                                                                      1140
aatcaacccg aggcaaggca aaaatgagac taactaatca atccgaggca aggggcaaat
                                                                      1200
tagacggaac ctgactctgg tctattaagc gacaactttc cctctgttgt attittcttt
                                                                      1260
```

```
tattcaatgt aaaaggataa aaactctcta aaactaaaaa caatgtttgt caggagttac
                                                                     1320
                                                                     1380
aaaccatgac caactaatta tggggaatca taaaatatga ctgtatgaga tcttgatggt
ttacaaagtg tacccactgt taatcacttt aaacattaat gaacttaaaa atgaatttac
                                                                      1440
                                                                      1500
ggagattgga atgtttcttt cctgttgtat tagttggctc aggctgccat aacaaaatac
cacagactgg gaggcttaag taacagaaat tcatttctca cagttctggg ggctggaagt
                                                                      1560
ccacgatcaa ggtgcaggaa aggcaggctt cattctgagg cccctctctt ggctcacatg
                                                                      1620
tggccaccct cccactgcgt gctcacatga cctctftgtg ctcctggaaa gagggtgtgg
                                                                      1680
gggacagagg gaaagagaag gagagggaac tctctggtgt ctcgtctttc aaggacccta
                                                                      1740
                                                                      1800
acctgggcca ctttggccca ggcactgtgg ggtggggggt tgtggctgct ctgctctgag
tggccaagat aaagcaacag aaaaatgtcc aaagctgtgc agcaaagaca agccaccgaa
                                                                      1860
                                                                      1920
cagggatctg ctcatcagtg tggggacctc caagtcggcc accctggagg caagccccca
cagageceat geaaggtgge ageageagaa gaagggaatt gteeetgtee ttggeaeatt
                                                                      1980
cctcaccgac ctggtgatgc tggacactgc gatgaatggt aatgtggatg agaatatgat
                                                                      2040
                                                                      2100
ggacteccag aaaaggagac ccagetgete aggtggetge aaateattac ageetteate
ctggggagga actgggggcc tggttctggg tcagagagca gcccagtgag ggtgagagct
                                                                      2160
acageetgte etgecagetg gatececagt eceggteaac cagtaateaa ggetgageag
                                                                      2220
atcaggette ceggagetgg tettgggaag ceagecetgg ggtgagttgg etectgetgt
                                                                      2280
                                                                      2340
ggtactgaga caatattgtc ataaattcaa tgcgcccttg tatccctttt tctttttat
                                                                      2400
ctgtctacat ctataatcac tatgcatact agtctttgtt agtgtttcta ttcmacttaa
                                                                      2417
tagagatatg ttatact
      <210> 347
<211> 320
      <212> DNA
      <213> Homo sapien
      <400> 347
cccctgaagg cttcttgtta gaaaatagta cagttacaac caataggaac aacaaaaaga
                                                                        60
aaaagtttgt gacattgtag tagggagtgt gtacccctta ctccccatca aaaaaaaaat
                                                                       120
ggatacatgg ttaaaggata raagggcaat attttatcat atgttctaaa agagaaggaa
                                                                       180
                                                                       240
gagaaaatac tactttctcr aaatggaagc ccttaaaggt gctttgatac tgaaggacac
aaatgtggcc gtccatcctc ctttaragtt gcatgacttg gacacggtaa ctgttgcagt
                                                                       300
                                                                       320
tttaractcm gcattgtgac
      <210> 348
<211> 539
      <212> DNA
      <213> Homo sapien
      <400> 348
                                                                        60
acgggactta tcaaataaag ataggaaaag aagaaaactc aaatattata ggcagaaatg
ctaaaggttt taaaatatgt caggattgga agaaggcatg gataaagaac aaagttcagt
                                                                       120
taggaaagag aaacacagaa ggaagagaca caataaaagt cattatgtat tctgtgagaa
                                                                       180
gtcagacagt aagatttgtg ggaaatgggt tggtttgttg tatggtatgt attttagcaa
                                                                       240
taatctttat ggcagagaaa gctaaaatcc tttagcttgc gtgaatgatc acttgctgaa
                                                                       300
ttcctcaagg taggcatgat gaaggaggt ttagaggaga cacagacaca atgaactgac
                                                                       360
                                                                       420
ctagatagaa agccttagta tactcagcta ggaatagtga ttctgagggc acactgtgac
atgattatgt cattacatgt atggtagtga tggggatgat aggaaggaag aacttatggc
                                                                       480
atattttcac ccccacaaaa gtcagttaaa tattgggaca ctaaccatcc aggtcaaga
                                                                       539
      <210> 349
<211> 2984
      <212> DNA
       <213> Homo sapien
       <400> 349
 atccctcctt ccccactctc ctttccagaa ggcacttggg gtcttatctg ttggactctg
                                                                        60
```

```
aaaacacttc aggcgccctt ccaaggcttc cccaaacccc taagcagccg cagaagcgct
                                                                      120
cccgagetge etteteceae acteaggtga tegagttgga gaggaagtte agecateaga
                                                                      180
agtacctgtc ggcccctgaa cgggcccacc tggccaagaa cctcaagctc acggagaccc
                                                                      240
aagtgaagat atggttccag aacagacgct ataagactaa gcgaaagcag ctctcctcgg
                                                                      300
agetgggaga ettggagaag cacteetett tgeeggeeet gaaagaggag geetteteee
                                                                      360
gggcctccct ggtctccgtg tataacagct atccttacta cccatacctg tactgcgtgg
                                                                      420
gcagctggag cccagctttt tggtaatgcc agctcaggtg acaaccatta tgatcaaaaa
                                                                      480
ctgccttccc cagggtgtct ctatgaaaag cacaaggggc caaggtcagg gagcaagagg
                                                                      540
tgtgcacacc aaagctattg gagatttgcg tggaaatctc asattcttca ctggtgagac
                                                                      600
aatgaaacaa cagagacagt gaaagtttta atacctaagt cattccccca gtgcatactg
                                                                      660
taggtcattt tttttgcttc tggctacctg tttgaagggg agagagggaa aatcaagtgg
                                                                      720
tattttccag cactttgtat gattttggat gagctgtaca cccaaggatt ctgttctgca
                                                                      780
actecatect cetgtgtcae tgaatateaa etetgaaaga geaaacetaa caggagaaag
                                                                      840
gacaaccagg atgaggatgt caccaactga attaaactta agtccagaag cctcctgttg
                                                                      900
gccttggaat atggccaagg ctctctctgt ccctgtaaaa gagaggggca aatagagagt
                                                                      960
ctccaagaga acgccctcat gctcagcaca tatttgcatg ggagggggag atgggtggga
                                                                     1020
ggagatgaaa atatcagctt ttcttattcc tttttattcc ttttaaaaatg gtatgccaac
                                                                     1080
ttaagtattt acagggtggc ccaaatagaa caagatgcac tcgctgtgat tttaagacaa
                                                                     1140_
gctgtataaa cagaactcca ctgcaagagg gggggccggg ccaggagaat ctccgcttgt
                                                                     1200
ccaagacagg ggcctaagga gggtctccac actgctgcta ggggctgttg catttttta
                                                                     1260
ttagtagaaa gtggaaaggc ctcttctcaa cttttttccc ttgggctgga qaatttagaa
                                                                     1320
tcagaagttt cctggagttt tcaggctatc atatatactg tatcctgaaa ggcaacataa
                                                                     1380
ttetteette ceteettta aaattttgtg tteetttttg cagcaattae teactaaaqq
                                                                     1440
getteatttt agteeagatt tttagtetgg etgeacetaa ettatgeete gettatttag
                                                                     1500
cccgagatet ggtettttt tttttttt tttttccgtc tccccaaage tttatctgtc
                                                                     1560
ttgacttttt aaaaaagttt gggggcagat tctgaattgg ctaaaagaca tgcatttta
                                                                     1620
aaactagcaa ctcttatttc tttcctttaa aaatacatag cattaaatcc caaatcctat
                                                                     1680
ttaaagacct gacagcttga gaaggtcact actgcattta taggaccttc tggtggttct
                                                                     1740
gctgttacgt ttgaagtctg acaatccttg agaatctttg catgcagagg aggtaagagg
                                                                     1800
tattggattt tcacagagga agaacacagc gcagaatgaa gggccaggct tactgagctg
                                                                     1860
tccagtggag ggctcatggg tgggacatgg aaaagaaggc agcctaggcc ctggggagcc
                                                                     1920
cagtccactg agcaagcaag ggactgagtg agccttttgc aggaaaaggc taagaaaaag
                                                                     1980
gaaaaccatt ctaaaacaca acaagaaact gtccaaatgc tttgggaact gtgtttattg
                                                                     2040
cctataatgg gtccccaaaa tgggtaacct agacttcaga gagaatgagc agagagcaaa
                                                                     2100
ggagaaatct ggctgtcctt ccattttcat tctgttatct caggtgagct ggtagaggg
                                                                    2160
agacattaga aaaaaatgaa acaacaaaac aattactaat gaggtacgct gaggcctggg
                                                                    2220
agtotottga otocactact taattoogtt tagtgagaaa ootttoaatt ttottttatt
                                                                    2280
agaagggcca gcttactgtt ggtggcaaaa ttgccaacat aagttaatag aaagttggcc
                                                                    2340
aatttcaccc cattttctgt ggtttgggct ccacattgca atgttcaatg ccacgtgctg
                                                                    24001
ctgacaccga ccggagtact agccagcaca aaaggcaggg tagcctgaat tgctttctgc
                                                                    2460
tetttacatt tettttaaaa taageattta gtgeteagte cetactgagt actetttete
                                                                    2520
teceeteete tgaatttaat tettteaact tgeaatttge aaggattaca cattteaetg
                                                                    2580
tgatgtatat tgtgttgcaa aaaaaaaaa aagtgtcttt gtttaaaatt acttggtttg
                                                                    2640
tgaatccatc ttgctttttc cccattggaa ctagtcatta acccatctcu gaactggtag
                                                                    2700
aaaaacatct gaagagctag tctatcagca tctgacaggt gaattggatg gttctcagaa
                                                                    2760
ccatttcacc cagacagcct gtttctatcc tgtttaataa attagtttgg gttctctaca
                                                                    2820
tgcataacaa accetgetee aatetgteae ataaaagtet gtgacttgaa gtttagteag
                                                                    2880
cacccccacc aaactttatt tttctatgtg ttttttgcaa catatgagtg ttttgaaaat
                                                                    2940
2984
      <210> 350
```

<211> 147

<212> PRT

<213> Homo sapien

<400> 350

Pro Ser Phe Pro Thr Leu Leu Ser Arg Arg His Leu Gly Ser Tyr Leu

1 10 15

```
Leu Asp Ser Glu Asn Thr Ser Gly Ala Leu Pro Arg Leu Pro Gln Thr
                                25
Pro Lys Gln Pro Gln Lys Arg Ser Arg Ala Ala Phe Ser His Thr Gln
                                                45
                            40
Val Ile Glu Leu Glu Arg Lys Phe Ser His Gln Lys Tyr Leu Ser Ala
                        55
                                            60
Pro Glu Arg Ala His Leu Ala Lys Asn Leu Lys Leu Thr Glu Thr Gln
                    70
                                        75
Val Lys Ile Trp Phe Gln Asn Arg Arg Tyr Lys Thr Lys Arg Lys Gln
                                    90
                85
Leu Ser Ser Glu Leu Gly Asp Leu Glu Lys His Ser Ser Leu Pro Ala
                                105
Leu Lys Glu Glu Ala Phe Ser Arg Ala Ser Leu Val Ser Val Tyr Asn
                            120
                                                125
Ser Tyr Pro Tyr Tyr Pro Tyr Leu Tyr Cys Val Gly Ser Trp Ser Pro
                        135
  · 130
Ala Phe Trp
145
     <210> 351
      <211> 1289
      <212> DNA
      <213> Homo sapien
      <400> 351
                                                                        60
agccaggcgt coctotgcct goccactcag tggcaacacc cgggagctgt tttgtccttt
gtggagcetc agcagttece tettteagaa etcaetgeca agageeetga acaggageea
                                                                       120
                                                                       180
ccatgcagtg cttcagcttc attaagacca tgatgatcct cttcaatttg ctcatctttc
tqtqtqqtqc aqccctgttq gcagtgggca tctgggtgtc aatcgatggg gcatcctttc
                                                                       240
tgaagatett egggeeactg tegteeagtg ceatgeagtt tgteaacgtg ggetacttee
                                                                       300
tcatcgcagc cggcgttgtg gtctttgctc ttggtttcct gggctgctat ggtgctaaga
                                                                       360
ctgagagcaa gtgtgccctc gtgacgttct tcttcatcct cctcctcatc ttcattgctg
                                                                       420
aggttgcagc tgctgtggtc gccttggtgt acaccacaat ggctgagcac ttcctgacgt
                                                                       480
tgctggtagt gcctgccatc aagaaagatt atggttccca ggaagacttc actcaagtgt
                                                                       540
ggaacaccac catgaaaggg ctcaagtgct gtggcttcac caactatacg gattttgagg
                                                                       600
actcacccta cttcaaagag aacagtgcct ttcccccatt ctgttgcaat gacaacgtca
                                                                       660
                                                                       720
ccaacacagc caatgaaacc tgcaccaagc aaaaggctca cgaccaaaaa gtagagggtt
gcttcaatca gcttttgtat gacatccgaa ctaatgcagt caccgtgggt ggtgtggcag
                                                                       780
ctggaattgg gggcctcgag ctggctgcca tgattgtgtc catgtatctg tactgcaatc
                                                                       840
                                                                       900
tacaataaqt ccacttctqc ctctqccact actqctqcca catqqqaact gtgaaqaqgc
                                                                       960
accetggeaa geageagtga ttgggggagg ggacaggate taacaatgte acttgggeea
gaatggacct gccctttctg ctccagactt ggggctagat agggaccact ccttttagcg
                                                                      1020
atgcctgact ttccttccat tggtgggtgg atgggtgggg ggcattccag agcctctaag
                                                                      1080
qtaqccaqtt ctgttqccca ttcccccagt ctattaaacc cttgatatgc cccctaggcc
                                                                      1140
tagtggtgat cccagtgctc tactggggga tgagagaaag gcattttata gcctgggcat
                                                                      1200
                                                                      1260
aaqtqaaatc aqcaqaqcct ctgggtggat gtgtagaagg cacttcaaaa tgcataaacc
                                                                      1289
tgttacaatg ttaaaaaaaa aaaaaaaaa
      <210> 352
<211> 241
      <212> PRT
      <213> Homo sapien
      <400> 352
Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu
                                    10
Leu Ile Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly Ile Trp Val
```

25

30

Ser	Ile	Asp 35	Gly	Ala	Ser	Phe	Leu 40	Lys	Ile	Phe	Gly	Pro 45	Leu	Ser	Ser	
Ser	Ala 50	Met	Gln	Phe	Val	Asn 55	Val	Gly	Tyr	Phe	Leu 60		Ala	Ala	Gly	
Val 65		Val	Phe	Ala	Leu 70		Phe	Leu	Gly	Cys 75	Tyr	Gly	Ala	Lys	Thr 80	
	Ser	Lys	Cys	Ala 85		Val	Thr	Phe	Phe 90		Ile	Leu	Leu	Leu 95		
Phe	Ile	Ala	Glu 100	Val	Ala	Ala	Ala	Val 105		Ala	Leu	Val	Tyr 110		Thr	
Met	Ala	Glu 115	His	Phe	Leu	Thr	Leu 120	Leu	Val	Val	Pro	Ala 125		Lys	Lys	
	130					135					Trp 140					
145					150					155	Thr				160	
				165					170		Pro		-	175		·
			180					185			Thr		190			
		195					200				Leu	205				
	210					215					Ala 220			_	_	
225 Gln	GIU	ren	Ala	Ala	Met 230	Ile	Val	Ser	Met	Tyr 235	Leu	Tyr	Суз	Asn	Leu 240	
		210>	353					•								•
<211		12>	DNA Homo	sap	oien						•				÷	
	<2	20>				•										
			misc	_		•				•						
			(1). n =			G										
2024		00>														
actg	gaac	ac a	tacc	caca	t ct	ttgt	tctg	gag agg	gata	att	ttct	gtga	ica o	atctt	ggaagg :gctgt	60 120
atat	tcaa	gc a	.cata	tgtt	a ta	tatt	atto	agt	tcca	tgt	ttat	agco	ta c	gtt		173
<211	<2 > 67	10>	354													
	<2	12>														
	<2	13>	Homo	sap	ien											
~~~		00>		a+						.						
cagg	tcaa	ag c	tgat	cttt	c to	gaat	gila gtca	cca	acca	agg	gggt	gaca	iga t	tcaa	tcaac aagcc	60 120
atco	acaa	gť c	atac	ctgg	a tg	tcag	cgaa	gag	qqca	caa	agge	agca	ac a	acca	ctggg	180
gaca	gcat	cg c	tgta	aaaa	g cc	tacc	aatg	aga	gctc	agt	tcaa	ggcg	aa c	caco	ccttc	240
ctgt	tctt	ta t	aagg	caca	c tc	atac	caac	acg	atcc	tat	tctg	tggc	aa q	ictto	cctct	300
ccct	aatc	ag a	tggg	gttg	a gt	aagg	ctca	gag	ttgc	aga	tgag	gtgo	ag a	gaca	atcct	360
yuga toat	Ctac	CC C	acgg	ccaa ctc+	a aa	gctg	ttca	cac	ctca	cgc	acct	ctgt	gc c	ccag	tttgc	420
tttq	ttaa	tc a	tqqa	aaaa	a yy g at	acct	ttat	gca	gaaa	acc	ttto	yıtg taar	cg a	aget	aaggc	480 540
_						<i></i>				,,				a		J 7 1 U

```
ggtgtctcat ttgagtgctg tccagtgaca tgatcaagtc aatgagtaaa attttaaggg
                                                                        600
 attagatttt cttgacttgt atgtatctgt gagatcttga ataagtgacc tgacatctct
                                                                        660
                                                                        676
 gcttaaagaa aaccag
       <210> 355
<211> 463
       <212> DNA
       <213> Homo sapien
       <400> 355
                                                                         60
 acttcatcag gccataatgg gtgcctcccg tgagaatcca agcacctttg gactgcgcga
 tgtagatgag ccggctgaag atcttgcgca tgcgcggctt cagggcgaag ttcttggcgc
                                                                        120
 ccccggtcac agaaatgacc aggttgggtg ttttcaggtg ccagtgctgg gtcagcagct
                                                                        180
 cgtaaaggat ttccgcgtcc gtgtcgcagg acagacgtat atacttccct ttcttcccca
                                                                        240
 gtgtctcaaa ctgaatatcc ccaaaggcgt cggtaggaaa ttccttggtg tgtttcttgt
                                                                        300
 agttccattt ctcactttgg ttgatctggg tgccttccat gtgctggctc tgggcatagc
                                                                        360
 cacacttgca cacattctcc ctgataagca cgatggtgtg gacaggaagg aaggatttca
                                                                        420
 ttgagcctgc ttatggaaac tggtattgtt agcttaaata gac
                                                                       463
<210> 356
<211> 2106
<212> DNA
<213> Homo sapiens
<400> 356
-atgcatcacc atcaccatca catgggctcc gacgttcgtg acctgaacgc actgctgccg 60
gcagtteegt ecetgggtgg tggtggtggt tgegeactge eggttagegg tgcageacag 120
tgggctccgg ttctggactt cgcaccgccg ggtgcatccg catacggttc cctgggtggt 180
ccggcaccgc cgccggcacc gccgccgccg ccgccgccgc cgccgcactc cttcatcaaa 240
caggaaccga gctggggtgg tgcagaaccg cacgaagaac agtgcctgag cgcattcacc 300
gttcacttct ccggccagtt cactggcaca gccggagcct gtcgctacgg gcccttcggt 360
cctcctccgc ccagccaggc gtcatccggc caggccagga tgtttcctaa cgcgccctac 420
ctgcccagct gcctcgagag ccagcccgct attcgcaatc agggttacag cacggtcacc 480
ttcgacggga cgcccagcta cggtcacacg ccctcgcacc atgcggcgca gttccccaac 540
cactcattca agcatgagga tcccatgggc cagcagggct cgctgggtga gcagcagtac 600
teggtgeege ecceggteta tggetgeeae acceecaceg acagetgeae eggeageeag 660
getttgetge tgaggaegee etacageagt gacaatttat accaaatgae atcceagett 720
gaatgcatga cctggaatca gatgaactta ggagccacct taaagggcca cagcacaggg 780
tacgagageg ataaccacac aacgeecate etetgeggag eccaatacag aatacacacg 840
cacqqtqtct tcaqaqqcat tcaqqatqtg cgacqtqtgc ctggaqtagc cccgactctt 900
gtacggtcgg catctgagac cagtgagaaa cgccccttca tgtgtgctta cccaggctgc 960
aataagagat attttaagct gtcccactta cagatgcaca gcaggaagca cactggtgag 1020
aaaccatacc agtgtgactt caaggactgt gaacgaaggt tttttcgttc agaccagctc 1080
aaaagacacc aaaggagaca tacaggtgtg aaaccattcc agtgtaaaac ttgtcagcga 1140
aagtteteee ggteegacea eetgaagaee cacaccagga etcatacagg tgaaaageee 1200
ttcagctgtc ggtggccaag ttgtcagaaa aagtttgccc ggtcagatga attagtccgc 1260
catcacaaca tgcatcagag aaacatgacc aaactccagc tggcgcttga attcatgtgg 1320
gtcccggttg tcttcctcac cctgtccgtg acgtggattg gtgctgcacc cctcatcctg 1380
tctcggattg tgggaggctg ggagtgcgag aagcattccc aaccctggca ggtgcttgtg 1440
gcetetegtg gcagggcagt etgeggeggt gttetggtge acceecagtg ggteeteaca 1500
gctgcccact gcatcaggaa caaaagcgtg atcttgctgg gtcggcacag cctgtttcat 1560
cctgaagaca caggccaggt atttcaggtc agccacagct tcccacaccc gctctacgat 1620
atgageetee tgaagaateg atteeteagg eeaggtgatg acteeageea egaceteatg 1680
ctgctccgcc tgtcagagcc tgccgagctc acggatgctg tgaaggtcat ggacctgccc 1740
acceaggage cagcactggg gaccacctgc tacgcctcag gctggggcag cattgaacca 1800
gaggagttet tgaccccaaa gaaacttcag tgtgtggacc tccatgttat ttccaatgac 1860
gtgtgtgcgc aagttcaccc tcagaaggtg accaagttca tgctgtgtgc tggacgctgg 1920
acaqqqqqca aaaqcacctg ctcqqqtqat tctqqqqqcc cacttqtctq taatqqtqtq 1980
```

cttcaaggta tcacgtcatg gggcagtgaa ccatgtgccc tgcccgaaag gccttccctg 2040 tacaccaagg tggtgcatta ccggaagtgg atcaaggaca ccatcgtggc caacccctga 2100 gaattc 2106

<210> 357

<211> 692

<212> PRT

<213> Homo sapiens

<400> 357

Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro 5 10 15

Ser Leu Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala 20 25 30

Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr 35 40 45

Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro Pro 50 55 60

Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly 65 70 75 80

Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe 85 90 95

Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe 100 105 110

Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
115 120 125

Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile 130 135 140

Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr 145 150 155 160

Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe 165 170 175

Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln 180 185 190

Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser 195 200 205

Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp 210 215 220

Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln 225 230 235 240

Met Asn Leu Gly Ala Thr Leu Lys Gly His Ser Thr Gly Tyr Glu Ser 245 250 255

Asp	Asn	His	Thr 260	Thr	Pro	Ile	Leu	Cys 265	Gly	Ala	Gln	Tyr	Arg 270	Ile	His
Thr	His	Gly 275	Val	Phe	Arg	Gly	Ile 280	Gln	Asp	Val	Arg	Arg 285	Val	Pro	Gly
Val	Ala 290	Pro	Thr	Leu	Val	Arg 295	Ser	Ala	Ser	Glu	Thr 300	Ser	Glu	Lys	Arg
Pro 305	Phe	Met	Суз	Ala	Tyr 310	Pro	Gly	Cys	Asn ·	Lys 315	Arg	Tyr	Phe	Lys	Leu 320
Ser	His	Leu	Gln	Met 325	His	Ser	Arg	Lys	His 330	Thr	Gly	Glu	Lys	Pro 335	Tyr
Gln	Cys	Asp	Phe 340	Lys	Asp	Суз	Glu	Arg 345	Arg	Phe	Phe	Arg	Ser 350	Asp	Gln
		355					360				Lys	365			
_	370					375					His 380				
385					390			•		395	Суз				400
•		•	-	405		Ī		•	410		Val			415	
			420				•	425			Ala		430		
		435					440				Thr	445			
	450					455					Trp 460				
465					470					475	Arg				480
_	_			485					490		Leu			495	
_			500					505			Arg		510		
		515					520				Ser	525			
His	Pro 530	Leu	Tyr	Asp	Met	Ser 535	Leu	Leu	Lys	Asn	Arg 540	Phe	Leu	Arg	Pro
Gly 545	Asp	Asp	Ser	Ser	His 550	Asp	Leu	Met	Leu	Leu 555	Arg	Leu	Ser	Glu	Pro 560

- Ala Glu Leu Thr Asp Ala Val Lys Val Met Asp Leu Pro Thr Gln Glu 565 570 575
- Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile Glu 580 585 590
- Pro Glu Glu Phe Leu Thr Pro Lys Lys Leu Gln Cys Val Asp Leu His 595 600 605
- Val Ile Ser Asn Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr 610 615 620
- Lys Phe Met Leu Cys Ala Gly Arg Trp Thr Gly Gly Lys Ser Thr Cys 625 630 635 640
- Ser Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gln Gly 645 650 655
- Ile Thr Ser Trp Gly Ser Glu Pro Cys Ala Leu Pro Glu Arg Pro Ser 660 665 670
- Leu Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr Ile 675 680 685

Val Ala Asn Pro 690